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ABSTRACT 
Introduction: Despite the continuously escalating psychological, societal and 
economic burden of depression, there is a lack of evidence regarding the 
effectiveness of available interventions on important functional areas beyond 
specific depressive symptoms. Therefore, the main objective of this thesis is to give 
an insight into the current measurement of treatment effectiveness in depression and 
to provide recommendations for its improvement. 
Methods: The first part of the thesis critically reviews the current measurement of 
treatment effectiveness in depression and provides a systematic assessment of the 
effectiveness of available psychological and pharmacological interventions on 
psychosocial functioning in depression. The section consists of three articles - a 
systematic literature review and two meta-analyses. The second part of the thesis is 
dedicated to the collection of empirical evidence designed as a response to all the 
limitations of the current research identified in the first part of the thesis. The 
evidence is collected from a multi-country cross-sectional study, a qualitative study 
with patients with depression, and an expert survey with representatives from 
clinical practice. At the end research recommendations for improving treatment 
effectiveness measurement in depression are provided. 
Results: The effectiveness of available interventions for depression is assessed 
mainly in terms of reduction of clinical symptoms, whereas other areas of 
functioning are neglected. In addition, all interventions for depression perform 
better at reducing symptom severity than at improving areas of functioning others 
than symptomatology. Several limitations in research were identified – 1) a very 
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small number of studies to apply functional outcome measures; 2) a majority of 
studies with poor quality; 3) heterogeneous instruments addressing distinct areas of 
functioning; 4) lack of long-term reports on the effectiveness of interventions; 5) 
high percentage of papers reporting sum-scores rather than domain-specific 
information; and 6) lack of personalized information on the effectiveness of specific 
treatments on specific areas of functioning or particular group of individuals. 
  As an answer to these limitations, results from the multi-country 
epidemiological study revealed that there was a variation in the level of impairment 
in different functioning domains across countries. Gender differences in the 
functional impairment of depression were also found. Clinical experts and 
depressed patients highlighted the importance of both depressive symptoms and 
functional areas beyond symptoms. A set of the most important functional areas in 
depression, namely mental functions, sleep, energy level, somatic problems, 
interpersonal relationships and interaction, recreation and daily activities, 
communication, social participation, daily tasks and demands, work and 
educational difficulties, and personal factors such as self-efficacy or self-awareness 
was defined. In addition, clinicians and patients identified a number of differences 
regarding the areas improved by psychotherapeutic or pharmacological 
interventions that were not addressed by the pertinent literature.  
Conclusions: Five main recommendations for future improvement of the 
measurement of treatment effectiveness in depression were derived from the 
research we carried out. Firstly, a new instrument comprehensively assessing all 
relevant psychosocial difficulties in depression has to be created. Secondly, the new 
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functional tool has to be cross-nationally applicable. Thirdly, report of domain-
specific information has to be included in clinical trials. Fourthly, broader remission 
criteria for depression including psychosocial functioning beyond symptoms are 
needed. Finally, there is a need of a more personalized approach in treatment 
decision making, acknowledging specific patient needs and accounting for a more 
comprehensive array of functional domains.  
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RESUMEN 
Introducción: A pesar de la creciente carga psicológica, social y económica de la 
depresión, hay escasa evidencia sobre la eficacia de las intervenciones disponibles en 
áreas funcionales importantes distintas de los síntomas depresivos específicos. Por lo 
tanto, el objetivo principal de esta tesis es informar sobre el estado de la cuestión en  
la  medición de la efectividad de los tratamientos en la depresión y proporcionar 
recomendaciones para su mejora. 
Metodología: La primera parte de la tesis se dedica a una revisión crítica de la 
medición actual de la efectividad de los tratamientos en la depresión y proporciona 
una evaluación sistemática de la efectividad de las intervenciones psicológicas y 
farmacológicas en el funcionamiento psicosocial de  la depresión. La sección consta 
de tres artículos - una revisión sistemática de la literatura y dos meta-análisis. La 
segunda parte de la tesis se dedica a la recolección de evidencia empírica diseñada 
como una respuesta a todas las limitaciones de la investigación actual previamente 
identificadas en la primera parte de la tesis. La evidencia fue recogida a través de un 
estudio transversal en diversos países, un estudio cualitativo con pacientes con 
depresión, y una encuesta con clínicos expertos en depresión. Finalmente, se 
proporciona una lista de recomendaciones científicas para mejorar la medición de la 
efectividad de los tratamientos en la depresión. 
Resultados: La eficacia de las intervenciones en depresión se evalúa principalmente 
en términos de una reducción de los síntomas depresivos, mientras que otras áreas de 
funcionamiento no se abordan. Además, todas las intervenciones en depresión 
obtuvieron  mejores resultados en la reducción de la severidad de los síntomas que en 
5 
 
la mejora de áreas de funcionamiento no relacionados con la sintomatología. 
Asimismo, se identificaron varias limitaciones en la investigación - 1) un número 
muy pequeño de estudios aplicaron medidas de funcionamiento; 2) la mayoría de los 
estudios fueron de  baja calidad; 3) los instrumentos fueron  heterogéneos y 
abordaron áreas distintas de funcionamiento; 4) hubo escasos estudios sobre la 
eficacia de las intervenciones en términos de funcionamiento a largo plazo; 5) un alto 
porcentaje de artículos presentaron puntuaciones totales en lugar de información 
sobre dominios de funcionamiento específicos. Como resultado a todas estas 
limitaciones hubo una falta de información personalizada sobre la eficacia de los 
tratamientos específicos en áreas concretas de funcionamiento o grupos de individuos 
particulares. 
             Para dar respuesta a estas limitaciones, los resultados del estudio 
epidemiológico con datos recogidos en varios países revelaron la existencia de  una 
variación en el nivel de importancia de los diferentes dominios de funcionamiento en 
todos los países. También se encontraron diferencias de género en las áreas de 
deterioro funcional en las personas con depresión. Los médicos y los pacientes 
deprimidos subrayaron la importancia de los síntomas y las diferentes áreas 
funcionales  de los síntomas. Se definió un conjunto de  áreas funcionales más 
importantes de la depresión - las funciones mentales, el sueño, el nivel de energía, los 
problemas somáticos, las relaciones interpersonales, la recreación y las actividades 
diarias, la comunicación, la participación social, las tareas y las exigencias diarias, el 
trabajo y las dificultades educativas, y factores personales como la auto-eficacia y la 
auto-conciencia. Además, los médicos y los pacientes identificaron una serie de 
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diferencias con respecto a las áreas mejoradas por las intervenciones 
psicoterapéuticas o farmacológicas que no fueron abordadas por la bibliografía 
pertinente. 
Conclusiones: Como corolario de la investigación llevada a cabo en esta tesis 
doctoral, se derivaron cinco recomendaciones principales para la mejora de la futura 
medición de la efectividad en los tratamientos de la depresión. 
En primer lugar, se debería crear un nuevo instrumento de evaluación que integre las 
dificultades psicosociales más relevantes en la depresión. En segundo lugar, la nueva 
herramienta funcional tendría que ser aplicable a nivel internacional. En tercer lugar, 
información específica de diferentes dominios tendría que ser incluida en los ensayos 
clínicos como medidas de resultado. En cuarto lugar, se necesitarían crear criterios de 
remisión más amplios para la depresión, incluyendo en la definición áreas de 
funcionamiento psicosocial más allá de los síntomas. Por último, existe la necesidad 
de un enfoque más personalizado de evidencia científica que guie la toma de 
decisiones sobre los tratamientos, reconociendo las necesidades específicas del 
paciente y considerando una gama más amplia de áreas funcionales. 
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1. INTRODUCTION 
1.1.Prevalence of depression   
  Depression
1
 is characterized by symptoms such as sadness, loss of interest 
in activities, decreased energy, loss of confidence and self-esteem, feeling of guilt, 
thoughts of death and suicide, disturbance of sleep and appetite, etc. The most 
commonly used classification systems for mental disorders - DSM-5 and ICD-10 
identify main depressive symptoms needed to be met in the two weeks previous to 
the assessment for a diagnosis of depression (American Psychiatric Association, 
2013; World Health Organization, 1992). In DSM-5 these are depressed mood and 
anhedonia, as at least one of them must be present for a diagnosis, whereas in ICD-
10 there are three typical depressive symptoms - depressed mood, anhedonia, and 
reduced energy, two of which should be present for a diagnosis.  
  The prevalence of depression varies across countries, but is always among 
the most highly prevalent disorders. Statistics states that 11% of EU citizens 
experience depression at some point in their life (European Pact for Mental Health 
and Well-being, 2008). A population-based study with more than 38000 
participants from 10 countries revealed differences in the lifetime prevalence of 
depression ranging from 1.5/100 adults in Taiwan to 19.0/100 adults in Beirut 
(Weissman et al., 1996).  The World Health Organization (WHO) Psychological 
Problems in General Health Care (PPGHC) study further showed a 15-fold 
variation in major depression prevalence, from lowest prevalence in Japan and 
                                                          
1
 Depression in this thesis refers to major depressive disorder, depressive episode and dysthymia. Other disorders 
that are also characterized by the presence of depressive symptoms such as bipolar disorder, adjustment disorders 
or cyclothymic disorder are not subject of the present study.  
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China to highest prevalence in Brazil and Chile (Simon et al., 2002). A subsequent 
study found lifetime prevalence estimates of MDD of 16.9% in the US, 8.3% in 
Canada and 9.0% in Chile (Andrade et al., 2003). 
1.2.Interventions for depression  
  There are various methods of managing depression (Chisholm et al., 
2004). The WHO mhGAP Intervention Guide (World Health Organization, 2010) 
recommends as first choice treatment options psychosocial support together with 
antidepressant medication (Selective serotonin reuptake inhibitors  [SSRIs], 
Serotonin–norepinephrine reuptake inhibitors [SNRIs], Tricyclic antidepressants 
[TCAs]) or psychotherapy (e.g. Cognitive Behavior Therapy [CBT], Interpersonal 
Psychotherapy [IPT], Problem Solving Therapy [PST]). Results from randomized 
controlled trials and clinical guidelines suggest that internet based treatments and 
some complementary or alternative therapies, such as exercise or sleep deprivation, 
are also effective in the short term (Caliyurt and Guducu, 2005; Kvam et al., 2016).  
1.2.1 Pharmacotherapy  
  Pharmacotherapy is the most studied and best evidenced treatment for 
depression. Since year 2000, at least 250 randomized controlled trials and 145 
meta-analyses have been published on antidepressant medications for major 
depressive disorder. The most recognized guidelines (Kennedy et al., 2016; 
McAllister-Williams, 2006) indicate that the SSRIs and SNRIs are considered as 
first-line medications due to their better safety and tolerability profiles, whereas 
older medications like TCAs and monoamine oxidase (MAO) inhibitors are second-
line medication. However, the choice of first-line medication still depends on 
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individual assessment and clinical factors like tolerability, patient and health 
professional preference, costs, and other health system related variables. The most 
commonly known antidepressant groups are presented below:  
1.2.1.1. Selective serotonin reuptake inhibitors (SSRIs) 
   Selective serotonin reuptake inhibitors or serotonin-specific reuptake 
inhibitors (SSRIs) are the most commonly prescribed antidepressants against 
depression. Citalopram, escitalopram, fluoxetine, paroxetine, and sertraline are 
among the most commonly used SSRI agents. The mechanism of work involves the 
increase of the extracellular level of the neurotransmitter serotonin by stopping 
its reabsorption into the presynaptic cell, thus increasing the level of serotonin in 
the synaptic cleft  (Preskorn et al., 2004). The SSRIs are commonly prescribed for 
severe depression in many countries. They are recommended by the National 
Institute for Health and Care Excellence (NICE) as a first-line treatment of severe 
depression and for the treatment of mild-to-moderate depression (McAllister-
Williams, 2006). However, their efficacy in mild or moderate cases of depression 
has been disputed (Fournier et al., 2010; Pies, 2010). Two meta-analyses found the 
effect of SSRIs in mild and moderate depression to be small or none compared to 
placebo (Fournier et al., 2010; Kirsch et al., 2008).   
1.2.1.2. Serotonin–norepinephrine reuptake inhibitors (SNRIs) 
             SNRIs are second-generation antidepressants commonly prescribed for 
depression. Unlike SSRIs, which act upon serotonin alone, SNRIs are powerful 
inhibitors of the reuptake of serotonin and norepinephrine, thus controlling the 
mood (Cashman and Ghirmai, 2009). Studies have shown that SNRIs are generally 
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as effective as SSRIs, having a modest efficacy advantage compared to SSRIs in 
treating MDD (Papakostas et al., 2007), but being slightly less well tolerated 
(Nemeroff and Thase, 2007). Venlafaxine, duloxetine, milnacipran and 
levomilnacipran are among the most commonly used SNRI agents.  
1.2.1.3. Tricyclic antidepressants (TCAs) 
  TCAs have been for many years the first choice pharmacological treatment 
for clinical depression.  They have been first discovered and marketed in the early 
1950s (Carson, 2000).  They are named after their chemical structure based on 
three rings of atoms.  In recent times TCAs have been largely replaced in clinical 
use worldwide by newer antidepressants such as SSRIs and SNRIs due to their 
improved safety and side effect profile (Trindade et al., 1998). However, some 
evidence suggests that tricyclic antidepressants are more effective for melancholic 
depression than other antidepressants (Mitchell and Mitchell, 1994). The most 
commonly used TCA agents are clomipramine, imipramine, nortriptyline and 
doxepin.  
                 In general, recent meta-analyses have not found evidence for significant 
differences among different groups of agents (Linde et al., 2015). Recent meta-
analytical studies have focused on comparing individual antidepressants rather than 
bigger groups of agents. Evidence from systematically comparative meta-analyses 
for individual agents have indicated that only sertraline had evidence for superior 
efficacy compared to other antidepressants (Cipriani et al., 2008). Later on, a 
multiple comparisons network meta-analysis compared 12 antidepressants and 
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identified a small superiority in response rates for escitalopram, mirtazapine, 
sertraline and venlafaxine compared to the others (Cipriani et al., 2009).  
              Despite its wide proliferation, the efficacy of antidepressant treatment for 
depression has been a matter of numerous debates due to three main reasons. 
Firstly, some of the RCTs for antidepressants are conducted by pharmaceutical 
companies selecting patients that may not reflect the real world clinical practice 
(Kennedy, 2001). Even the most recent larger scale effectiveness trials addressing 
generalizability, such as the U.S. Sequenced Treatment Alternatives to Relieve 
Depression (STAR*D) trial (Rush et al., 2004) are still limited by numerous 
methodological deficiencies, such as the presence of study participants with 
comorbidities or concomitant psychotropic medications, or the lack of measures of 
adherence to medication (Hu et al., 2007). Secondly, early discontinuation rates of 
antidepressants are moderate-to-high. Clinical practice guidelines recommend 
minimum 6–12 months duration of antidepressant treatment for MDD, but more 
than about 30% of patients discontinue medications within 30 days and more than 
40% within 90 days (Olfson et al., 2006). The main reasons for discontinuation are 
lack of quick response, stigma associated with having a psychiatric illness, and side 
effects (Hodgkin et al., 2007). Thirdly, several serious adverse effects of 
antidepressants have been reported during the use of antidepressants. People on 
TCAs at therapeutic doses have higher risk for seizures compared to general 
population (0.4–1.2%) (Deshauer, 2007). Studies using systematic assessment of 
sexual function report rates up to 50% of sexual dysfunction with SSRIs and 
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slightly lower rates with SNRIs (Taylor et al., 2005), greater for fluoxetine and 
paroxetine, and lower for citalopram/escitalopram.  
1.2.2. Psychotherapy 
                     Psychotherapy refers to a treatment approach through a method of 
communicating between a patient who seeks alleviation of current or prevention of 
recurrence of symptoms and a therapist. Nowadays, with the advent of computers, 
internet and other technologies, a relationship could be established between the 
patient and the psychological model itself. Despite the existence of dozens of 
psychological modalities for depression, all of them share some key components: 
(1) maintenance of a professional but fully supportive and working alliance 
between patient and psychotherapist (2) alleviation of the core factors responsible 
for the health condition , (3) following of a specific method to deliver the therapy 
(typically a manual), (4) current state monitoring, (5) psychoeducation, and (g) 
time-limits (Hunsley et al., 2013). The therapy can be delivered in a group or 
individual format.  
                 The provision of psychotherapy depends on many factors – patient 
preferences, provider and health system. Clinical guidelines usually recommend 
psychotherapy for mild and moderately depressed patients, but discourage 
monotherapy with psychotherapy for severe cases or suicidal patients (Kennedy et 
al., 2016; McAllister-Williams, 2006). There is no clear economic evidence that 
psychotherapy should be a preferable treatment choice compared to 
pharmacotherapy (Bosmans et al., 2008). However, a recent meta-analysis reveals a 
strong patient preference for psychological treatment over medication (McHugh et 
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al., 2013). Moreover, evidence states that the majority of people expressing 
personal preference for psychological therapy choose not to get treated at all rather 
than receive medication (Layard et al., 2007).  
                 In the next section the most commonly used psychotherapies for 
depression are presented: 
1.2.2.1. Cognitive Behavioral Therapy (CBT) 
                CBT is the most researched therapy within the last 30 years. It is an 
intensive, symptom focused psychotherapy built on the premise that distorted 
beliefs about the self and the world trigger depressive affect. The aim of CBT is to 
change these maladaptive thinking patterns and to convert them in adaptive ways of 
responding. CBT is especially effective for symptoms of social withdrawal, 
anhedonia, and the engagement of persons in their environment (Parikh et al., 
2016). The evidence coming from more than hundred randomized controlled trials 
published since 1977 indicates that CBT is an effective therapy in treating MDD 
(mild to moderate severity), being equivalent to antidepressant medication (effect 
size 0.38) for the acute phase episode and superior over control conditions (effect 
size 0.82) (Gloaguen et al., 1998).  
                 Furthermore, no difference between CBT and antidepressant medication 
has been found in severely depressed patients (DeRubeis et al., 2005; Luty et al., 
2007). Findings from the STAR*D project show that there are no significant 
differences in remission rates and fewer side effects when patients have switched 
antidepressant to CBT compared to switching to a different antidepressant (Thase et 
al., 2007). Lastly, a meta-analysis shows that after stopping CBT and medication 
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after successful acute treatment, patients who initially received CBT have lower 
rates of relapse (Vittengl et al., 2007).  
1.2.2.2.Interpersonal Therapy (IPT) 
                  IPT was initially developed in the 1970's for the outpatient treatment of 
individuals with MDD. IPT is focused on improving interpersonal relationships and 
immediate social context. More specifically, the 16 sessions center on role 
transitions, interpersonal role disputes, grief or interpersonal deficits, etc. The most 
extensive meta-analysis on IPT to date (Cuijpers et al., 2011) shows an overall 
effect size of 0.63 in favour of IPT over control conditions, a nonsignificant 
differential effect size of 0.04 comparing IPT to other psychological treatments, and 
0.19 in favour of pharmacotherapy over IPT.  
1.2.2.3.Other psychotherapies 
                  CBT and IPT had been recommended as first line treatments for MDD 
by all clinical guidelines. Other psychotherapies, such as Psychodynamic 
Psychotherapy, Problem Solving Therapy, Behavioral activation, Cognitive-
Behavioral Analysis System of Psychotherapy, Motivational Interviewing, 
Acceptance and Commitment Therapy, Mindfulness Based Cognitive Therapy and 
Emotion Focused Therapy,  have all shown significantly better results compared to 
control conditions, but the amount of research is still not sufficient to be proposed 
as first-line treatments (Barth et al., 2013). 
1.2.3. Combination of psychotherapy and pharmacotherapy 
                   Combined treatment for MDD can be either sequential (first acute 
medication, followed by psychotherapy) or concurrent (starting both treatments 
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together). There is not much literature comparing combined therapy versus each 
treatment alone due to the various modes of delivery, differential dosage or number 
of sessions (Parikh et al., 2016). However, a meta-analysis with over 1800 subjects 
revealed that concurrent medication and psychotherapy was superior to 
psychotherapy alone, with a small to moderate effect size of 0.35 (Cuijpers et al., 
2009). Another meta-analysis showed clear superiority of combined concurrent 
therapy in terms of symptom reduction and reduction of patient drop-out rates 
(Pampallona et al., 2004). A study by de Jonghe et al. (2004) reveals strong 
preference of the patients for combined treatment. Even though the evidence is still 
not sufficient and cost-effectiveness analyses comparing combined approach to 
treatment alone are scarce, given that the patient preference is a major concern in 
psychiatric treatment, this result needs serious consideration in treatment 
recommendations.  
1.2.4. Other interventions, complementary and alternative treatments 
                Aside from the psychotherapeutic and pharmacological treatments, there 
exist other therapies that can be simply categorized as complementary and 
alternative treatments. A big group of alternative treatments is the group of 
neurostimulation treatment. Neurostimulation refers to the delivery of a physical 
intervention through electric current or a magnetic field to reach specific brain 
regions (Kennedy et al., 2009). Electroconvulsive therapy (ECT) has the most 
extensive evidence. Repetitive transcranial magnetic (rTMS) and vagus nerve 
stimulation (VNS) are well established for treating MDD (Kennedy et al., 2009), 
and deep brain stimulation (DBS) is effective for treatment resistant depression 
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(Lozano et al., 2008), but all three having much smaller evidence base. Light 
therapy, sleep deprivation, yoga, exercise, acupuncture, nutraceutical therapies, and 
herbal therapies like St. John’s wort, have been also studied in depression and 
found to be superior to placebo, but the evidence is still limited (Ravindran et al., 
2009). Nevertheless, with the continuous failure of both psychotherapy and 
pharmacotherapy to show better than just small to moderate effects for improving 
depression, these alternative therapies become more and more attractive for 
individuals seeking treatment (Ravindran et al., 2009). 
1.3. Escalating burden of depression 
 In spite of the large number of available interventions for depression and 
the huge evidence on their effectiveness, data show that up to 30% of all cases of 
depression are not adequately solved by first-agent treatments (National 
Collaborating Centre for Mental Health, 2010). The meta-analytical evidence of 
treatment effectiveness of these first agents is also modest (Cuijpers et al., 2010; 
Khan and Brown, 2015). Moreover, depression has been consecutively ranked as 
one of the leading causes of burden in the Global Burden of Disease studies since 
1990 (Whiteford et al., 2013). It is predicted to be the greatest cause of disability 
worldwide by 2030 (Ferrari et al., 2013; World Health Organization, 2003). 
According to the World Health Organization (WHO), approximately one million 
people die from suicide every year (World Health Organization, 2003), as the 
majority of cases appear in people suffering from depression (Mann et al., 2005). 
Depression affects not just the individuals, but also their closest circle of friends 
and relatives. Studies show that family members are affected enormously by the 
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burden of the disease and sometimes even develop depression themselves (Shah et 
al., 2010). Besides the psychological burden on individuals, depression has also 
significant socio‐economic costs. The direct and indirect costs of depression in the 
EU are estimated at €92 billion in 2010 (Olesen et al., 2012). Nearly half of the 
costs are result of productivity loss, indicating the enormous negative impact 
depression has on populations’ economy. 
1.4. Measurement of treatment effectiveness 
 To be effective, one treatment has to address individual´s needs and return 
his level of functioning as before suffering from depression. There are various 
operational definitions of critical change points in the course of a major depressive 
episode, such as remission, recovery, relapse and recurrence (Furukawa et al., 
2008). Remission of depression, considered as the optimal outcome in clinical 
research (Keller, 2003), is currently defined solely in terms of symptom reduction 
(Zimmerman et al., 2006b) according to cut-off scores on symptom severity scales 
such as the Hamilton Rating Scale for Depression (HRSD) (Hamilton, 1967), Beck 
Depression Inventory (BDI) (Beck et al., 1961) or the Montgomery–Åsberg 
Depression Rating Scale (Montgomery and Asberg, 1979). Other studies 
operationalize remission as a state with no more than one or two mild depressive 
criterion symptoms, and recovery as eight or more weeks of remission (Keller et al., 
1982).   
 Recent literature has suggested that improvement of functioning areas 
other than symptomatology, such as social and occupational functioning or quality 
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of life  might be equally important for people with depression as their symptom 
amelioration (IsHak et al., 2011; Lam et al., 2015; Zimmerman et al., 2006a). 
Patients have prioritized general functioning over symptomatic outcomes and 
determined the return to a normal level of functioning at work, home or school as a 
significant factor for remission in depression (Zimmerman et al., 2006a). Research 
suggests that functional recovery appears later than the symptomatic one and 
certain level of impairment continue even after the symptomatology is ameliorated 
(Kennedy et al., 2007). This residual functional impairment has been found to 
evoke relapse and recurrences in depressed patients (Vittengl et al., 2009). 
Furthermore, it has been suggested that depressive symptoms and QoL do not share 
high proportion of common variance (Coryell et al., 1993; Trompenaars et al., 
2006).  
  The concept of functioning problems have been included for diagnosing 
depressive disorders both in WHO’s ICD-10 and in APA’s DSM-IV-TR and DSM-
5 (American Psychiatric Association, 2000; American Psychiatric Association, 
2013; World Health Organization, 1992). According to the DSM criteria, “impaired 
function: social, occupational, educational” is one of the requirements for 
establishing a diagnosis of depression, whereas the ICD considers “social, work or 
domestic activities” as considerably impaired in depression.  Thus, the 
measurement of functioning has always been implicitly included in all classificatory 
systems but rarely taken into practice to establish diagnosis.   
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   In summary, there are number of psychological, pharmacological and 
complementary interventions with large evidence for their effectiveness in terms of 
reduction of symptoms. However, depression still represents a huge problem to 
society. Further investigation of all relevant functional areas in depression is 
needed. 
1.5. Psychosocial difficulties in depression  
  It is generally accepted that a psychosocial difficulty refers to any type of 
difficulty related to one's psychological state or social environment (Ro and Clark, 
2009). There have been multiple definitions of psychosocial functioning in 
literature throughout the years. Definitions are generally broad and typically 
describe the interaction between individuals and their social environment. Some 
authors refer to psychosocial functioning only in terms of social functioning within 
the context of daily living, that is, individuals’ performance in their environment in 
terms of significant aspects of daily living (e.g., work, relationships). More 
specifically, Weissman et al. (1981) describes social functioning as “the interplay 
between the individual and the social environment”.  Tyrer (1993) elaborates and 
adds that in this interplay, the functioning ranges from self-preservation and basic 
living skills to the relationship with others in society. Keller (2001) adds that 
“social function defines an individual’s interaction with work, family and social 
contacts”. 
  On the other hand, many authors consider quality of life/satisfaction as a 
measure of psychosocial functioning. Some authors refer to psychosocial 
functioning as the individuals’ performance in their environment in terms of 
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significant aspects of a vital life (e.g., quality of life, pursuit of values) (Ro and 
Clark, 2009). WHO defines QoL as the “individuals’ perceptions of their position 
in life in the context of the culture and value systems in which they live and in 
relation to their goals, expectations, standards and concerns” (Whoqol Group, 
1998). Satisfaction has been identified as a necessary component in defining 
psychosocial functioning fully, as people with disabilities may have difficulties 
carrying out day-to-day tasks, but differ in terms of satisfaction with their life.  
  Some of these definitions, however, focus only on specific areas directly 
affected by the disorder (e.g. psychopathological symptoms, social functioning). 
Thus, instruments assessing psychosocial outcomes cover only fragments of the 
generic health state and do not provide an overall picture of the psychosocial 
functioning of depressed individuals.  
  A universal, common language embracing not just the health condition 
(symptomatology), but also the activities problems, participations restrictions and 
the interaction between the underlying depression and the contextual factors 
(environmental or personal) is needed to facilitate the process of assessment, 
diagnosis and treatment of depression. A step towards achieving this goal is the 
creation of the WHO International Classification of Functioning, Disability and 
Health (ICF) (World Health Organization, 2001), a framework and classification 
defining the spectrum of problems in functioning in patients with mental disorders 
and in particular - depression.  
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1.5.1. ICF approach for psychosocial difficulties 
  The ICF provides a comprehensive conceptual framework and a unified 
language to describe the psychosocial difficulties and functioning. Originally 
developed as a complement of the International Statistical Classification of 
Diseases and Related Health Problems (ICD-10) (World Health Organization, 
1992), ICF provides a biopsychosocial perspective, comprising six components of 
health: Health Condition, Body Functions and Structures, Activities, Participation, 
Environmental Factors, and Personal Factors. The central concepts within this 
model are functioning and disability. Both terms have been used interchangeably in 
previous literature, but within the frames of this model functioning has been 
considered as an umbrella term for body functions, body structures, activities and 
participation. More specifically, functioning depicts the complex interaction 
between the individual and his/her health condition and his/her contextual 
environment. Disability indicates the impairments of body functions and body 
structures, the activity limitations and participation restrictions. More specifically, 
disability represents the negative outcome of interaction between the individual and 
his/her health condition and his/her contextual environment. These 
conceptualizations are useful for clarifying communications among researchers and 
clinicians (Ro and Clark, 2009). Figure 1 shows the interaction between the 
components of the ICF model for psychosocial difficulties.   
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Figure 1. ICF model of disability and health
 
 
  An important difference between the ICF and other disability 
classifications is that the ICF conceptualizes functioning as a holistic component of 
health rather than merely consequence of suffering a disease (World Health 
Organization, 2001). The ICF framework considers as problems of functioning the 
areas directly affected by health condition (symptoms) as well as other areas not 
directly derived by health condition but also impaired. The DSM, in contrast, 
separates symptoms from functioning. Another very important difference is that the 
ICF includes multiple categories (i.e., bodily, individual, and societal level 
functioning), providing a stronger theoretical basis for comprehensive and 
multidimensional assessment of functioning (Ro and Clark, 2009). 
  The ICF book consists of more than 1400 categories, organized within a 
hierarchically nested structure, representing the actual units of the classification. 
Each category is denoted by a code composed by a letter (b: Body Functions; s: 
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Body Structures; d: Activities and Participation and e: Environmental Factors), 
followed by a numeric code. Series of ICF Core Sets for individual disorders have 
been created lately to simplify this long list of functioning problems and to facilitate 
the assessment process. Even though the model has not been sufficiently 
implemented in research studies until now perhaps due to its complexity or large 
number of categories selected (Alvarezz, 2012), it still provides a universal 
terminology to describe functioning and disability independently of place, culture, 
country, or health care system.  
  The ICF approach for classifying and assessing psychosocial difficulties 
was used in this thesis, mainly because it is a comprehensive research tool, 
facilitating the process of selection of study populations and measurement of 
generic health, but also because it can be used in clinical settings and rehabilitation 
to structure and lead through the treatment process. Within the frames of the ICF, 
psychosocial difficulties are defined as any “impairments of mental functions, 
activity limitations and participation restrictions that include both the individual’s 
mental capacities and his or her social interactions (such as in work, family life and 
leisure activities)”. Impairments of body functions under central nervous system 
control such as pain and sexual interest problems are also included as PSDs 
(Cabello et al., 2012). 
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Despite all the knowledge on depression, it is still unclear whether current literature covers all the psychosocial difficulties (PSDs)
important for depressed patients. The aim of the present study was to identify the gaps in the recent literature concerning
PSDs and their related variables. Psychosocial difficulties were defined according to the World Health Organization International
Classification of Functioning, Disability and Health (ICF). A comparative approach between a systematic literature review, a focus
group, and individual interviews with depressed patients was used. Literature reported the main psychosocial difficulties almost
fully, but not in the same degree of importance as patients’ reports. Furthermore, the covered areas were very general and related
to symptomatology. Regarding the related variables, literature focused on clinical variables and treatments above all but did not
report thatmany psychosocial difficulties influence other PSDs.This study identifiedmany existing research gaps in recent literature
mainly in the area of related variables of PSDs. Future steps in this direction are needed. Moreover, we suggest that clinicians select
interventions covering not only symptoms, but also PSDs and their modifiable related variables. Furthermore, identification of
interventions for particular psychosocial difficulties and personalisation of therapies according to individuals’ PSDs are necessary.
1. Introduction
Depression is amajor public health issue due to its prevalence,
highmortality rates [1], suicide risk [2], and economic impact
on the society [3]. It is considered to be the major cause of
years lived with disability (YLD) and by 2020 is expected
to be among the two main causes of disability adjusted
years (DALYs) together with ischemic heart disease [4]. The
functional limitations caused by depression are equal to or
even sometimes greater than the ones engendered by many
other chronic medical conditions [5]. In spite of the great
advances achieved in treatment of depression during the last
decades, between 20 and 30% of cases are not adequately
solved by first agent treatments (also known as treatment-
resistant depression in literature) [6].
This evidence suggests that usual management strategies
do not address sufficiently relevant areas of depression.
One substantial dimension of depression comprises the psy-
chosocial difficulties (PSDs) which people experience. PSDs
constitute the impairment on psychological and social daily
functioning of individuals, linked with their particular health
condition [7]. The broad range of PSDs encompasses not
only the personal, but also the economic and social impacts
of the disorder. Therefore, it is of extreme importance that
these psychosocial difficulties and their related variables are
analyzed accordingly. Such information can throw light on
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patients’ real needs, can help clinicians determine the areas in
depression that are to be improved and investigated further,
may help to prevent the onset of disability, and last, but
not least, may guide policy makers to design better health
policies.
Previous scientific literature provides different definitions
of psychosocial difficulties in depression but has some lim-
itations: the methods either focus only on specific areas or
consider the PSDs as a result of depression. Recent studies
[7–9], however, provide a new definition of PSDs, based on
WHO’s InternationalClassification of Functioning,Disability
and Health (ICF) [10]. This new approach covers the whole
course, determinants and onset of psychosocial problems,
and embodies an innovative holistic model of health. More
specifically, it states that PSDs are “. . .impairments of mental
functions, activity limitations and participation restrictions
that include both the individual’s mental capacities and
his or her social interactions (such as in work, family life
and leisure activities)” [7]. Moreover, impairments of body
functions under central nervous system control such as pain
and sexual interest problems are also included as PSDs. A
detailed description of the utility of the ICF classification for
depression can be found elsewhere [11].
Once this comprehensive definition of psychosocial dif-
ficulties has been extracted from the literature, it is very
important to incorporate the patient perspective in clinical
practice and research. The majority of studies on this topic
are quantitative; however, the literature that uses qualitative
methodologies—which could provide deeper, richer, and
more elaborated data, exploratory analyses on patients’ needs
and standpoints, and thus more objective results—is sparse.
Furthermore, this kind of studies can provide a general view
if particular psychosocial difficulties, named by patients as
important, are missing in the literature.
There are few existing studies using qualitative research to
identify a full list of PSDswhich depressed people experience.
Yet, none of them has applied a comprehensive approach
in order to encompass all the psychosocial difficulties from
different perspectives. An example is a study by Lasch et
al. [12], which aimed to develop a specific questionnaire to
assess symptoms for adult major depressive patients and to
track their functional status. The authors have conducted ten
focus groups and individual cognitive interviews and iden-
tified several general domains containing different concepts.
However, this study does not combine the patient perspective
with information from the literature.
An article by Bru¨tt et al. [13] based itself on a three-
dimensional design—systematic review of literature, patient
focus groups, and an expert panel aimed to identify a
core set of activities and participation for individuals with
mental disorders. Moreover, this research paper relied on
the International Classification of Functioning,Disability and
Health (ICF) as a conceptual framework for describing func-
tional impairments in patients. Despite the comprehensive
approach, the study has focused only on ICF categories of the
component activities and participation and has not taken into
account the other elements of the framework. Furthermore,
it has not included information regarding related variables of
psychosocial difficulties in depression.
To date, no study has analyzed the full set of PSDs
and their related variables in depression by including both
literature and patient perspective. The aim of the present
study is to tackle this research gap and discover whether the
recent scientific literature actually reports the PSDs and their
related variables that are important for depressed patients.
Our objective is to obtain information about whether the
latest literature extensively covers the issues that are pointed
out as problematic by depressed individuals, or if there are
particular areas, which should receive more attention. More-
over, a potential identification of these missing previously-
ignored questions in literature will enhance the quality of
future research and enable new strategies for treatment and
rehabilitation in depression.
2. Materials and Methods
In order to compare whether the psychosocial difficulties
experienced by depressed patients are actually reported by
recent literature in depression, we included a step by step
methodology.
2.1. Extraction of the Information. We gathered information
from three different studies.
2.1.1. Systematic Literature Review. First, a systematic review
to directly collect information reported in recent literature,
consulting the MEDLINE and PsycINFO databases, was
conducted. Search terms were adapted to each database
combining the MeSH headings of “Depression,” “Depressive
Disorder,” and “Depressive Disorder, Major” with “depress∗”
(title) in MEDLINE database and (DE=) “Major Depres-
sion,” “Recurrent Depression,” and “Depressive disorder”
in PsycINFO. For psychosocial difficulties the following
keywords were used: “psychosocial∗,” exp Quality of life/,
exp Personal satisfaction/exp Human activities/exp social
support/disabilit∗, homelessness, environmental factor∗, exp
Interpersonal relations/, exp Quality of life/, exp per-
sonal satisfaction/, exp human activities/, exp paternal-
ism/, prejudice/, psychosocial deprivation/, social values/,
exp Social Problems/, Social Adjustment/, social isola-
tion/stereotyping/, exp Social environment/, exp emotions/,
exp family/, exp socioeconomic factors/exp life style/exp
Disability evaluation/, exp Communication Barriers/, “Adap-
tation”, exp Psychological/, exp Aggression/, exp Psycho-
logical stress/, exp community (no microbial community)/,
Sexual∗ or intimacy. Inclusion criteria were articles reporting
information on psychosocial difficulties in people with a
diagnosis of major or minor depression according to DSM-
III-TR, DSM-IV, or DSM-IV-TR [14–16], or a depressive
episode or depressive disorders according to ICD-10 criteria
[17]. Qualitative articles and longitudinal observational and
interventional studies were also considered. Additional crite-
ria required the studies to be published in English between
2005 and 2010. Full results of the literature review can be
seen elsewhere [7]. Furthermore, studies were also excluded
if they were cross-sectional and psychometric or if they had
not included a standardized diagnosis of depression. Articles
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reporting patients with bipolar depression, dysthymia, or
postpartum depression were also excluded.
Once all the included studies were selected, we extracted
information about the sample characteristics and then col-
lected the variables, the tools, the psychosocial difficulties and
their related variables. Related variables in literature refer to
determinants of PSDs since only longitudinal studies were
included. Determinants in literature were those variables
that were longitudinal predictors for incidence or changing
of psychosocial difficulties, so consequently a causal rela-
tionship with the PSDs can be hypothesized. Extraction of
the information was double checked by two independent
reviewers in 20% of the articles (MC and BM) (Kappa =
0.80). Kappa’s coefficient was calculated according to Fleiss
and Cohen rules [20].
2.1.2. Focus Group. On the other hand, the collection of
patients’ perspectives was performed including information
from two studies. The first one consisted of one focus group
composed of seven depressed patients. We based our sample
size decisions on literature recommendations, “The ideal size
of a focus group formost noncommercial topics is five to eight
participants” [21] and the concern that a larger group could
make participants reserved or there would not be enough
time to hear everyone’s contribution. Inclusion criteria for
participating in the session were patients older than 18 years,
with a diagnosis of a depressive episode or a depressive
disorder according to ICD-10 during the last year. Eight
patients from the Hospital Universitario de la Princesa in
Madrid were invited to participate. Selection was done by
their main mental health care provider (psychiatrist) taking
into consideration the maximum variability of sampling in
gender, work status, and clinical status (totally remitted,
partially remitted, and nonremitted), consulting the patients’
clinical records. Eight patients were invited to participate
and one of them did not consent to participate reporting
having no time for this. Participation in this study was not
mandatory and only patients with motivation to participate
were included in the final sample; therefore a selection bias
could have affected our results. Participation was formally
agreed after signing a consent informed form.Onemoderator
and one assistant (MC and IL), who had been previously
trained, encouraged all themembers to participate during the
session.
Four open questions were posed: (1) which psychoso-
cial difficulties are usually experienced due to participant’s
depression; (2) which ones are more relevant (ranking the
five most important ones for each participant); (3) how
these difficulties changed overtime; and (4) which events are
responsible for the onset or change of these psychosocial
difficulties overtime. All the dialogues were digitally recorded
and subsequently transcribed.
2.1.3. Individual Interviews. Finally, in order to gather other
difficulties that are not usually reported during focus group
sessions because of potential unwillingness of self-disclosure
[22], we included data from 80 individual interviews. The
preselection of participants was done by their health care
providers (psychiatrist and GPs) according to the study
inclusion and exclusion criteria. All the patients that fulfilled
the inclusion criteria were invited to participate and pro-
videdbasic information (name and telephone) to researchers
to make an appointment. Only four patients did not agree
to participate. From these, two justifiedtheir denial with
the argument “I have no time to participate,” one had no
interest in research studies, and one showed no interest in
this particular study. During the initial interview researchers
verified the fulfillment of the inclusion criteria. At that point
five patients that were derived from the primary care center
were excluded because they met diagnostic criteria for other
different disorders: bipolar disorders (2), generalized anxiety
disorder (1), substance use disorder (1), and complicated grief
(𝑛 = 1) and thus satisfied one of the exclusion criteria.
Patients were singly asked, among other questions, which
were the five most disabling psychosocial difficulties that
they experienced due to depression and which were the
variables that were responsible for the onset or the change
of these problems. A causal relationship with the PSDs and
extraction of determinants, unlike in the literature, cannot
be established, because of the nature of the focus group and
the individual interviews; therefore we will refer to these
variables of onset or change of PSDs according to the patient
perspective as related variables.
Trained interviewers (MC, BM) conducted all the indi-
vidual interviews. Inclusion criteria for individual interviews
were patients older than 18 years with a diagnosis of depres-
sive episode or major depression criteria according to ICD-
10. All patients were collected in “Santa Hortensia” Primary
Care center of Madrid or in the outpatient psychiatric service
at the Hospital Universitario de la Princesa in Madrid. In
both study sites patients were chosen according to their
availability and were invited to participate by their primary
care doctors or psychiatrists. All participants signed an
informed consent form. Both studies were independently
reviewed and approved by the Hospital Ethics Committee for
Clinical Research.
2.2. Agreement on the Terminology to Describe PSDs and
Their Related Variables. After gathering information from
the three different studies, we needed to establish a com-
mon language necessary to directly compare outcomes. For
that purpose a list of common categories for classifying
psychosocial difficulties was agreed on during one research
group meeting. Participants were researchers who had been
involved in data collection for different health conditions.
Researchers involved in the data collection of depression (IL,
BM, and MC) also participated. All of them were requested
to share with the group the PSDs that they had identified in
the different studies and the terminology they had used to
name them. After each naming, the working group was asked
whether they agreed with the terminology proposed. After a
brief discussion, stating pros and cons for the proposal, an
agreed-on term was decided and documented for each PSD.
The same procedure was followed to extract the names of
related variables in subsequent working group sessions with
the same participants.
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2.3. Linking Process of Concepts. After obtaining the list of
common categories, we associated the different concepts
extracted in the studies to the agreed category list. For
personal factors we used the definition given by the WHO’s
International Classification of Functioning, Disability and
Health: “Personal factorsare the particular background of
an individual’s life and living, and comprise features of the
individual that are not part of a health condition or health
states. These factors may include gender, race, age, other
health conditions, fitness, lifestyle, habits, upbringing, coping
styles, social background, education, profession, past and
current experience (past life events and concurrent events),
overall behaviour pattern and character style, individual
psychological assets and other characteristics, all or any of
which may play a role in disability at any level. Personal
factors are not classified in ICF.” [10]. The liking process
was made by two independent researchers according to ICF
linking rules [23]. BM and MC participated in the linking
process for the focus group and literature review information
(Kappa = 0.92 and 0.88, resp.,) and KK and MC performed it
for individual interviews (Kappa = 0.85). Disagreements on
categories were solved consulting a third expert opinion.
2.4. Analysis of Data. Focusing on the information extracted
from the literature, a frequency analysis was performed
regarding how many different studies particularly reported
the psychosocial difficulties or related variables. In the case
of individual interviews, the number of times that the
different participants reported the psychosocial difficulties
and their related variables was calculated. Finally, for the
focus group, digital recordings were analyzed in order to
extract the number of times in which psychosocial difficulties
and related variables had been a topic during the session (i.e.,
number of times that these issues had been repeated by a
different participant). These analyses were performed with
the software for qualitative research NVIVO.
3. Results
3.1. Characteristics of the Participants in the Focus Group
and the Individual Interviews. Tables 1 and 2 show the
characteristics of the participants in the focus group and the
individual interviews.
3.2. Does Recent Literature Report the Main PSDs? Compari-
son between the literature review and the studies reporting
patient’s opinion showed that literature does cover almost
fully the main psychosocial difficulties directly addressed by
depressed individuals. There were relatively few PSDs, not
covered by the recent scientific literature. Table 3 summarizes
these outcomes.
Emotional functions [24–26], energy and drive functioning
[27–29], cognitive functions [30–32], employment [33–35],
and relationship with the others [36–38] were the most com-
mon psychosocial problems emerging both in the literature
and the patients’ answers.The frequency of the appearance of
PSDs was also comparatively identical.
However, somemain PSDs in the patient reports were not
covered enough by the literature. Carrying out daily routine
was pointed out by ten patients in the individual interviews
(making it the fifth most important PSD), but it has been
investigated less than three times in the revised literature.
Communication with others was among the most impor-
tant psychosocial problems, according to the participants
in the focus group, but our systematic review did not find
it mentioned anywhere in the literature. Moreover, weight
maintenance functions and doing houseworkwere highlighted
by the patients in the individual interviews, but literature
omitted them as significant and important psychosocial
difficulties in depression. In addition, there were some
main categories, which did not meet the same ranking of
significance when the different sources of information were
compared. Pain [39–41] and sleep [42, 43], for example,
were among the most important categories according to the
literature, but in the focus group and individual interviews
they were not emphasized notably by patients.
3.3. Specific PSDs. Regardless of these few above mentioned
PSDs, literature in general addresses substantially the main
psychosocial difficulties in depression. Therefore, we con-
ducted an elaborate second level analysis to investigate
whether the specific psychosocial difficulties (components
within the main PSD categories), reported in the focus
group and individual interviews, were also identified in the
literature. Once more, the results demonstrated that the
literature, with some exceptions, almost fully covers the range
of specific psychosocial difficulties, experienced by depressed
patients.
However, as can be seen in Table 4, some specific PSDs
were reported with different degrees of importance when
the three sources of information were compared. Loneliness
and distress (part of emotional functions) were among the
most important and commonly mentioned difficulties by
the patients, whereas these specific PSDs were reported less
than three times in the literature. The same is valid for
attention and memory (part of cognitive functions), efficiency
(employment), and intimate relationships (relationships with
others).
3.4. Does Recent Literature Report the Related Variables of
PSDs? Additionally, we investigated whether literature suffi-
ciently reports themost important related variables of change
and onset for psychosocial problems in depression that are
addressed by patients. All related variables can be seen in
Table 5. Literature reported only few related variables of onset
of PSDs. In fact, scientific literature reported clinical variables
and treatments above all. In contrast, the patients’ perspec-
tive, extracted by the focus group and individual interviews
we conducted, focused on how particular psychosocial dif-
ficulties lead to other PSDs. For instance, treatment [44–
46] was a related variable of change in several studies as
reported in literature, but participants in the focus group
identified it also as a related variable of onset for specific
PSDs. The same was valid for the role of the emotions in
change of PSDs, which was frequently indicated by literature,
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Table 1: Characteristics of the participants in the focus group.
Case Gender Age Work status Comorbidity Mental health status
1 Female 51 Retired Fibromyalgia Partial remission
2 Male 44 Self-employed No Total remission
3 Male 50 Employed Hepatitis C Partial remission
4 Female 50 Disabled Cancer Depression
5 Male 49 Unemployed No Partial remission
6 Female 46 Disabled Arthrosis Total remission
7 Male 55 Retired No Depression
whereas patients reported these emotional functions as a
cause of psychosocial difficulties as well. Specifically, results
showed that the literature did not analyse sufficiently cognitive
functions, relationships with others, energy and drive, and
employment problems as causes of PSDs.
4. Discussion
The current study aimed to analyse whether the recent
scientific literature reports those psychosocial difficulties
and their related variables that are important for depressed
patients. Our findings indicated that the literature does report
almost fully the main psychosocial difficulties, experienced
by patients with depression, but the degree of importance
of each PSD depended on the source of information. The
same refers to the specific PSDs, extracted by a second level
analysis. Contrary to themain PSDs reported, however, only a
few related variables of onset of PSDs were currently reported
in literature. In addition, literaturewas specifically focused on
clinical variables as related to the PSDs, whereas it ignored
that some PSDs can also become related variables for other
PSDs.
To our knowledge, this is the first study to throw light
on whether the latest scientific literature actually reflects the
issues that are indicated as problematic by depressed patients.
However, all the subsequent comments on the literature have
to be considered with respect to the only 103 existing studies
within our period of search that covered the whole spectrum
of PSDs in depression and the fact that their average quality
rate is not high [7]. In this sense, this amount of articles seems
insufficient, since the literature review aimed to identify a list
of studies examining a wide range of psychosocial problems
in depression. It is not in the scope of the current paper to
elaborate on this deficit, but, given the present results, it is
important to mention that besides the existing information
gaps in the specialized publications, the quantity of adequate
studies addressing the most common difficulties and related
variables represents an additional limitation in the literature.
With regard to the most common psychosocial difficul-
ties, the literature and the patients’ outcomesmatched almost
entirely. Emotional functions stood out as an evident problem
for depressed patients, as part of the outcomes of 62 research
studies and being mentioned more than 100 times during the
focus group and individual interviews. A review by Brockow
et al. [47], based on the ICF classification, confirms the notion
that the emotional functioning is among the most affected
areas of depression. A second level analysis, conducted
to examine the specific segments of the main categories,
however, showed some discrepancies between the litera-
ture and the patients’ perspective. Incongruence regarding
depressive mood and symptoms [48–50] (being highlighted
in literature whereas downplayed by patients) or feelings
of loneliness and distress (emphasized notably by depressed
patients but narrowly explored in the literature) can be
explained through the literature tendency to focus mainly on
those PSDs which belong to the symptomatology spectrum.
In addition, according to our results, the literature usually
reported major PSD concepts. However, other more specific
and smaller categories, also highly affecting the emotional
functioning of individuals—like loneliness and distress—were
neglected.
The same applies to other groups like cognitive functions,
where research studies have focused on capital subcategories
of the main PSDs, such as cognitive functions in general,
thought functions, employment in general, or relationshipswith
the others in general, but have not elaborated on smaller
features. According to the present results, patients emphasize
the importance of the specific problem they experience, even
if it is very distinctive anddifferential.Therefore, the literature
should include adequate instruments to address these par-
ticular psychosocial issues and encompass the most delicate
and uncovered features of the psychosocial functioning of
individuals with depression.
Furthermore, another interesting discrepancy between
research and patient perspective regarding the consideration
of pain and sleep as important PSDscan be noticed. Both
problems have been frequently emphasized by different
research studies as essential for depression, while only few
participants in the focus group and individual interviews
mentioned them as important. One possible explanation
is the hiatus in people’s perceptions between depression
and physical symptoms. Although somatic symptoms are
a common feature of depression [51], a substantial per-
centage of patients, diagnosed with depression, understand
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Table 2: Characteristics of the participants in the individual
interviews.
Variables Setting
Specialized care Primary care
(𝑛 = 61, 75.3%) (𝑛 = 20, 24.7%)
Age (𝑛 = 61) (𝑛 = 20)
18–34 4 (6.6%) 4 (20.0%)
35–49 14 (23.0%) 6 (30.0%)
50–64 29 (47.0%) 5 (25.0%)
65+ 14 (23.0%) 5 (25.0%)
Gender
Female 50 (82.0%) 17 (85.0%)
Level of education
Less than primary school 11 (18.0%) 3 (15.0%)
Primary school
completed 9 (14.8%) 4 (20.0%)
Secondary school
completed 5 (8.2%) 4 (20.0%)
High School 10 (16.4%) 4 (20.0%)
University 20 (32.8%) 2 (10.0%)
Postgraduate studies
completed 6 (9.8%) 3 (15.0%)
Work situation
Working 14 (23.0%) 8 (40%)
Working (sick leave) 9 (14.7%) 1 (5.0%)
Unemployed 18 (29.5%) 4 (20.0%)
Homemaker 8 (13.1%) 4 (20.0%)
Student 1 (1.6%) —
Retired 7 (11.5%) 1 (5.0%)
Disability pension 3 (4.9%) —
Others 1 (1.6%) 2 (10.0%)
Number of previous
depressive episodes (𝑛 = 48) (𝑛 = 80)
0 (first episode) 7 (11.5%) 3 (15.0%)
1-2 26 (41.7%) 11 (55.0%)
+2 15 (24.5%) 2 (10.0%)
Self-administered
Comorbidity Questionnaire
(SCQ) [18], MD (SD)
12.8 (5.1) 11.8 (5.1)
Hamilton Depression
Rating Scale-17 (HDRS)∗
(𝑛 = 59) (𝑛 = 20)
Mild 4 (6.6%) 11 (55.0%)
Moderate 13 (21.3%) 8 (40.0%)
Severe 42 (68.9%) 1 (5.0%)
Suicide attempts (𝑛 = 57) (𝑛 = 19)
No 48 (78.7%) 15 (75.0%)
Yes 9 (14.8%) 4 (20.0%)
∗Cutoff points based on [19].
both as separate entities. Moreover, they frequently indicate
only physical symptoms as the reason for seeking medical
assistance [52]. Therefore, many depressed outpatients in
the present studies might have omitted some physical com-
plaints, disregarding any association between them and their
depressive condition. Another reason could be the nature
of the commonly used outcome instruments in depression
studies. Most of them, such as the Hamilton Rating Scale
for Depression (HRSD) [53], the Short Form Health Survey
(SF-36) [54], or the WHOQOL-100 [55], include physical
symptom items. Therefore, outcomes such as pain and sleep
disturbances are often included in scientific studies. Further
qualitative studies should confirmwhether or not these PSDs
are really important for depressed patients, because in that
case literature might be overestimating their relevance in
depression.
Regarding the related variables of PSDs, the results of
our analysis revealed interesting and alarming gaps in the
recent literature. Essentially, only few related variables of
onset of PSDs were reported in research. Emotional functions,
for example, being the leading related variable of onset for
participants in the focus group, have been considered only as
a determinant of change in literature. The same applies for
treatment. Depressed patients very often stated that the cause
of their PSDs was the type of treatment they received. As can
be extracted from literature, however, treatment is only able
to change the course of the disease (generally as a facilitator).
Literature should therefore consider the positive and negative
consequences of treatments on patient’s PSDs and not only
report the positive impact on them.This type of information
would be useful to help clinicians decide among the wide
range of interventions available.
On the other hand, current scientific literature con-
centrates on clinical variables and treatments as the only
PSDs’ related variables, whereas patients additionally high-
light the relationships between different PSDs. Specifically, if
the patient perspective is considered, literature on cognitive
functions, relationships with others, energy and drive, and
employment problems as related variables of PSDs would
have to be described as insufficient. These components
are fundamental to the understanding of the psychosocial
functioning of depressed patients.Hence, if the aim is to reach
a general development in this direction, future research needs
to focus on these gaps.
Overall, these findings reveal the fact that there is a
discrepancy between the patient’s and the health science
researchers’ perspective when analysing not only the bio-
logical and psychological factors of depression, but also the
socioeconomic and environmental variables. The subject’s
view of his health and functioning is not usually taken into
account when designing research studies in depression. In
this sense, future studies may address this wider view in a
more accurate way by taking into account additional sources
that are primarily focused on the subject and its sociological
environment. From a sociological point of view it could
be claimed that the mainstream perspective from which
most institutions and professionals develop their work is not
reflecting the quotidian environmental stressors that interfere
with an adaptive and healthy development of everyday life
in people with depression. It could be hypothesized that
this is a result of the current and most common definition
of depression through a list of symptoms facilitated by
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Table 3: Ranking of the main psychosocial difficulties according to literature and patient reports.
Literature review (number of studies) [ICF
code]
Focus group (number of times the PSDs
were a topic)
[ICF code]
Individual interviews (number of people)
[ICF code]
(1) Emotional functions (62) [b152]
(2) Pain (20) [b280–b289]
(3) Energy and drive (18) [b130, b640]
(4) Cognitive functions (17) [b140–b189,
b117]
(5) Employment (13) [d845–d859]
(6) Relationship with others (13) [d7]
(7) Self-care (12) [d5]
(8) Sleep (11) [b134]
(9) Temperament and personality functions
(10) [b126]
(10) Perception and experience of social
support (7) [pf]
(11) Participation in social activities (6)
[d920]
(12) Self-perception (6) [pf]
(13) Psychopathological symptoms (5) [b160,
b147, b152, b130]
(14) Mobility (5) [d4]
(15) Locus of control (4) [pf]
(16) Psychomotor functions (4) [b147]
(17) Driving (3) [d475]
(18) Perception and experience of stigma (3)
[pf]
(19) Self-efficacy (3) [pf]
(20) Coping strategies (3∗) [pf]
(1) Emotional functions (49) [b152]
(2) Cognitive functions (11) [b140–b189,
b117]
(3) Employment (11) [d845–d859]
(4) Perception and experience of social
support (9) [pf]
(5) Self-perception (9) [pf]
(6) Energy and drive (8) [b130, b640]
(7) Communication with others (7) [d350]
(8) Participating in social activities (6)
[d920]
(9) Relationship with others (6) [d7]
(10) Coping strategies (5) [pf]
(11) Psychopathological symptoms (4) [b160,
b147, b152, b130]
(12) Self-care (4) [d5]
(13) Carrying out daily activities (3) [d230]
(14) Perception and experience of stigma (3)
[pf]
(15) Sleep (3) [b134]
(1) Emotional functions (52) [b152]
(2) Energy and drive (31) [b130, b640]
(3) Relationship with others (24) [d7]
(4) Cognitive functions (23) [b140–b189,
b117]
(5) Carrying out daily routine (10) [d230]
(6) Self-perception (8) [pf]
(7) Pain (7) [b280–b289]
(8) Employment (6) [d845–d859]
(9) Participating in social activities (5)
[d920]
(10) Sleep (5) [b134]
(11) Weight maintenance functions (5)
[b530]
(12) Mobility (5) [d4]
(13) Doing housework (3) [d640, d630]
∗Only PSDs addressed more than three times in the literature or mentioned more than three times by the participants in the focus group and the individual
interviews are shown here.
Table 4: Ranking of the specific psychosocial difficulties according to literature and patient reports.
Main PSD categories Literature review (number of studies) Focus group(number of times thePSDs were a topic)
Individual interviews
(number of persons
mentioned the PSD)
Emotional functions
Depressive mood and symptoms (54)
Anxiety (8)
In general (5)
Emotional regulation (3∗)
In general (20)
Anxiety (10)
Depressive mood and symptoms (7)
Loneliness (6)
Distress (4)
Depressed mood (14)
Anxiety (14)
Emotional regulation (9)
Loneliness (8)
In general (5)
Cognitive functions
In general (5)
Thought functions (5)
Executive functions (3)
Thought functions (6)
Attention (3)
Attention (10)
Memory (7)
Employment In general (10) In general (11) Efficiency (5)In general (3)
Energy and Drive
Fatigue (8)
Vitality (7)
Libido (3)
Motivation (3)
In general (8)
Motivation(3)
In general (10)
Fatigue (9)
Family (10)
Relationship with
others
In general (6)
Family (5) In general (6)
Intimate relationships (9)
In general (4)
∗Only PSDs addressed more than three times in the literature or mentioned more than three times by the participants in the focus group and the individual
interviews are shown here.
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Table 5: Related variables of psychosocial difficulties in literature and patient reports.
Literature review (type of determinant and
number of studies)
Focus group (number of times PSD was a
topic)
Individual interviews (number of
people mentioned with PSD)
Patient treatment (DC∗) (26)
Health condition: symptoms (DC) (16)
Health condition: severity (DC) (8)
Temperament and personality (DC) (6)
Comorbidity (DC) (5)
Perception and experience of social support
(DC) (5)
Patient treatment ∗ treatment duration (DC) (4)
Emotional functions (DC) (3)
Overall score: ADL (DC) (3)
Health condition: duration of episode (DC) (3)
Stressful life events (DC) (3)
Stigma (DO) (3)
Self-perception (DO) (3∗∗)
Emotional functions (RVO) (18)
Stressful life events (RVO) (7)
Employment (RVO) (7)
Cognitive functions (RVO) (7)
Perception and experience of social support
(RVO) (6)
Energy and drive (RVO) (5)
Temperament and personality (RVO) (4)
Self-perception (RVO) (4)
Comorbidity (RVO) (4)
Patient treatment (RVC) (4)
Self-perception (RVO) (4)
Patient treatment (RVO) (3)
Relationship with others (RVC) (29)
Patient treatment (RVC) (23)
Emotional functions (RVC) (19)
Stressful life events (RVC) (7)
Health condition: symptoms (RVC) (7)
Attitudes (RVC) (7)
Comorbidity (RVC) (6)
Energy and drive (RVC) (6)
Self-perception (RVC) (5)
Coping strategies (RVC) (4)
Participation in social activities
(RVC) (4)
Ageing (RVC) (3)
Cognitive functions (RVC) (3)
Employment (RVC) (3)
∗DC, determinant of change; DO, determinant of onset; RVC, related variable of change; RVO, related variable of onset.
∗∗Only PSDs addressed more than three times in the literature or mentioned more than three times by the participants in the focus group and the individual
interviews are shown here.
established diagnostic manuals: the DSM and ICD. They are
based on passive categorical labelling (mainly by health care
professionals), which list a number of prototype behaviours
that could occur if certain psychological problems occur.
This conceptualization within the medical model does not
take into account the life circumstances and biographical
context, which the individual interacts with, and thus the
psychological sense that provides the key to understanding
how this problem has been generated and why it remains is
disregarded.
The ICF model has been created by WHO as a comple-
mentary tool to the diagnostic systems (DSM and ICD) to
describe the day-to-day functioning of people. Within the
ICF model, psychosocial difficulties are seen as a continuum
and as a result of the complex interaction of environmental
variables, mental functions, personal variables, activities and
participation, and health status. Another option for person-
alization of medicine and treatment in real clinical settings
might be the inclusion of evaluations of daily functional
problems experienced by patients. Therefore we suggest cus-
tomization of healthcare—with therapeutic decisions being
tailored to the individual patient. The diagnostic testing has
to be adjusted accordingly for selecting appropriate therapies.
Eventually, engagement of patients in identifying specific
personal problems (e.g., dysfunctional patterns of emotional,
cognitive, and behavioural reactivity to natural environments
in daily life) could provide more personalized informa-
tion and change the pattern of diagnosing. For example,
ecological momentary assessments of patients via different
technologies, eventual self-monitoring, or even more collab-
orative interactions with therapists and professional carers
would enhance research in this direction and give us a new
insight. Recent literature based on ecological momentary
assessments (EMA) gives us promising results in this line.
Different studies [56, 57] have found the experience of pos-
itive affect to be prominent in resilience against depression
and to predict recovery [58]. Depression has been found to
influence work performance with significant decrease in task
focus and productivity [59]. Evidence shows that patients
with major depressive disorder experience fewer positive
events and perceive them as more stressful [60]. Among
adolescents, depressive symptoms have been found related to
less effective emotion regulation [61]. The EMA have been
implemented in research not only on depression, but also on
schizophrenia, anxiety, ADHD, bipolar disorder, and so forth.
Ecological momentary assessments have been initially
used to identify moment-to-moment patterns and mecha-
nisms of psychopathology [62], but with the development of
technologies and especially web based applications, real-life
data become available to patients and clinicians, making the
transformation of implicit real-life patterns into explicit ones
possible, thus improving personalized mental health care
[63].Themethod has been recently successfully implemented
in studies, aiming to explore whether self-monitoring can
also be used as an intervention to increase patients’ insights
in personalized patterns of positive affect [64]. The EMA
approach is just one promising way of overcoming the
discrepancy between the patient’s and the health science
researchers’ perspective when analysing the variety of factors
for depression. Its aim is not to replace the traditional face-
to-face contact with practitioners but to allow patients to take
an active role in their recovery process and to personalize the
treatment process.
Moreover, the patient perspective on PSDs and their
related variables has also an impact on the clinical arena.
Results of this study highlight the need for change and
adjustment of future strategies for treatment and rehabilita-
tion in depression. The process could be more productive,
when clinicians select interventions covering PSDs and their
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modifiable determinants or related variables, and not only
symptoms. Solving some activity problems, for example, can
help in improving other areas as well. Furthermore, per-
sonalization of therapies according to individuals’ PSDs will
enhance the treatment process. In general, identification of
specific interventions for particular psychosocial difficulties
is necessary and future research should address this issue.
4.1. Limitations. The findings of this study, however, have
to be interpreted assuming its limitations. First, only one
focus group of seven patients was performed and saturation
point—considering the quantity of information regarding
the analysed PSDs—was not reached; therefore the focus
group can be considered by some as nonrepresentative. As a
partial solution we included a heterogeneous group through
maximum sampling variation regarding sex, working status,
and clinical status. The age range, however, was between 44
and 55 years, which might have caused a potential bias in
the identification of PSDs. This is an important limitation,
since some psychosocial difficulties, usually experienced in
particular ages, like physical pain in older adults, or problems
with intimate relationships or loss of life goals in younger
adults, might have been omitted by the nonpresence of
representatives of these age groups in our focus group.
During the selection process, the psychiatrists who were
responsible for the recruitment of participants took into
consideration the maximum variability of sampling, but the
time frame and the profile of patients in the catchment
area of the Hospital Universitario de la Princesa in general
did not allow us to have a more representative sample in
terms of age. However, we decided to proceed with the
focus group, because, in fact, a more homogeneous sample of
participants is often preferable in terms of age, since it might
increase the group comfort level when discussing sensitive
topics. Therefore we could assess a wide variety of PSDs
including sexual problems, relationships with the therapist,
and somatic problems. Finally, in order to achieve more
reliable results, we conducted individual interviews with 80
patients ranging substantially in terms of age.Thereat, in spite
of this limitation, we found a high variability of PSDs and the
valuable finding about the discrepancies between literature
and patient reports. Further studies reaching saturation
points should be done to test if there are other underexplored
PSDs.
Second, a limited period of time was included for the
literature search (studies between 2005 and 2010).The search
was performed over papers published within the cited period
of time because of temporal limitations and because we were
interested in the recent literature outcomes rather than gen-
eral literature. However, we made replication of the original
search from 2011 to September 2013 in order to check if any
newPSDswill occur in comparisonwith the initial search and
the results did not identify newPSDs.The results of the review
have to be read in light of the limitations due to the type
of databases consulted. This review study was a component
of a larger project that gathered psychosocial factors from
severalmental health and neurological conditionswhere only
Medline and PsycINFO were included. As a consequence, an
amount of studies might have not been identified. As a limi-
tation concerning the reliability of the extraction process we
have to indicate that only 20% of articles were independently
double checked. Finally, by limiting our search to English
literature, we might have omitted relevant papers in other
languages.
5. Conclusions
The present study is, to our knowledge, the first to analyse
the full set of psychosocial difficulties and their related
variables in depression through the literature and the patient
perspective. We made an elaborate comparison between
both sources of information in order to verify whether
recent research literature reported all the PSDs and related
variables that are important for depressed patients and to
identify the existing gaps in this area. Regarding the research
on depression, the results obtained within our study show
the existence of many literature gaps and encourage future
studies to focus on them more in depth. Concerning the
clinical implications, this study emphasizes the need for
change and adjustment of future strategies for treatment and
rehabilitation in depression.We suggest that clinicians should
select interventions that cover PSDs and their modifiable
related variables and not only improve symptoms. Further-
more, eventual identification and personalization of therapies
according to individuals’ PSDs would potentially enhance the
rehabilitation process.
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1.5.3. Attempts for classification of psychosocial difficulties and limitations of 
current research 
 
 Classification of all relevant functional areas is needed to provide 
comprehensive information on the domains affected in depression. The above study 
by Kamenov et al. (2014) identified a large number of PSDs applied in the literature, 
but demonstrated that these areas are very general and related primarily to 
symptomatology. The study identified many gaps in current research mainly in the 
area of functional domains beyond symptoms.  
 There are several attempts for classification of psychosocial difficulties. The 
ICF Research Branch and the WHO developed an evidence-based Core Set for 
depression (Cieza et al., 2004) based on the ICF in an attempt to address the broad 
spectrum of functional limitations in individuals with depression. The set includes 45 
categories representing mental and body functions (more closed to symptomatology) 
and 48 covering different activities and social participation. The Core Set for 
depression, however, has not been sufficiently implemented in clinical research 
studies, perhaps due to its complexity or the great number of categories within 
(Alvarezz, 2012).  
 Apart from the ICF Core Set, there have been also other attempts for creating 
a universal instrument covering different areas of functioning in depression, but all 
of them are either limited or still in their infancy. The National Institute of Mental 
Health Affective Disorders Workgroup in USA created the Individual Burden of 
Illness Index for Depression (IBI-D) metric conceptualizing the individual burden of 
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illness to include symptom severity, impairment in functioning and reduction in 
quality of life (Cohen et al., 2013). However, the metric does not report domain-
specific information and has been validated in only one study. Zimmerman et al. 
(2013) developed a new instrument – The remission from Depression Questionnaire 
- to capture a more comprehensive array of domains considered by depressed 
patients relevant to remission. The instrument, however, has shown methodological 
weaknesses concerning its feasibility and validity. Thus, its broader usage in 
international research is limited. 
      Furthermore, two recently published studies evaluated the available 
instruments for measuring functioning in clinical trials. In search of an integrative 
measure of functioning, Madden et al. (2015) evaluated over 30 different commonly 
used instruments in literature using ICF as a reference, but did not find a generic 
measure of functioning relevant to people with a variety of functioning experiences, 
and capable of indicating support needs, progress and outcomes. The authors 
conclude that this failure has strong implications internationally for policy-relevant 
information for disability and rehabilitation. Later on, the Canadian Network for 
Mood and Anxiety Treatments together with representatives from clinical practice, 
professional societies, academia, industry, and government highlighted the lack of a 
gold standard tool for measuring functional capacities in depression as one of the 
research gaps in current literature (Lam et al., 2015).   
 Thus, despite the various attempts for a more comprehensive classification 
and assessment of psychosocial areas, literature is still limited and does not provide 
exhaustive information on the relevant affected areas in depression. A possible 
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reason for the limited coverage of relevant psychosocial areas in literature might be 
the narrowness and limitations of the available outcome measures. This, per se, 
questions the accuracy of the evidence and the measurement of treatment 
effectiveness in depression. These two research gaps are the main impetus for the 
present thesis.  
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2. OBJECTIVES 
 
General objective: To give an insight into the current measurement of treatment 
effectiveness for psychosocial functioning in depression and to provide 
recommendations for its improvement. 
 
Specific Objective 1: To provide an overview of the current assessment of treatment 
effectiveness for psychosocial impairment in depression. 
 To analyze which are the functioning outcome measures used in literature 
 To identify the gaps and the psychosocial areas addressed in literature 
 
Specific objective 2: To identify the efficacy of available interventions for 
psychosocial functioning in depression 
 To identify the absolute and relative efficacy of psychotherapeutic and 
pharmacological interventions on functioning and quality of life in depression 
 To identify the absolute and relative efficacy of Cognitive Behavioral 
Therapy on functioning and quality of life in depression 
 To critically review the level of evidence that current measures of 
functioning used in clinical trials for depression are providing  
 
Specific Objective 3: To provide empirical evidence for further improvement of 
treatment effectiveness measurement in depression 
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 To test if the psychosocial areas affected in depression have different level of 
importance in terms of their impact on quality of life 
 To test in an empirical study the cross-national commonalities across 
functional domains and the feasibility of a universal outcome measure for 
psychosocial functioning. 
 To obtain the perspectives of representatives of clinical practice and patients 
experiencing depression on the effectiveness of the available interventions for 
depression on psychosocial functioning. 
 
Specific objective 4: To provide research recommendations for improving 
measurement of treatment effectiveness in depression based on the comparison 
between current scientific literature, empirical evidence, and the perspectives of 
representatives from clinical practice and patients with depression. 
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2. OBJETIVOS  
 
Objetivo general: Informar sobre el estado de la medición actual de la efectividad de los 
tratamientos en la depresión y proporcionar recomendaciones para su mejora 
 
Objetivo específico 1: Proporcionar una visión general de la evaluación actual de la 
efectividad de los tratamientos en la mejora del deterioro psicosocial en la depresión. 
 
• Analizar cuáles son los instrumentos de funcionamiento usados  en la literatura clínica 
• Identificar  las áreas psicosociales abordadas en la literatura y cuáles son las áreas que 
no son tan abordadas por la misma 
Objetivo específico 2: Identificar la eficacia de las intervenciones en el funcionamiento 
psicosocial en la depresión 
 
• Identificar la eficacia absoluta y relativa de las intervenciones psicoterapéuticas y 
farmacológicas sobre el funcionamiento y la calidad de vida en la depresión 
• Identificar la eficacia absoluta y relativa de la terapia cognitivo conductual en el 
funcionamiento y la calidad de vida en la depresión 
• Revisar de forma crítica el tipo de evidencia que las medidas actuales de 
funcionamiento utilizadas en los ensayos clínicos de la depresión están proporcionando 
 
Objetivo específico 3: Proporcionar conocimiento empírico para la mejora de la 
medición de la efectividad de los tratamientos en la depresión 
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• Verificar  si las áreas psicosociales afectadas en la depresión tienen diferentes niveles 
de importancia en términos de su impacto sobre la calidad de vida 
• Poner a prueba en un estudio empírico la concordancia de los dominios funcionales 
entre países y la viabilidad de una medida de funcionamiento psicosocial universal  
• Obtener el punto de vista de los clínicos expertos en el tratamiento de pacientes con 
depresión  y la de los pacientes con depresión sobre la eficacia de las intervenciones 
disponibles para la depresión en el funcionamiento psicosocial. 
 
Objetivo específico 4: Aportar recomendaciones para mejorar la medición de la 
efectividad de los tratamientos en la depresión basadas en la comparación entre la 
literatura científica actual, la evidencia empírica, y las perspectivas de los clínicos y los 
pacientes con depresión. 
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3. HYPOTHESES 
 In the context of depression, some issues remain unclear with regard to the 
true effectiveness of different interventions on the overall psychosocial functioning 
of individuals. It is essential to add empirical evidence to the existing body of 
epidemiological literature in terms of investigation of the existing evidence, 
identification of limitations and provision of recommendations for improving the 
measurement of treatment effectiveness in depression.  
 The specific hypotheses corresponding to the objectives of this thesis 
dissertation are: 
Hypothesis 1: Scientific literature puts emphasis on symptomatic outcomes and 
neglects other psychosocial areas beyond symptomatology 
Hypothesis 2: Clinical trials applying functional outcome measures are scarce 
Hypothesis 3: Available psychotherapeutic and pharmacological interventions for 
depression are more efficacious for reducing symptom severity than improving other 
psychosocial areas beyond symptomatology  
Hypothesis 4: Psychosocial domains have differential impact on the quality of life 
of individuals with depression 
Hypothesis 5: There is a cross-national variability in the impact of different 
psychosocial domains on quality of life in depression 
Hypothesis 6: Clinicians and patients provide different and a more comprehensive 
array of psychosocial difficulties affected in depression compared to the ones applied 
in literature 
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3. HIPÓTESIS 
 
  En el contexto de la depresión, algunas cuestiones relativas a la verdadera 
efectividad de las diferentes intervenciones sobre el funcionamiento psicosocial global de 
los individuos siguen sin estar claras. Es esencial agregar evidencia empírica al conjunto 
existente de la literatura epidemiológica en relación a la investigación de las pruebas 
existentes, la identificación de las limitaciones y la provisión de recomendaciones para la 
mejora de la medición de la efectividad de los tratamientos en la depresión. 
  Las hipótesis específicas que corresponden a los objetivos de esta tesis son: 
Hipótesis 1: La literatura científica pone énfasis en los resultados sintomáticos, no 
abordando otras áreas psicosociales diferentes de la sintomatología 
Hipótesis 2: Los ensayos clínicos que aplican como medidas de resultado, instrumentos 
de funcionamiento, son escasos 
Hipótesis 3: Las intervenciones psicoterapéuticas y farmacológicas para la depresión son 
más eficaces a la hora de reducir la gravedad de los síntomas depresivos que a la hora de 
mejorar otras áreas psicosociales más allá  de la sintomatología depresiva 
Hipótesis 4: La afectación de unos dominios psicosociales y no otros tendrá un diferente 
impacto y relevancia en la calidad de vida de las personas con depresión 
Hipótesis 5: Hay una variabilidad entre países en el efecto que tienen diferentes 
dominios psicosociales en la calidad de vida en las personas con depresión  
Hipótesis 6: Los médicos y los pacientes proporcionan una gama diferente y más amplia 
de dificultades psicosociales afectadas en la depresión en comparación con las analizadas 
en la literatura 
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4. METHODS 
 This thesis is based on a multi-informant approach, including data from a 
systematic literature review, two meta-analyses, a multi-country cross-sectional 
study, an online survey with expert clinicians in the field of depression, and 
individual qualitative interviews with patients having depression (figure 2). The 
systematic literature review is essential for exploring the current status quo of 
scientific research and identifying the gaps and the areas addressed in studies. The 
two meta-analyses provide comprehensive information on the efficacy of different 
interventions on psychosocial functioning, but also serve as a basis for critical 
review of the level of evidence of the efficacy of treatments. The empirical study 
includes data on functioning from nine low-, middle-, and high-income countries and 
provides excellent opportunity for investigating cross-national differences in 
psychosocial areas affected by depression, and for identification of the most 
burdensome functional areas. Clinical experts opinion is essential for informing the 
context of clinical research and necessary to overcome the gap between clinical 
research and the care of individual patients (Tonelli, 1999). On the other hand, 
qualitative research with patients living with a mental disorder was identified as one 
of the research priorities for public mental health in Europe (Forsman et al., 2015). 
Obtaining the patient perspective provides a fundamental knowledge on the 
complexity of public mental health and enhanced understanding of the community 
context.  
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Figure 2. Methodological plan of the thesis 
 
RESEARCH RECOMMENDATIONS FOR IMPROVING MEASUREMENT OF 
TREATMENT EFFECTIVENESS IN DEPRESSION 
COLLECTION OF EMPIRICAL EVIDENCE FOR FURTHER IMPROVEMENT 
OF TREATMENT EFFECTIVENESS MEASUREMENT IN DEPRESSION 
 
MULTI-COUNTRY STUDY 
To identify cross-national 
differences in psychosocial 
impairment 
 
 
QUALITATIVE STUDY 
To obtain the perspective of 
patients experiencing depression 
on treatment effectiveness 
 
EXPERT SURVEY 
To obtain the perspective of 
representatives of clinical practice 
on treatment effectiveness 
IDENTIFICATION OF LIMITATIONS 
CURRENT MEASUREMENT OF TREATMENT EFFECTIVENESS IN 
DEPRESSION 
SYSTEMATIC LITERATURE REVIEW 
To analyze which are the functioning outcome 
measures used in literature 
To identify the gaps and the psychosocial areas 
addressed in literature 
META-ANALYSES 
To identify the efficacy of available interventions on 
psychosocial functioning in depression 
To critically review the level of evidence that current 
measures of functioning provide  
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4.1.  Current measurement of treatment effectiveness in depression 
4.1.1. Summary of methodology of a systematic literature review 
  Studies were included if (1) participants were older than 18 years, (2) the 
diagnosis was established by a standardized diagnostic tool including major 
depressive episode, major  depressive disorder or dysthymic disorder according to 
Diagnostic and Statistical Manual of Mental Disorders DSM-IV, DSM-IV-TR or 
DSM-5 criteria (American Psychiatric Association, 1994; American Psychiatric 
Association, 2000; American Psychiatric Association, 2013), or a depressive 
episode, recurrent depressive disorder or dysthymia according to the International 
Classification of Diseases, 10th edition criteria (World Health Organization, 1992), 
and (3) the sample included at least 10 participants. 
  Randomized controlled trials, quasi-experimental studies and longitudinal 
observational studies were included. Interventions were grouped in three main 
categories: psychotherapy, pharmacotherapy and complementary and alternative 
medicine therapies (Patten et al., 2009). Customized electronic search for studies 
assessing interventions in depressive disorders was performed in four databases – 
PsycINFO, PubMed, Web of science, and the Cochrane Central Register of 
Controlled Trials for studies published in English from January 2005 to January 
2014. Studies were identified by combining terms indicative for intervention: 
intervention* OR *therapy OR treatment OR pharmacotherapy OR psychotherapy 
OR behavior therapy OR cognitive analytic therapy OR cognitive behavior therapy 
OR cognitive behavior therapy OR counseling OR family therapy OR marital 
therapy OR psychoanalytic therapy OR psychoanalysis OR psychodynamic OR 
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social Skill OR relaxation therapy OR yoga OR homeopathy OR medication OR 
reminiscence OR life review OR rehabilitation; depression: Depression/ 
Depressive/Major Depressive disorder [MeSH]; and functioning: psychosocial* OR 
Quality of Life OR Life Satisfaction OR Unemployment OR Employability OR 
Reemployment OR Retirement OR Traveling OR Leisure Time OR Exercise OR 
Physical Activity OR Physical Fitness OR Driving Behavior OR Aggressive Driving 
Behavior OR Driving Under the Influence OR Activities of Daily Living OR Social 
Support. The reference lists of included articles and relevant systematic reviews 
were also checked manually for additional studies. 
  Content analysis was done after all individual items from the outcome 
instruments were extracted and linked to the ICF by applying the established linking 
rules (Cieza et al., 2005). The linking process was done by two researchers. In order 
to identify gaps in the measurement of treatment effectiveness, the list of functional 
areas extracted was compared to the ICF Core Set for depression (Cieza et al., 2004). 
The ICF Core Set includes 45 categories representing mental and body functions 
(symptomatology) and 48 from the component Activities and Participation. The 
comparison between our results and the ICF Core Set allowed us to identify all the 
functional areas that were selected as crucial for persons living with depression but 
not considered in the treatment effectiveness measurement process. 
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4.1.2. Meta-analysis on the efficacy of psychotherapy, pharmacotherapy and their 
combination for functioning and quality of life in depression: Summary of 
Methodology 
  Methods and results were presented according to the PRISMA statement for 
reporting systematic reviews (Moher et al., 2010). A systematic literature search 
combining the terms depressive disorder OR depression OR major depressive 
disorder (MeSH terms) AND functioning OR disability OR disability evaluation OR 
disabled persons OR sick leave OR activities of daily living OR leisure activities OR 
quality of life AND treatment OR intervention OR clinical trial OR therapy (MeSH 
terms, key words and text words) was performed in Pubmed, PsycINFO and the 
Cochrane Central Register of Controlled Trials. In the first two databases, the 
relevant option was selected to limit the search to Randomized Controlled Trials.  
  The review included all randomized controlled trials that compared 1) 
psychotherapy or pharmacotherapy against treatment as usual (TAU), placebo, 
waiting list (WL) or other control group, 2) psychotherapy against pharmacotherapy 
or 3) the combination of psychotherapy and pharmacotherapy against either one. All 
studies had to report at least one validated outcome measure assessing functioning 
(any difficulty experienced in maintaining daily activities or participation in social 
life (Lam et al., 2015) or quality of life (one’s satisfaction with these activities and 
perception of his/her health (IsHak et al., 2002; World Health Organization Quality 
of Life Group, 1997).  The diagnosis of depression had to be established by a 
standardized diagnostic interview according to ICD or DSM criteria (American 
Psychiatric Association, 1980, 1987, 2000; World Health Organization, 1992). Four 
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criteria of the Cochrane Collaboration risk of bias tool were used for assessing 
methodological quality of the studies — sequence generation, allocation 
concealment, blinding of assessors, and incomplete outcome data (Higgins et al., 
2011).  
  Statistical analyses were performed using the program Comprehensive Meta-
Analysis, version 2.0. The effect size for each individual meta-analysis was 
calculated, aggregating the pooled difference between the two groups of treatments 
at the end of the intervention. Hedges’ g was preferred as an effect estimate because 
of its capability to provide a better effect estimate for small sample sizes (Deeks et 
al., 2008). Publication bias was assessed in each of the meta-analyses by visual 
inspection of the funnel plots and the trim-and-fill procedure to analyze the changes 
after the accounting for publication bias (Duval and Tweedie, 2000).  
  Sensitivity analyses were performed to detect differences between studies 
with higher and lower quality. Since the selected studies were heterogeneous with 
respect to comparator groups, study populations, included interventions and outcome 
measures, series of subgroup analyses were performed. We examined whether there 
were differences in terms of age groups (adults vs. older adults), psychotherapies 
(CBT, IPT, PST), others), medication (SSRIs, SNRIs, TCAs, others), control groups 
(WL, TAU, Placebo, others), outcome measures and types of depression (Major 
Depressive Disorder, Dysthymia, Subthreshold depression, others). For the 
continuous moderators, simple meta-regression analyses were performed to explore 
whether 1) there was a relationship between the effect sizes of functioning or quality 
of life and severity of symptoms, 2) sample size had an impact on the estimates, 3) 
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the year of publication was associated with the effect estimates and 4) the amount of 
psychotherapeutic sessions or dosage of medication were relevant. 
4.1.3. Meta-analysis on the efficacy of Cognitive Behavioral Therapy for 
functioning and quality of life in depression: Summary of Methodology 
  Methods and results are presented according to the PRISMA statement for 
reporting systematic reviews (Moher et al., 2010). A systematic literature search 
combining the terms depressive disorder OR depression OR major depressive 
disorder (MeSH terms) AND functioning OR disability OR disabled persons OR 
sick leave OR activities of daily living OR leisure activities OR quality of life AND 
treatment OR intervention OR clinical trial OR therapy (MeSH terms, key words and 
text words) was performed in Pubmed, PsycINFO and the Cochrane Central Register 
of Controlled Trials. The search in the first two databases was limited to randomized 
controlled trials. Terms specifically related to cognitive behavioural therapy were not 
included to guarantee the inclusion of any possible relevant study applying CBT but 
not as a central topic.  Articles, published in English between January 2000 and 
August 2015 were considered.  
 Manuscripts were included if they met the following criteria: 1) use of a 
randomized controlled research design; 2) inclusion of a CBT treatment arm (CBT 
had to include at least cognitive restructuring and behavioural activation procedures 
for depression); 3) inclusion of participants aged 18 or more; 4) report of at least one 
validated outcome measure assessing functioning or quality of life (functioning was 
defined as any difficulty experienced in maintaining daily activities or participation 
in social life (Lam et al., 2015), whereas QoL as one’s satisfaction with these 
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activities and perception of one’s health (IsHak et al., 2002; World Health 
Organization Quality of Life Group, 1997)); 5) diagnosis of depression, established 
by a standardized diagnostic interview according to DSM-IV, DSM-IV-TR and ICD-
10 criteria (American Psychiatric Association, 1994; American Psychiatric 
Association, 2000; World Health Organization, 1992). Four over six criteria of the 
Cochrane Collaboration risk of bias tool were used for assessing methodological 
quality of the studies —sequence generation, allocation concealment, blinding of 
assessors, and incomplete outcome data (Higgins et al., 2011).  
 All statistical analyses were performed using the program Comprehensive 
Meta-Analysis, version 2.0. The effect size for each study was calculated 
aggregating the pooled difference between the two groups of treatments at the end of 
the intervention. Hedges’ g was preferred as an effect estimate because it provides 
better effect estimate for small sample sizes (Deeks et al., 2008). Statistics were 
based on intention-to-treat (ITT) data, but when missing, on completer data. Due to 
the inclusion of a wide range of outcome measures, sensitivity analyses were 
performed to assess whether one single instrument had a strong impact on the overall 
effect size. The following subgroup analyses were performed in order to examine 
whether certain characteristics of the studies were related to the effect sizes: 1) 
differences between age groups (adults vs. older adults); 2) delivery format (face-to-
face vs. internet or telephone delivered CBT); 3) differences in the control group 
(WL or TAU); 4) quality of studies (high vs. lower quality; ITT vs. completer 
data).In addition, simple meta-regression analyses were performed to explore 
whether 1) there was any association between the effect size of depressive symptoms 
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and the estimates of functioning and quality of life, 2) sample size had an impact on 
the estimates, and 3) the amount of psychotherapeutic sessions were important. 
Publication bias was assessed by visual inspection of funnel plots and the trim-and-
fill procedure to analyze the changes after the accounting for publication bias (Duval 
and Tweedie, 2000).  
4.2.  Identification of limitations and collection of empirical evidence for 
further improvement of the measurement of treatment effectiveness in 
depression 
4.2.1. Empirical multi-country cross-sectional study: Summary of methodology 
  For this study, data obtained from the World Health Organization’s (WHO) 
Study on Global Ageing and Adult Health (SAGE) and the Collaborative Research 
on Ageing in Europe (COURAGE in Europe),  two multi-country projects conducted 
between 2007 and 2012 (Kowal et al., 2012; Leonardi et al., 2014). The COURAGE 
survey was conducted in Finland, Poland, and Spain, whereas the SAGE survey was 
undertaken in China, Ghana, India, Mexico, the Russian Federation, and South 
Africa. The selected countries represent different geographical locations and levels 
of socio-economic and demographic status. Both projects collected data on 
participants aged 18+ years, with an emphasis on people aged 50+ years, from 
nationally representative samples. The sample comprised 4051 non-institutionalized 
adults (18+) who were currently experiencing an episode of depression from China 
(296), Ghana (428), India (1522), Mexico (291), Russia (321), South Africa (168), 
Poland (288), Finland (136) and Spain (601). Informed consent from all participants 
was obtained. Ethical approval was obtained from the WHO Ethical Review 
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Committee for SAGE and by Neurological Institute Besta for COURAGE, and by all 
local ethics research review boards.  
  Participants who had been diagnosed with depression by a physician and had 
been receiving treatment during the last 12 months were included in the study. In 
addition, since there are many cases of undiagnosed persons who actually experience 
depressive episodes (Sheehan, 2004; Volicer, 2011), we assessed depression with a 
set of symptomatic questions derived from the World Mental Health Survey version 
of the Composite International Diagnostic Interview (CIDI) for depression (Kessler 
and Ustun, 2004). The individual items were included in a diagnostic algorithm 
generating a diagnosis of “depressive episode” according to the criteria specified in 
the International Statistical Classification of Diseases and Related Health Problems, 
10th revision, Diagnostic Criteria for Research (World Health Organization, 1992).  
  Functioning was assessed with a multi-domain measure (Salomon et al., 
2003), previously used in 70 countries from the World Health Survey (Salomon et 
al., 2003), assessing the following 8 functioning domains: mobility, self-care, 
cognition, pain, interpersonal activities, domestic life and work, sleep and energy, 
and affect. Quality of life was assessed using a short version of the WHO Quality of 
Life (WHOQOL) instrument (Power, 2003; Skevington et al., 2004). Country, age, 
sex, marital status, presence of comorbid physical chronic conditions (angina, 
hypertension, asthma, arthritis or diabetes) and level of education were included in 
the analysis as control variables. 
  To examine the independent contributions of all domains of functioning on 
QoL, a multiple regression analysis was conducted. Age, sex, country, marital status, 
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comorbidity and educational level were introduced as covariates to control for 
potential confounders. In addition, the analysis was carried out on the entire sample 
of depressed individuals, on men and women and on each country separately. 
Standardized (β) coefficients indicated the level of association between the 
functioning domains and the covariates and QoL, since (β) can be applied as effect 
size in regression models. STATA version 11.0 (Stata Corp, 2009) was used to 
analyse the socio-demographic data, to calculate the factor scores and to conduct the 
regression models. Amos version 22 (Arbuckle, 2013) was used for the confirmatory 
factor analyses.  
4.2.2. Online expert survey: Summary of Methodology 
  The online survey was available between March 2015 and March 2016. It 
was designed to collect data from practicing clinicians in the field of depression 
on the interventions used in their daily practice and the psychosocial 
difficulties addressed by these treatments. The short survey consisted of two 
questions: 1) “Choose the type of intervention(s) you usually use in your daily 
practice”; and 2) “List the psychosocial difficulties that this intervention(s) aims to 
improve in individuals with depression”. Participants could choose up to 10 
interventions. The aim was to obtain experts’ opinion on the areas that are captured 
by the specific treatments and that should be included in the assessment of 
interventions for depression. All the answers concerning psychosocial difficulties 
were linked to the ICF categories according to the existing rules (Cieza et al., 2005). 
Demographic data was also collected.  
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  To reflect different opinions and achieve a maximum variation sampling, a 
wide range of clinicians was approached - psychiatrists, psychotherapists, primary 
health care doctors, social workers, nurses and physicians amongst others. Selection 
of experts was based on available people within a purposive sampling. The clinicians 
were selected according to the following criteria: 1) at least 2 years of clinical 
expertise treating people with depression; 2) variability by age, gender, nationality 
and type of therapy used in daily practice. In addition, only European experts were 
approached, but for comparison purposes data from non-European experts were also 
collected. Potential participants were identified through a number of sources: internal 
data bases of international experts working in depression; heads of departments of 
psychiatric hospitals and departments, professional websites for clinicians working 
in depression (e.g. www.commonlanguagepsychotherapy.org), and though a 
snowball approach. Experts were sent an email invitation for participation in the 
survey. We expected a 50-70% of non-response (Archer, 2008; Horgan and 
Dimitriou, 2015). Our target was to obtain a sample of 100 experts; therefore the 
survey was sent to nearly 250 worldwide experts in depression.  
4.2.3. Qualitative interviews with patients with depression: Summary of 
methodology 
  Unstructured qualitative individual interviews with outpatients diagnosed 
with depression were performed. The aim of the study was to collect data from 
individuals living with depression on the treatments they receive/have received for 
depression and the psychosocial difficulties addressed by the interventions. 
Participants had to meet the following inclusion criteria: 1) current or experience of 
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depressive episode in the previous 12 months as main diagnosis - depressive episode 
(F32.), recurrent depressive episode (F33), or currently in partial or total remission 
(F33.4) according to the International Classification of Diseases (World Health 
Organization, 1992); 2) enough cognitive capacity to participate in an interview 
(score > 26 in the mini-mental status examination (MMSE) (Folstein et al., 1975); 3) 
knowledge of local language (Spanish); 4) age ≥ 18 years; 5)  currently receiving 
treatment for depression, namely psychotherapy, pharmacotherapy or other treatment 
prescribed by their mental health professional, 6) to be informed of the purpose and 
rationale of the study, and have understood both; and to sign the patient consent 
form. Ethics approval was obtained by the “La Princesa” Hospital Ethics Committee 
for Clinical Research in Madrid. 
  The recruitment of participants and data collection was performed in a public 
outpatient mental health unit in Hospital la Princesa (Madrid, Spain). Collection was 
done by two mental health professionals working in the unit (one psychologist and 
one psychiatrist) between September 2015 and March 2016. All patients who met the 
inclusion criteria were informed about the study and invited to participate. All 
participants who agreed to participate gave their consent. The study consisted of a 
face-to-face interview with one research team member and comprised of two parts. 
The first part was series of demographic and clinical questions, which aimed to 
recollect information on the patients’ background. Data on gender, age, type of 
depression, number of previous episodes, onset of the disorder, occupation, etc. was 
collected. The second part assessed the type of treatment (psychotherapeutic, 
pharmacological or others) patients had received or were receiving, and their 
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experience being under treatment. During an open personal interview, participants 
were asked about the psychosocial difficulties they experience, and the ones that 
were improved/not improved by the specific treatment they received.  
  Data collection continued until reaching a saturation point—when the 
collection of new data did not shed any further light on the investigation we stopped 
with the recruitment process (Glaser and Strauss, 1967). More specifically, we 
defined one major rule for determining saturation – when three consecutive patients 
under the same group of treatment do not report a new psychosocial difficulty that 
has not been mentioned before. Medication usage was allowed in the cases receiving 
psychotherapy only if the dosage had not been changed one month prior to the start 
of the psychotherapeutic sessions or during the psychotherapeutic treatment. In order 
to assess the true effects of antidepressants on the overall condition of depression, 
only patients who had initiated the medication treatment at least three months before 
the start of the psychotherapy were included.  
  The recording of the individual interview session was transcribed verbatim. 
The transcript was checked by the moderator and the information was extracted and 
double checked. All the contents concerning psychosocial difficulties were translated 
into English and coded according to ICF categories following the ICF existing 
linking rules (Cieza et al., 2005). Codification of themes and subthemes for both 
interventions and psychosocial difficulties was double checked by an independent 
researcher and analyzed by NVIVO program, version 11, following content-analyses 
theory (Mayring, 2014). All frequencies were analyzed with SPSS, version 21. 
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4.3. Research recommendations for improving treatment effectiveness 
measurement in depression 
  This thesis dissertation will present a set of final recommendations for 
improving measurement of treatment effectiveness in depression by linking the 
limitations identified in the systematic literature review and two meta-analyses to the 
empirical evidence collected from the cross-national study, expert survey and 
qualitative interviews with patient.  
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5. RESULTS 
5.1.  Overview and evaluation of the current evidence for the measurement of 
treatment effectiveness on psychosocial impairment in depression 
  The first part of the Results section is dedicated to the findings of the 
evaluation of current measurement of treatment effectiveness in depression, 
collected from the systematic literature review and the two meta-analyses. A brief 
summary of the results and the weaknesses identified in the papers is presented 
before the articles. For further information consult full-text articles. 
5.1.1. Summary of findings 
 The effectiveness of all available interventions for depression is assessed 
mainly in terms of reduction of clinical symptoms, whereas other areas of 
functioning are neglected.  
 Every study analyzed in the systematic review applied at least one measure of 
severity of symptoms, but only less than 20% of all questionnaires addressed other 
areas of functioning.  
 Areas of functioning such as interpersonal relationships (family and partner 
relationships, informal relationships with friends), leisure activities, daily tasks and 
demands, major life areas, such as employment or education, were neglected in 
literature 
 Psychotherapeutic and pharmacological interventions were efficacious for 
improving psychosocial functioning, but the effect sizes were modest 
 All interventions performed better at reducing symptom severity compared to 
improving areas of functioning beyond symptomatology 
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 There was a lack of available studies to perform some of the analyzes  
 The instruments were heterogeneous and addressed different areas of 
functioning 
 Few studies reported long-term effectiveness of interventions 
 Studies reported sum-scores rather than domain-specific information 
Personalized information on the effectiveness of specific treatments on specific areas 
of functioning or particular group of individuals could not be obtained 
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In spite of all evidence based treatments, unipolar depressive
disorders still represent a huge burden to society and health ser-
vices (Chisholm et al., 2004). Statistical data show that 11% of EU
citizens experience depression at some point in their lives (Eur-
opean Pact for Mental Health and Well-being, 2008) and it is the
second leading cause for disability worldwide (Ferrari et al., 2013).
Previous studies on global burden of disease underline the
importance of functioning in all disorders (Murray and Lopez,
1996; World Health Organization, 2004). More speciﬁcally, the
reports on depressive disorders particularly point out the negative
impact of depression on person's functioning as one of the reasons
for the public health priority given to the disease (Ferrari et al.,
2013; Ustun et al., 2004). Functioning embraces not only impair-
ment of mental or body functions, indicating symptomatology
according to DSM and ICD diagnostic tools (American Psychiatric
Association, 2000; World Health Organization, 1992), but also ac-
tivity limitations or participation restrictions in domains of life,
such as social functioning, daily activities, etc. (World Health Or-
ganization, 2001).
Existing meta-analyses on the effectiveness of interventions in
depression focus primarily on outcome measures that address
symptoms, such as the Hamilton Depression Rating Scale (HDRS)
(Hamilton, 1960), Beck Depression Inventory (Beck et al., 1961), or
Montgomery Asberg Depression Rating Scale (Montgomery and
Asberg, 1979). More speciﬁcally, full remission, deﬁned as a sig-
niﬁcant reduction in the number of symptoms, is considered the
optimal outcome in clinical research (Keller, 2003).
However, many studies have reported that other functional
areas beyond speciﬁc symptoms, like interpersonal problems,
communication difﬁculties, or problems in mobility and self-care
are also relevant for depression (McKnight and Kashdan, 2009)
and might even predict more accurately the clinical course of the
disorder (Stefos et al., 1996). Nevertheless, instruments assessing
those areas of functioning, if considered, are mostly secondary
outcomes and barely accounted for systematic analyses (Williams
et al., 2000). Thus, a possible reason for the continuous burden of
the disease might be that the evidence on which the guidelines for
depression are built does not consider relevant functional pro-
blems for the disorder. Moreover, some authors point out that this
lack in evidence might explain to some extent why treatment
guidelines are not so widely implemented in mental health care
settings (Drake et al., 2001).
A review by Brockow et al. (2004) was conducted to identify
the concepts contained in outcome measures of trials on depres-
sive disorders. The content analysis revealed that more than 80% of
all functional areas covered in literature represented symptoma-
tology. Activities of daily functioning or participation in life si-
tuations were under-represented in the assessment of treatment
effectiveness in depression.The current study was set to analyze whether the way of
measuring treatment effectiveness in depression has changed and
incorporated all relevant functional areas ten years after the
publication of the Brockow’s study and the second global burden
of disease report, in which depression was marked as the ﬁrst
cause of disability by 2030 (Brockow et al., 2004; World Health
Organization, 2004). Our overall objective was to identify which
areas are addressed and what are the gaps in the measurement of
treatment effectiveness in depression. The study particularly
aimed to (1) identify the instruments used as outcome measures
of effectiveness in studies assessing psychotherapeutic, pharma-
cological, and complementary and alternative interventions;
(2) analyze the functional areas addressed in the instruments and
whether they vary across the three types of interventions;
(3) identify gaps in the measurement of effectiveness using an
universally accepted framework for functional assessment of de-
pression as a reference, the International Classiﬁcation of Func-
tioning, Disability and Health (ICF) Core Set for depression. (Cieza
et al., 2004). This ICF Core Set provides a list of functioning areas
covering the spectrum of symptoms and aspects of activities and
participation relevant for individuals with depression. The study
and analyses performed had explorative character and speciﬁc
hypotheses had not been tested.2. Methods
2.1. Search
Customized electronic search for studies assessing interven-
tions in depressive disorders was performed in four databases –
PsycINFO, PubMed, Web of science, and the Cochrane Central
Register of Controlled Trials for studies published in English from
January 2005 to January 2014. Studies were identiﬁed by com-
bining terms indicative for intervention: intervention* OR *therapy
OR treatment OR pharmacotherapy OR psychotherapy OR behavior-
therapy OR cognitive analytic therapy OR cognitive behavior therapy
OR cognitive behavior therapy OR counseling OR family therapy OR
marital therapy OR psychoanalytic therapy OR psychoanalysis OR
psychodynamic OR social Skill OR relaxation therapy OR yoga OR
homeopathy OR medication OR reminiscence OR life review OR re-
habilitation; depression: Depression/ Depressive/Major Depressive
disorder [Msh]; and functioning: psychosocial* OR Quality of Life OR
Life Satisfaction OR Unemployment OR Employability OR Reemploy-
ment OR Retirement OR Traveling OR Leisure Time OR Exercise OR
Physical Activity OR Physical Fitness OR Driving Behavior OR Ag-
gressive Driving Behavior OR Driving Under the Inﬂuence OR Activ-
ities of Daily Living OR Social Support. The reference lists of included
articles and relevant systematic reviews were also checked
manually for additional studies.
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Studies were included if (1) participants were older than 18
years, (2) the diagnosis was established by a standardized diag-
nostic tool including major depressive episode, major depressive
disorder or dysthymic disorder according to Diagnostic and Sta-
tistical Manual of Mental Disorders DSM-IV criteria (American
Psychiatric Association, 1994) or DSM-IV-TR criteria (American
Psychiatric Association, 2000), or a depressive episode, recurrent
depressive disorder or dysthymia according to the International
Classiﬁcation of Diseases, 10th edition criteria (World Health Or-
ganization, 1992), and (3) the sample included at least 10 partici-
pants. Randomized controlled trials, quasi-experimental studies
and longitudinal observational studies were included. In case of
multiple publications, the journal with the highest impact factor
was considered. Comments, letters, editorials, conference reports,
primary prevention studies, phase I studies, cross-sectional stu-
dies, ecological studies, and case studies were excluded.3. Procedure
3.1. Abstract check and full text data extraction
Firstly, abstracts were checked according to the inclusion cri-
teria. For quality assurance, 20% of the papers were randomly se-
lected and the abstracts were double checked by another blinded
reviewer (MCa). Cohen's kappa was used to estimate the level of
agreement and calculated according to Fleiss and Cohen rules
(Fleiss and Cohen, 1973). Secondly, full texts of included studies
were read to check again inclusion criteria and eligibility for fur-
ther analysis.
For the included studies the following data were extracted:
study-related and demographic data of participants (e.g., sample
size, gender, and diagnosis), type of interventions and instruments
used as outcome measures. Again, a second reviewer (MCa)
checked 10% of the papers independently.
3.2. Identiﬁcation of outcome measures of treatment effectiveness
Interventions were grouped in three main categories: psy-
chotherapy, pharmacotherapy and complementary and alternative
medicine therapies (Patten et al., 2009). A combination of two or
more therapies was separated for the analysis in a fourth category:
“combined treatment”. Neurostimulation interventions were in-
cluded within the category of complementary and alternative
treatments. The outcome measures assessing effectiveness of in-
terventions were included only if applied at least twice in the
assessment process. Only the instruments validated in depression
samples and used in more than three studies were taken into
consideration for further analysis. The outcome measures included
both clinician rated scales and patient-reported outcome
instruments.
3.3. Content analysis of the functional areas included in the outcome
measures
All individual items of the selected instruments were extracted.
This included instruments generally assessing functioning, quality
of life but also those ones that covered mainly symptomatology. It
has to be noted that many instruments used to measure sympto-
matology contain single items that also address other areas of
functioning as well. For operationalization, the items were linked
to the ICF by applying the established linking rules (Cieza et al.,
2005). The linking process was done by two researchers. In case of
disagreement between the two researchers a structureddiscussion under the supervision of a third researcher was in-
itiated to agree on the ﬁnal linking. The items were grouped into
10 overarching categories based on the ICF classiﬁcation. It is im-
portant to note that the current study used the ICF as a framework,
but did not intend to follow precisely its hierarchical structure.
Thus, if similar psychosocial difﬁculties were prevalent (at least 3%
of all areas identiﬁed) (e.g. maintenance of sleep, onset of sleep),
they were grouped in a single category (sleep problems) but not in
the ICF higher level category (global mental functions).
Furthermore, only functional areas identiﬁed more than ﬁve
times across all studies were included in the analysis. Difﬁculties
identiﬁed more than once within an instrument were counted
once for statistical analysis. Thus, difﬁculty in mobility, for ex-
ample, represented in more than one item of SF-36 (Ware and
Sherbourne, 1992), such as “Lifting or carrying groceries” and
“Climbing several ﬂights of stairs”, was counted just once within the
instrument. Our goal was to identify areas covered by the instru-
ment, not the number of times they were addressed within. After a
list of functional problems was established, a frequency analysis
was performed to show the percentage of the areas stratiﬁed by
type of intervention.
3.4. Identifying gaps in the measurement of treatment effectiveness
The list of functional areas was compared to the ICF Core Set for
depression (Cieza et al., 2004). The ICF Core Set includes 45 cate-
gories representing mental and body functions (symptomatology)
and 48 from the component Activities and Participation. The
comparison between our results and the ICF Core Set allowed us to
identify all the functional areas that were selected as crucial for
persons living with depression but not considered in the treat-
ment effectiveness measurement process.4. Quality assurance
The methodological quality of the included randomized clinical
trials was assessed by the ﬁrst four components of the Cochrane
“Risk of bias” assessment tool: sequence generation, allocation
concealment, blinding of assessors, and incomplete outcome data.
Selective outcome reporting and other sources of bias are not
demonstrated to inﬂuence validity (Higgins and Altman, 2008).
Since it is impossible for many non-pharmacological studies to
apply a double blind design, the blinding of assessors included
only outcome assessors in masking procedures.
4.1. Statistical analyses
The data included the number of times one speciﬁc functional
area was reported in a speciﬁc study type (psychotherapy, phar-
macotherapy, combined treatment or alternative therapy) and the
total number of functional areas reported for that intervention
type. Consequently, there were different total numbers for each
group (intervention type), mainly because the total number of
articles for each intervention type was different. In order to ana-
lyze whether there were signiﬁcantly different percentages of
functional areas between the different types of interventions, a
logistic regression was performed on STATA version 11 (StataCorp.,
2010). Intervention type was taken as independent variable (Ref
Cat¼pharmacotherapy) and ﬁtted values of the speciﬁc functional
areas for each of the intervention types were dependent variables.
The data were analyzed with the blogit STATA command. In total,
10 different logistic regressions for the 10 functional areas were
performed. Wald test Chi-Square was used to verify if logistic re-
gression model detected differences between the different inter-
vention types (using the STATA ttestparm command). If Wald test
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ventions on a particular functional area, pairwise comparisons
were run using the STATA command prtesti to ﬁnd between which
types of therapies the differences appeared.5. Results
5.1. Characteristics of studies
The study selection process can be seen in Fig. 1. Of 2234 hits
for potential inclusion through database and manual search, 247
articles were included in the ﬁnal synthesis. The most frequent
reason for exclusion was a non-depressed or mixed sample (52%).
The rates of agreement expressed by Kappa of Cohen (Fleiss and
Cohen, 1973) were 0.91 in the abstract selection and 0.85 in the
selection of papers after reading the full text. A total of 71904
participants were included, the majority of whom female – 65.4%.
The studies were mainly randomized controlled trials (71.7%) and
included mostly outpatients diagnosed with major depressive
disorder or dysthymic disorder (American Psychiatric Association,
2000).
A total of 66 interventions were identiﬁed, all of them grouped
in three main categories – psychotherapies, pharmacotherapies or
complementary and alternative therapies. The most common in-
tervention within the psychotherapeutic category was CBT. Dif-
ferent SSRI antidepressants, especially ﬂuoxetine, were prevalent
in pharmacological studies; as for the complementary and alter-
native treatments, exercise therapy and St. John’s wort were the
most studied ones. Studies measuring combination of interven-
tions included mostly psychotherapy as an adjunct to pharmaco-
logical treatment. Risk of bias varied among studies (0–4), as some
clinical trials (12) did not meet any of the four criteria for quality
assurance. We performed separate analysis excluding these 12
studies, but no signiﬁcant changes were observed. There were only
59 (33%) clinical trials meeting the four criteria of quality assess-
ment and consequently high quality. Due to the large number of
studies included, full summary of the study characteristics can be
found in Supplementary Appendix 1.
5.2. Identiﬁcation of outcome measures of treatment effectiveness
In total, 27 outcome measures were identiﬁed for further
analysis. The majority of the instruments were patient-reportedFig. 1. Flow chart of the paper selection.outcome measures with the exception of HDRS and the Clinical
Global Impression scale (CGI) (Guy, 1976), which are clinician-
rated tools. Table 1 shows the frequency of each of the ques-
tionnaires within the three types of interventions. HDRS was the
most common instrument, used in almost 30% of the included
studies. In general, instruments exclusively assessing severity of
symptoms were included in approximately 80% of all studies. The
quality of life measures represented 14%, 15.2% and 18.8% of the
overall number of instruments used in studies assessing effec-
tiveness of psychotherapeutic, pharmacological and alternative
interventions, respectively. Finally, instruments that assessed
other areas of functioning (e.g. social functioning) were 7.5% in
psychotherapy, 3.2% in pharmacotherapy and 5.3% in com-
plementary and alternative treatments. More than 90% of all stu-
dies reported only total scores of the instruments.
5.3. Content analysis of the functional areas included in the outcome
measures
The total number of functional areas addressed in the instru-
ments was 57. These areas were grouped in 10 main categories.
Fig. 2 shows the frequency of each of the 10 categories in psy-
chotherapy, pharmacotherapy, complementary and alternative
treatments, and combined treatments (combination of two
therapies). The category “others” consisted of functional domains
such as mobility, self-care, making decisions, communication,
learning and applying knowledge, each of them representing a
negligible percentage to be shown as a separate group. Overall,
items related to clinical symptoms like global mental functions
(optimism, conﬁdence, temperament and personality functions,
psychic stability, orientation functions, etc.), speciﬁc mental
functions (emotional functions, attention functions, body image,
experience of self, thought functions, etc.), energy and drive (e.g.
energy level, appetite) and sleep functions (maintenance of sleep,
onset of sleep) accounted for about 65% of the total number of
functional areas addressed within the outcome measures. Other
body functions representing somatic symptoms (e.g. pain, diges-
tive or sexual problems) represented additional 15–18% of all
functional difﬁculties in the categories of interventions.
Other areas of functioning beyond symptomatology, such as
interpersonal relationships (family and partner relationships, in-
formal relationships with friends), recreation and leisure activities,
general tasks and demands (difﬁculties in maintaining daily ac-
tivities, domestic life, doing housework, etc.), or major life areas,
such as maintaining employment or education, represented a very
small percentage – 15–20% varying across the categories of inter-
ventions. The analysis showed that there were statistically sig-
niﬁcant differences in the frequencies reported for “global mental
functions” and “others” regarding the type of intervention (Fig. 2).
Particularly, psychotherapy was the group with the highest re-
presentation of global mental functions (18%), signiﬁcantly differ-
ent than the other three interventions types, whereas studies re-
porting alternative therapies were the second most prevalent
group for this functional domain (14.6%). There are also differences
in the number of times the category “others” was reported. The
group of alternative interventions was signiﬁcantly higher than
the rest, whereas no signiﬁcant differences were found among
pharmacotherapy, psychotherapy and combined treatment.
5.4. Identifying gaps in the measurement of treatment effectiveness
Table 2 shows all functional difﬁculties that are included in the
ICF Core Set for depression, but aren’t found in any of the outcome
measures of effectiveness. Categories such as problems in do-
mestic life or community, social and civic life were not covered by
any questionnaire. Many speciﬁc areas such as self-care activities
Table 1
Frequency of the instruments used as outcome measures in interventional studies.
Instrument Author (Year) Domain Psychotherapy (%)a Pharmacotherapy (%) Alternative thera-
pies (%)
Combined treat-
ment (%)
All studies
(%)
HDRS Hamilton (1960) Severity of depression 22.7 29.1 23.5 25.0 23.55
BDI Beck et al. (1961) Severity of depression 10.2 5.2 11.1 5.6 7.68
BDI-II Beck et al. (1996) Severity of depression 12.6 1.7 3.27 0.0 5.29
BAI Beck and Steer (1993) Severity of anxiety 6.1 0.0 2.0 0.0 2.73
BHS Beck et al. (1974) Hopelessness 1.9 0.4 0.0 0.0 0.85
CGI Guy (1976) Severity of symptoms 2.8 14.2 5.9 8.3 8.87
GDS Yesavage et al. (1982) Severity of depression 2.8 1.4 4.6 0.0 2.73
HADS Zigmond and Snaith
(1983)
Severity of depression/
anxiety
0.0 1.0 1.3 0.0 0.85
HAM-A Hamilton (1959) Severity of anxiety 1.4 4.8 2.0 5.6 3.24
MADRS Montgomery and As-
berg (1979)
Severity of depression 4.2 13.2 7.2 5.6 9.04
IDS Rush et al. (1986) Severity of depression 1.4 2.4 2.0 2.8 1.88
PHQ-9 Spitzer et al. (1999) Diagnosis of Depression 1.4 0.4 2.0 2.8 1.37
MMSE Folstein et al. (1975) Cognitive impairment 0.0 1.0 1.3 5.6 0.85
SCL-90 Derogatis (1994) Symptomatology 4.6 0.7 4.6 8.3 3.25
DAS Weissman and Beck
(1978)
Intensity of dysfunctional
attitudes
1.9 0.4 2.6 2.8 1.37
EQ-5D EuroQol Group (1990) QOL and health outcome 0.9 1.4 2.6 2.8 1.71
GAF Endicott et al. (1993) Psychological functioning 2.3 0.4 2.6 0.0 1.71
IIP-64 Horowitz et al. (1988) Interpersonal difﬁculties 2.8 0.7 0.7 2.8 1.19
PSQI Buysse et al. (1989) Sleep quality 0.5 1.0 1.3 2.8 0.85
QIDS Rush et al. (2003) Severity of symptoms 1.9 4.5 0.0 2.8 2.56
QLES-Q Endicott et al. (1993) QOL 4.2 6.6 2.6 2.8 5.46
RSES Rosenberg (1965) Global Self-Worth 0.9 0.0 0.7 0.0 0.51
SAS Weissman et al. (1978) Social functioning 1.9 0.7 0.7 0.0 0.85
SF-36 Ware and Sherbourne
(1992)
Health Status 6.1 5.5 10.5 11.1 7.00
SDS Sheehan (1983) Disability and Impairment 0.5 1.4 1.3 2.8 1.37
WHOQOL WHOQOL Group (1995) QOL 2.8 1.7 3.1 0.0 2.39
HDRS – Hamilton Depression Rating Scale, BDI – Beck Depression Inventory, BAI – Beck Anxiety Inventory, BHS – Beck Hopelessness scale, CGI – Clinical Global Impression,
GDS – Geriatric Depression Scale, HADS – Hospital Anxiety and Depression Scale, HAM-A – Hamilton Anxiety Rating Scale, MADRS – Montgomery Asberg Depression Rating
Scale, IDS – Inventory of depressive Symptomatology, PHQ-9 – Patient Health Questionnaire-9, MMSE – Mini Mental State Examination, SCL¼90, Symptom Checklist-90,
DAS – Dysfunctional Attitudes Scale, GAF – Global Assessment of Functioning, IIP-64 – Inventory of Interpersonal problems, PSQI – Pittsburgh Sleep Quality Index, QIDS –
Quick Inventory of Depressive Symptoms, Q-LES-Q – Quality of Life Enjoyment and Satisfaction Questionnaire, RSES – Rosenberg Self-Esteem Scale, SAS – Social Adjustment
Scale, SF-36 – Short Form (36) Health Survey, SDS – Sheehan Disability Scale
a Percentage of the total number of questionnaires used in the studies.
Fig. 2. Percentage of the functional areas contained in the outcome measures used in studies assessing psychotherapeutic, pharmacological, alternative or combination of
interventions. Note 1: *po0.05, ***po0.001. Note 2: Pairwise comparisons between different types of interventions: “a” psychotherapy vs pharmacotherapy, “b” psy-
chotherapy vs alternative treatment, “c” psychotherapy vs combined treatment, “d” alternative treatment vs pharmacotherapy, “e” alternative treatment vs psychotherapy.
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Table 2
Functional areas included in the ICF Core Set for depression, but not found in the
outcome measures of effectiveness.
Domain Categories Functional areas
Mental functions
(symptoms included)
Global mental
functions
Intellectual functions
Extraversion
Agreeableness
Conscientiousness
Speciﬁc mental
functions
Psychomotor functions
Appropriateness of emotion
Regulation of emotion
Range of emotion
Pace of thought
Form of thought
Control of thought
Organization and planning
Management
Insight
Judgement
Experience of self
Energy and drive
functions
Motivation
Impulse control
Sleep functions Amount of sleep
Quality of sleep
Functions involving the sleep
cycle
Activities and partici-
pation (functional
areas beyond
symptoms)
Interpersonal
relationships
Complex interpersonal
interactions
Relating with strangers
Informal social relationships
Intimate relationships
General tasks and
demands
Undertaking a single task
Managing daily routine
Completing the daily routine
Managing one’s own activity
level
Handling stress
Major life areas Acquiring, keeping and termi-
nating a job
Basic economic transactions
Complex economic transactions
Economic self-sufﬁciency
Others
Learning and ap-
plying knowledge
Watching
Listening
Thinking
Reading
Solving problems
Communication Receiving spoken messages
Receiving non-verbal messages
Speaking
Producing non-verbal messages
Conversation
Receiving spoken messages re-
ceiving non-verbal messages
speaking roducing non-verbal
messages conversation
Mobility Using transportation
Driving
Self-care Washing oneself
Carrying for body parts
Dressing
Eating
Drinking
Looking after one's health
Domestic life Acquisition of goods and
services
Caring for household objects
Assisting others
Community, social
and civic life
Community life
Religion and spirituality
Political life and citizenship
K. Kamenov et al. / Journal of Affective Disorders 188 (2015) 89–9694like dressing, eating or washing oneself, areas related to personal
coping such as handling stress and solving problems, or partici-
pation restrictions like using transportation, maintaining a job,
religious or political life, were not measured in any study. Some
important areas related to symptomatology like regulation of
emotions, motivation, or psychomotor functions were not mea-
sured either.6. Discussion
This literature review aimed to critically examine the current
way of measuring effectiveness of interventions for depression.
The results are consistent with the ﬁndings of the study of
Brockow et al. (2004), which reviewed the literature after the ﬁrst
global burden of disease study was published (Murray and Lopez,
1996). Our results show that almost 20 years after the ﬁrst and
more than ten years after the second burden of disease studies
which speciﬁcally underlined the need for taking into account
disability across all disorders, the effectiveness of all available in-
terventions for depression is still assessed mainly in terms of re-
duction of clinical symptoms, whereas other areas of functioning
are neglected (Murray and Lopez, 1996; World Health Organiza-
tion, 2004). This is imposingly demonstrated by the fact that every
study analyzed in our review applied at least one measure of se-
verity of symptoms, but only less than 20% of the applied ques-
tionnaires addressed other areas of functioning. Similarly, the
elaborate content item analysis revealed that around 80% of the
areas covered by the outcome measures represented clinical
symptomatology. This discordance between established research
priorities and actual implementation debates the adequacy of
published studies and poses the question how much do we know
about the level of effectiveness of interventions for depression on
vital areas of everyday life.
Another interesting point to emphasize is the contradiction
between the theoretical background and the objectives of the in-
terventions and their actual effectiveness assessment in research.
In terms of pharmacological treatments, it has been postulated
that improvement in speciﬁc aspects of social functioning may
depend on whether antidepressant treatment targets speciﬁc
noradrenaline or serotonin neurotransmitters (Dubini et al., 1997).
The majority of psychotherapeutic treatments aim to develop
coping strategies for solving problems and stress management,
communicational skills for appropriate perception and responses
to social cues, behavioral changes towards better interpersonal
interactions, and skills for increasing occupational functioning
(Barth et al., 2013). Cognitive behavioral therapy, for instance,
which is the most commonly used psychotherapeutic approach
found in this review, includes techniques developed primarily for
overcoming obstacles to participating in enjoyable activities or
creating coping skills in individuals for handling stress, problem
solving and scheduling pleasurable experiences (Hawton et al.,
1989). None of these areas, however, has been sufﬁciently in-
vestigated in research. Our results show that there is no difference
how effectiveness of psychotherapeutic, pharmacological and al-
ternative treatments has been measured in clinical research. Thus,
the primary objectives set in the theoretical foundations of the
treatments have not been considered in the measurement process.
Apart from reporting the areas addressed in studies, this is the
ﬁrst study to report the gaps in the measurement process. On this
line, results indicate that particular areas of functioning (e.g. in-
terpersonal relationships, general tasks and demands) are in-
sufﬁciently covered by the identiﬁed instruments. Furthermore,
there are crucial areas for the experience of depression like
handling stress, solving problems, organization and planning, time
management, keeping and terminating a job, education,
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addressed by any of the analyzed outcome measures. This means
that we do not have any information on the effectiveness of the
interventions on these affected areas. Given their importance, this
again might question the quality of evidence we possess on the
effectiveness of commonly used treatments for depression in
general.
This status quo might be remodeled by means of certain
changes at research and clinical level. On one hand, a more com-
prehensive measurement in research is needed. It might be
achieved by the inclusion of unique tool that should be compre-
hensive enough in regard to the health condition and quick to
administrate if needed to be applied in a clinical setting where
practitioners have limited time and resources (Wittchen et al.,
2001). This option would provide comparability across studies.
Another possibility could be the use of a battery of instruments,
each covering a certain domain relevant for depression. However,
this predominantly depends on the research study resources, as it
might be again time consuming thus causing bias in the answers
of the participants. A third option could be the use of particular
instruments created to cover not all but at least a wide range of the
major functional difﬁculties. The Social Adaptation Self-evaluation
Scale (SASS) (Bosc et al., 1997) is an example of a developed and
validated instrument, measuring problems at work, relationships
with family, friends, intellectual interests, hobbies, satisfaction
with performance, and ability to manage one’s environment. It
might be used in addition to instruments assessing reduction of
symptoms. However, it has to be noted that all the three options
provided above are seen through the scope of the ICF philosophy,
considering all functional areas as equally important. Future re-
search could classify all functional areas affected in depression
based on their importance. Thus, an outcome measure covering
the most important and relevant areas could be implemented
successfully in research studies.
On the other hand, a change in intervention design in depres-
sion might be also necessary to switch the paradigm from symp-
tom oriented therapies to more rehabilitation and functioning
oriented therapies, focusing on wider range of deteriorated func-
tions. A recently developed functional remediation intervention
for bipolar disorder, for example, combining neurocognitive
techniques and training with psychoeducational and problem-
solving techniques, shows promising results on patients (Marti-
nez-Aran et al., 2011). Cognitive remediation therapy designed to
improve social cognition and thereby better the functioning out-
comes in schizophrenic patients also shows signiﬁcant results
(Wykes et al., 2007). Adaptations of these therapies might be ap-
plied for depression, accelerating the functional remission of de-
pressed individuals and alleviating wide range of difﬁculties.
Regardless of the chosen strategy, we recommend authors to
report detailed information on speciﬁc functional areas covered by
the questionnaire(s) instead of reporting the overall scores of in-
struments (e.g., BDI sum score). Our results show that more than
90% of the studies reported only total scores of questionnaires.
Even the studies providing more detailed results were somewhat
limited, as they reported changes in a broader subdomain, thus
not exploring thoroughly what drove the overall score change. The
limitation of reporting total score is that it mixes different con-
cepts that have different levels of relevance and that we do not
obtain information on the sequence of improvement (which area
is improved ﬁrst). An elaborate analysis providing detailed in-
formation on the outcome measures will enable researchers to
follow the changes in particular areas over time. Furthermore, it
might provide evidence on which treatments are better in im-
proving speciﬁc areas of functioning. This information would be
essential to make systematic and evidence-based treatment
decisions.7. Limitations
The current review has to be seen in light of certain limitations.
First, the literature search was limited to articles published be-
tween 2005 and 2014. However, this time period was chosen be-
cause we intended to analyze the trends in measuring treatment
effectiveness in depression after the publication of the last review
of literature (Brockow et al., 2004). Second, articles were only
selected if published in English. This could have left out relevant
information published in other languages. Third, because of the
wide variety of studies, we analyzed only instruments used in
more than three studies included in the review. Thus, we might
have omitted a comprehensive outcome measure with a broader
scope. Another methodological limitation is the inclusion of trials
that did not meet any quality criteria. This was done to avoid any
publication bias and capture in a comprehensive way the literature
on depression in its current form.8. Conclusions
This study comprehensively review the current way of ana-
lyzing the effectiveness of interventions for depression. The ﬁnd-
ings encourage researchers to consider the consequences of
choosing outcome measures in interventional studies. The effec-
tiveness of many well recognized interventions might be over-
estimated considering the fact that the evidence so far has been
mainly based on reduction of symptoms, whereas other relevant
functional areas have been unconsidered. Future steps towards
improvement include use of comprehensive assessment tools,
obtainment of more detailed information from outcome measures,
design of functional impairment oriented therapies, and more
qualitative and expert panel studies. This information can perso-
nalize our ﬁndings by identifying the functional difﬁculties re-
levant for each therapy, thus making the treatment decision pro-
cess easier and meaningful.Acknowledgements
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Abstract 
Background: There is growing recognition of the importance of both functioning and 
quality of life (QoL) outcomes in the treatment of depressive disorders, but the meta-analytic 
evidence is scarce.  The objective of this meta-analysis of randomized controlled trials (RCTs) 
was to determine the absolute and relative effects of psychotherapy, pharmacotherapy and their 
combination on functioning and quality of life in patients with depression. Methods: 153 
outcome trials involving 29,879 participants with depressive disorders were identified through 
database searching in Pubmed, PsycINFO and the Cochrane Central Register of Controlled 
Trials. Results: Compared to control conditions, psychotherapy and pharmacotherapy yielded 
small to moderate effect sizes for functioning and QoL, ranging from g = 0.31 to g = 0.43. When 
compared directly, initial analysis yielded no evidence that one of them was superior. After 
adjusting for publication bias, psychotherapy was more efficacious than pharmacotherapy (g = 
0.21) for QoL. The combination of psychotherapy and medication performed significantly better 
for both outcomes when compared to each treatment alone yielding small effect sizes (g = 0.32 
to g = 0.39). Both interventions improved depression symptom severity more than functioning 
and QoL. Conclusion: Despite the small number of comparative trials for some of the analyses, 
this study reveals that combined treatment is superior, but psychotherapy and pharmacotherapy 
alone are also efficacious for improving functioning and QoL. The overall relatively modest 
effects suggest that future tailoring of therapies could be warranted to better meet the needs of 
individuals with functioning and quality of life problems.  
Keywords: meta-analysis, depression, functioning, quality of life, psychotherapy, 
pharmacotherapy
3 
 
Introduction 
A considerable number of meta-analyses published in the last decade have clearly shown 
that both psychological and pharmacological treatments are efficacious for reducing symptoms 
in depression (Cuijpers et al., 2011, Cuijpers et al., 2013, Spielmans et al., 2011). Recent 
literature, however, has suggested that functioning and quality of life improvement might be 
equally important for people with depression as their symptom amelioration (IsHak et al., 2011a, 
Lam et al., 2015, Zimmerman et al., 2006). The Canadian Network for Mood and Anxiety 
Treatments (CANMAT) highlighted the need for evidence-based interventions that demonstrate 
improvement in functioning (Lam et al., 2015). From a clinical perspective, patients have 
prioritized functional over symptomatic outcomes and determined the return to a normal level of 
functioning at work, home or school as a significant factor for remission in depression 
(Zimmerman et al., 2006). Furthermore, improvement in quality of life has been considered the 
ultimate outcome measure that indicates whether certain treatments have succeeded (IsHak et al., 
2011a).   
Despite the importance given to functioning and quality of life, both dimensions remain 
under-researched in interventional studies (Kamenov et al., 2015). The terms have been used 
interchangeably in previous studies, but there is agreement that these concepts are not identical 
(Lam et al., 2015). Generally, functioning refers to one’s performance in daily or social activities 
and QoL as one’s satisfaction with these activities and perception of his/her health (IsHak et al., 
2002, IsHak et al., 2011a).  
The conclusions drawn from the few published meta-analyses on functioning are limited. 
A review by De Silva et al. (2013) assessed the effect of psychosocial interventions on social 
functioning in depression. The article, however, reported only data from low- and middle-income 
countries. A later meta-analysis by Renner et al. (2014) also assessed the effect of psychotherapy 
4 
 
on social functioning. The study, however, examined only the absolute efficacy of psychological 
interventions and certain functional difficulties such as problems in daily activities were not 
considered in the assessment of functioning. On the other hand, many meta-analyses have 
included QoL as a secondary measure of efficacy of various interventions (Spielmans et al., 
2013, von Wolff et al., 2012). However, research so far has been mainly fragmentary, focusing 
only on specific types of treatments, and there exists only one narrative systematic review 
analyzing the impact of pharmacotherapy and psychotherapy on QoL in depression (Ishak et al., 
2011b). 
To our knowledge, there is no meta-analysis that comprehensively assesses the efficacy 
of interventions primarily aimed at depression treatment on functioning and QoL in depression. 
Determining this efficacy would have important implications for clinical decisions and policy 
making in terms of provision of treatments in primary and secondary mental health services. 
Therefore, this meta-analysis of randomized controlled trials aimed to assess 1) the effects of 
psychotherapy and pharmacotherapy compared to control conditions on functioning and quality 
of life; 2) the effect of both when compared directly, and 3) the effect of their combination 
against either one. Additional sensitivity, subgroup and meta-regression analyses were 
performed.   
Methods 
Methods and results are presented according to the PRISMA statement for reporting 
systematic reviews (Moher et al., 2010).  
Search strategy 
A systematic literature search combining the terms depressive disorder OR depression 
OR major depressive disorder (Mesh terms) AND functioning OR disability OR disability 
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evaluation OR disabled persons OR sick leave OR activities of daily living OR leisure activities 
OR quality of life AND treatment OR intervention OR clinical trial OR therapy (MeSH terms, 
key words and text words) was performed in Pubmed, PsycINFO and the Cochrane Central 
Register of Controlled Trials. In the first two databases, the relevant option was selected to limit 
the search to Randomized Controlled Trials. Although non-randomized controlled trials provide 
valuable information in terms of ecological validity, RCTs minimize the influence of errors and 
bias on findings and offer the most rigorous method of determining whether a cause-effect 
relation exists between treatment and outcome (Sibbald and Roland, 1998, Spring, 2007). Their 
sole inclusion safeguarded the validity of the findings and ensured methodological 
consistency. The search was performed in June 2015. The search was restricted by language 
(only articles published in English were considered) and age (only participants older than 18). In 
addition, the references of published meta-analyses and relevant articles were also checked. 
Study selection 
 The review included all randomized controlled trials that compared 1) 
psychotherapy or pharmacotherapy against treatment as usual (TAU), placebo, waiting list (WL) 
or other control group: 2) psychotherapy against pharmacotherapy; or 3) the combination of 
psychotherapy and pharmacotherapy against either one. Psychotherapy was defined by the 
American Psychiatric Association as “the informed and intentional application of clinical 
methods and interpersonal stances derived from established psychological principles for the 
purpose of assisting people to modify their behaviors, cognitions, emotions, and/or other 
personal characteristics in directions that the participants deem desirable" (Norcross, 1990). 
More specifically, different psychotherapeutic approaches were defined according to definition 
previously developed in comparative meta-analyses (Cuijpers et al., 2008a). All studies had to 
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report at least one validated outcome measure assessing functioning (any difficulty experienced 
in maintaining daily activities or participation in social life (Lam et al., 2015) or quality of life 
(one’s satisfaction with these activities and perception of his/her health (IsHak et al., 2002, 
World Health Organization Quality of Life Group, 1997).  Information on symptom severity was 
extracted only from validated instruments that explicitly measured symptoms of depression (e.g. 
Hamilton Depression Rating Scale (HDRS) (Hamilton, 1960).  The diagnosis of depression had 
to be established by a standardized diagnostic interview according to ICD or DSM criteria 
(American Psychiatric Association, 1980, 1987, 2000, World Health Organization, 1992). 
Studies including bipolar or schizoaffective disorder or reporting results from maintenance or 
continuation therapies were excluded. The abstract screening was done by one researcher (K.K.) 
and a random selection of 20% of the abstracts was double checked independently by another 
two researchers (M.C. and C.T.).  
Data extraction and quality assessment 
Data from the selected studies were extracted by one researcher (K.K) and checked for 
consistency independently by two other researchers. Divergences were resolved by consensus. In 
case of missing data, authors were contacted. When results from more than one outcome measure 
assessing the same concept (either functioning or QoL) were available in a study, data from all 
were extracted and combined as a mean effect size. To avoid double counting, the effects of 
different intervention arms representing the same generic intervention (e.g. GP-delivered 
psychotherapy and clinician-delivered psychotherapy)  included in a single study were averaged 
and entered once in the analysis (Senn, 2009). SF-36 (Ware and Sherbourne, 1992) was 
considered as an outcome measure of quality of life (Ishak et al., 2011b) but if a study reported 
post assessment score on the social functioning subdomain, it was included separately as an 
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outcome measure of functioning. Global measures of functioning were considered only if they 
included domains of social functioning and daily activities (De Silva et al., 2013). Data on effect 
estimates were extracted at post-assessment. The instruments were patient self-assessments and 
clinician-rated tools.  
Four criteria of the Cochrane Collaboration risk of bias tool were used for assessing 
methodological quality of the studies —sequence generation, allocation concealment, blinding of 
assessors, and incomplete outcome data (Higgins et al., 2011). It is impossible for the majority of 
psychotherapeutic designs to employ a double blind design, therefore blinding of assessors in 
these studies was adapted to include only outcome assessors in masking procedures.  
Statistical analyses 
Statistical analyses were performed using the program Comprehensive Meta-Analysis, 
version 2.0. The effect size for each individual meta-analysis was calculated, aggregating the 
pooled difference between the two groups of treatments at the end of the intervention. Hedges’ g 
was preferred as an effect estimate because of its capability to provide a better effect estimate for 
small sample sizes (Deeks et al., 2008). The magnitude of the effect size may be interpreted as 
small (0.2), medium (0.5), and large (0.8) (Cohen, 1988). We used a random effects meta-
analysis model which assumes that variance in observed effects is explained not only by 
sampling variability (as in fixed effect analysis) but also real differences in treatment effects 
resulting from heterogeneity in study populations, intervention delivery, follow-up length and 
other factors (Riley et al., 2011).  To test the heterogeneity, Higgins’ I² statistic was calculated. 
A value of 0% indicates no heterogeneity, 25% indicate low heterogeneity, 50% - moderate 
heterogeneity, and 75% high heterogeneity (Higgins et al., 2003). Publication bias was assessed 
in each of the meta-analyses by visual inspection of the funnel plots and the trim-and-fill 
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procedure to analyze the changes after the accounting for publication bias (Duval and Tweedie, 
2000). In addition to the analyses on functioning and QoL, we performed a series of individual 
meta-analyses to assess the effect of psychotherapy, pharmacotherapy and their combination on 
depression symptom severity. The outcome was a reduction of symptom severity according to 
the instruments’ scores.  
In order to check the robustness of the results, sensitivity analyses were conducted. First, 
the main analyses were repeated after exclusion of low quality studies. Then, to test whether one 
single outcome measure had a strong impact on the overall effect size, a series of sensitivity 
analyses were performed after the exclusion of each of the instruments. Lastly, the effect size 
was calculated for studies with a treatment duration of 3 months or less and compared with 
studies with a treatment duration of more than 3 months. The results of the sensitivity analyses 
were considered “consistent” with the primary analysis if there was no change in the magnitude 
of the effect size (from high to moderate, from moderate to small, etc.). Since the selected studies 
were heterogeneous with respect to comparator groups, study populations, included interventions 
and outcome measures, series of subgroup analyses were performed. We examined whether there 
were differences in terms of age groups – adults (18-65 years) vs. older adults (65+), 
psychotherapies (Cognitive Behavioral Therapy [CBT], Interpersonal Therapy [IPT], Problem 
Solving Therapy [PST], others), medication (SSRIs, SNRIs, TCAs, others), control groups (WL, 
TAU, Placebo, others), outcome measures, duration of treatment (3 months vs. more than 3 
months) and types of depression (Major Depressive Disorder, Dysthymia, Subthreshold 
Depression, others). Long-term effects were not assessed, because a very small number of 
studies reported any follow-up data and the reported outcomes differed widely between studies. 
Follow-up periods differed significantly (e.g. 3 months vs 12 months) and the nature of the 
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follow-ups was different: some studies reported only naturalistic outcomes, whereas others 
delivered booster sessions and maintenance treatments during the follow-up period. A mixed 
effect model, combining a random-effects model within subgroups and a fixed-effect model 
across subgroups, was used. Multivariate meta-regression analyses were conducted using Stata 
12.0 for Windows (Stata Corporation, USA). In these analyses the outcome variable was the 
weighted effect sizes of psychotherapy, pharmacotherapy or their combination on functioning 
and QoL at posttreatment. The predictors were severity of depression (effect size at 
posttreatment), number of psychotherapeutic sessions (where possible), duration of treatment in 
weeks, duration of trial in weeks, and year of publication. All the predictors used were 
continuous variables. The regression coefficient obtained from the meta-regression analysis 
revealed how the intervention effect changes with a unit increase in the predictors and whether 
there was a linear relationship between the intervention effect and the predictors.  
Results 
Study selection 
After removal of duplicates, 3447 articles were identified for abstract check. Of these, 
354 were selected for full-text screening. 153 articles met the inclusion criteria and were 
included in the analyses. The main reasons for exclusion were lack of functional or quality of life 
measures and non-standardized diagnosis of depression. Some studies included outcome 
measures for both functioning and QoL, resulting in their inclusion in more than one analysis. 
The selection process can be seen in Figure 1.  
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Figure 1. Flow chart of Study Selection 
 
Description of included studies 
 Selected characteristics of the studies can be seen in Table 1. A total of 29,879 
participants were included in all trials. The majority of the participants were adults aged between 
18 and 65 years.  60.1% of all individuals had major depressive disorder. The duration of the 
trials ranged from four weeks to one year. The most common psychotherapeutic intervention 
found in the literature was CBT, based on two specific tasks - cognitive restructuring and 
behavioral approach (such as exposure and response prevention). Interpersonal therapy - a 
structured therapy with a predominant focus on addressing interpersonal issues - was also 
commonly used in studies. The number and format of psychotherapeutic sessions differed across 
studies, ranging between 4 and 20, weekly and biweekly, individual and group sessions. We 
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defined pharmacotherapy as any treatment by means of pharmaceutical drugs, e.g. 
antidepressants. The most frequently used drug in the studies was duloxetine. The dosage given 
to participants varied depending on the type of drug and the duration of the trials. 
 In terms of instruments for measuring functioning, Sheehan Disability Scale (SDS) 
(Sheehan, 1983) and Social Adjustment Scale (SAS) (Weissman et al., 1978) were the most 
commonly used ones, as for QoL – Quality of Life Enjoyment and Satisfaction Questionnaire 
(Q-LES-Q) (Endicott et al., 1993) and SF-36. The majority of the trials were conducted in USA, 
UK or The Netherlands. The quality of the studies varied. There were 47 trials (30.7%) meeting 
all four quality criteria, whereas 75 studies (49%) were missing two or more components. A full 
table including all study characteristics and references of the included articles can be found in 
Supplementary Material 1. 
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Table 1. Selected characteristics of the included studies 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Psychotherapy and pharmacotherapy vs. control condition 
 Figure 2 provides information on the total effects of each of the 4 individual meta-
analyses (full details on individual studies are available in Supplementary Material 2A and 2B). 
When compared to control conditions, both psychotherapy and pharmacotherapy had small to 
moderate effects on functioning, with slight superiority of psychotherapy. The mean effect of 
psychotherapy on functioning resulting from 52 comparisons was g=0.43 (95% CI 0.33-0.54; 
I²=74.94, 95% CI 67.24-80.27). After adjusting for publication bias, the effect size decreased to 
Characteristic N (studies) % 
Diagnosis   
   MDD 92 60.1 
   Dysthymia 22 14.4 
   Subthreshold Depression 10   6.5 
   Other 29 18.9 
Target Group   
   Adults 120 78.4 
   Older Adults 15   9.8 
   Women 18 11.8 
Type of Psychotherapy   
   CBT 31 31.3 
   IPT 17 17.2 
   PST 9   9.1 
   Other 42 42.4 
Type of pharmacotherapy   
   SSRIs 35 37.6 
   SNRIs 31 33.3 
   TCAs 19 20.4 
   Other 8   8.6 
Study Quality   
    ≤2 75  49 
    ≥3 78  51 
Country   
   USA 71 46.4 
   UK 28 18.3 
   Netherlands 11   7.2 
   Others 45 29.4 
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0.35 (95% CI 0.24-0.46). For pharmacotherapy, the 53 comparisons yielded an effect of g= 0.31 
(95% CI 0.26-0.36; I²=64.91, 95% CI=51.66-73.21). After adjusting for publication bias, the 
effect size decreased to 0.27 (95% CI 0.21-0.32).  
 For quality of life, both psychotherapy and pharmacotherapy yielded small effect 
sizes. The 37 comparisons yielded a mean effect of psychotherapy g=0.35 (95% CI 0.26-0.44; 
I²=68.24, 95% CI 53.74-76.65). The effect of pharmacotherapy coming from 33 studies was 
g=0.31 (95% CI 0.24-0.38; I²=81.18, 95% CI 74.25-85.55).  
Figure 2. Total standardized effect sizes (Hedges’ g) of psychotherapy and pharmacotherapy against 
control condition for functioning and QoL. 
 
Psychotherapy vs. pharmacotherapy 
 For both functioning and quality of life, there was no significant difference between 
therapies. In terms of functioning, the mean effect size was 0.03 (95% CI -0.13-0.19; I²=77.85, 
95% CI 63.98-84.79) in favor of psychotherapy (Figure 3). After adjusting for publication bias, 
Hedges’ g was still insignificant, but increased substantially to 0.12 (95% CI -0.06-0.30) in favor 
of psychotherapy. For quality of life, the effect size was 0.05 (95% CI -0.19-0.29; I²=90.72, 95% 
CI 84.47-93.71) in favor of psychotherapy. After adjusting for publication bias the effect size 
was small, but significant in favor of psychotherapy (g=0.21, 95% CI 0.01-0.43).  
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Figure 3. Standardized effect sizes (Hedges’ g) of psychotherapy against pharmacotherapy on functioning 
and QoL 
 
Combination of psychotherapy and pharmacotherapy vs. either one 
 The effects of the direct comparisons between combination of psychotherapy and 
pharmacotherapy against either one on functioning or quality of life are presented in Figure 4. In 
all four analyses, the combined treatment was significantly superior to each treatment alone 
yielding small effect sizes. For functioning, the 19 comparisons between combined treatment and 
pharmacotherapy alone resulted in effect size of g=0.34 (95% CI 0.18-0.50; I²=69.51, 95% CI 
47.22-79.85) in favor of combined treatment. When combined treatment was compared to 
psychotherapy alone in 10 studies, the analysis yielded an effect size of 0.32 (95% CI 0.14-0.49; 
I²=66.98, 95% CI 21.02-81.43). 
 Six studies compared combined treatment against pharmacotherapy and three 
against psychotherapy on QoL. This weakened the power of the analysis. Compared to 
medication, combined treatment was significantly more efficacious (g=0.36, 95% CI 0.11-0.62; 
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I²=66.91, 95% CI 0.00-84.11). The studies comparing combined treatment with psychological 
interventions yielded an effect size of 0.39 (95% CI 0.19-0.58) in favor of combined treatment.  
Figure 4. Standardized effect sizes (Hedges’ g) of combined treatment against psychotherapy and 
medication alone on functioning and QoL 
 
Effect of psychotherapy and pharmacotherapy on depressive symptoms 
 Psychotherapy showed a better result (g=0.60, 95% CI 0.51-0.68; I²=80.15, 95% CI 
75.53-83.52) than pharmacotherapy (g=0.33, 95% CI 0.29-0.38; I²=54.37, 95% CI 35.77-65.71) 
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when both interventions were compared to control condition. After adjusting for publication bias, 
the effect of psychotherapy dropped to g=0.45, whereas the effect of pharmacotherapy remained 
similar (g=0.30). When both treatments were compared directly, there was no statistically 
significant difference: g=-0.03 (95% CI -0.15-0.10) in favor of medication. The combination of 
treatments was superior to psychotherapy and pharmacotherapy alone, yielding small effect 
sizes- g=0.30, (95% CI 0.16-0.45) and g=0.34 (95% CI 0.18-050), respectively. 
Sensitivity and subgroup analyses 
 The sensitivity analyses revealed some major differences in the effects of psychotherapy, 
pharmacotherapy and their combination on functioning and QoL according to the duration of the 
interventions applied. When psychotherapy was compared directly to medication on QoL, the 
trials with three month or less treatment duration yielded an effect of g=-0.08 (95% CI -0.26-
0.09) in favor of medication, whereas trials with a treatment duration of more than 3 months 
showed superiority of psychotherapy (g=0.26, 95% CI -0.24-0.76). The same applied for 
combined treatment against pharmacotherapy for QoL (g=0.22, 95% CI -0.12-0.56 vs. g=0.64, 
95% CI 0.37-0.92 respectively). The subsequent subgroup analyses comparing the duration of 
treatment, however, found no significant differences among studies. This might be due to low 
power because of the low number of studies included in the analyses. 
 Furthermore, sensitivity analyses were performed after the exclusion of low quality 
studies. For all analyses we found small deviations of the effect sizes, which did not affect the 
magnitude of the effect estimates. However, subgroup analyses were conducted to compare high 
quality (meeting three or four components of the Cochrane risk of bias tool) to low quality 
(missing two or more components).  Results revealed significant changes only in studies 
comparing pharmacotherapy to control conditions on functioning (high-quality studies – g=0.26, 
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95% CI 0.21-0.31 vs. low quality – g=0.36, 95% CI 0.28-0.44, p=.05) and QoL (high quality 
g=0.22, 95% CI 0.11-0.33 vs. low quality g=0.36, 95% CI 0.27-0.45 p<.05). Lastly, to 
investigate the impact of individual outcome measures on the overall effect sizes, we conducted 
a series of sensitivity analyses. Here, we excluded one instrument at a time and examined 
consequent deviations in effect sizes. For all analyses, we found small deviations of the effect 
sizes of no more than 0.10, which indicated that no individual outcome measure had a strong 
impact on the overall effect size. The subsequent subgroup analyses comparing grouped studies 
according to the instruments used did not show any significant differences across subgroups. 
 Differences in the effects of psychotherapy compared to TAU, WL or placebo on 
functioning and QoL were also assessed in subgroup analyses.  The effect of psychotherapy on 
functioning was significantly higher (p<.05) in studies with waiting list controls (g=0.61, 95% CI 
0.40-0.81) than in studies with TAU (g=0.36, 95% CI 0.24-0.48). The effect size of studies 
comparing psychotherapy to waiting list (g=0.47, 95% CI 0.34-0.59) on QoL was significantly 
higher (p<.05) than studies with TAU (g=0.34, 95% CI 0.23-0.45) or placebo controls (g=0.20, 
95% CI 0.03-0.37). Similar subgroup analyses could not be performed for pharmacotherapy, as 
95% of the studies used placebo controls. Furthermore, clinician-rated scales were compared to 
self-rated tools. Studies applying clinician-rated tools yielded slightly higher effect sizes in all 
analyses performed, but statistically significant differences were not found. Regarding age 
groups, only studies comparing pharmacotherapy to control condition for QoL revealed 
significant difference between age groups (g=0.35, 95% CI 0.27-0.42 for adults vs. g=0.16, 95% 
CI 0.04-0.27 for older adults). The rest of the subgroup analyses did not reveal any significant 
differences across subgroups for depression type (Major Depressive Disorder, Dysthymia, 
Subthreshold Depression, others), type of psychotherapy - CBT, IPT, PST, or others, or type of 
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medication – SSRIs, SNRIs, TCAs, or others. All subgroups were directly compared to each 
other, or each subgroup was compared to the other subgroups pooled. All subgroup analyses are  
available upon request.   
Meta-regression analyses 
 Multivariate meta-regression analyses assessing potential predictors were performed. The 
effect size of depression severity was a significant predictor of the effects of psychotherapy and 
pharmacotherapy on functioning (B=0.59, 95% CI=0.42-0.76, p<.001 and B=0.94, 95% 
CI=0.59-1.29, p<.001, respectively) and Qol (B=0.35, 95% CI=0.1-0.61, p<.01 and B=0.94, 95% 
CI=0.59-1.30, p<.001) when they were compared to control conditions, and when 
pharmacotherapy was compared directly to psychotherapy (B=29.55, 95% CI= 5.83-53.27, 
p<.05) and combined treatment (B=0.001, 95% CI=0.0004-0.002, p<.01) for functioning. This 
indicates when symptom severity is reduced, the effect size of psychotherapy and 
pharmacotherapy on improving functioning and QoL increases. The remaining predictors— 
number of sessions, duration of treatment, and duration of trial—were not significant in any of 
the meta-regression analyses we performed. Number of sessions (B=0.02, 95% CI=0.09-0.60, 
p<.05) and year of publication (B=0.001, 95% CI=0.0003-0.002, p<.01) were found significant 
only when the effect of psychotherapy on QoL was compared to control conditions. This 
indicated that the effect size of psychotherapy on QoL increases with higher number of 
psychotherapeutic sessions and in recent publications. All analyses can be found in 
supplementary file 4.  
Discussion 
 This meta-analysis was the first to systematically assess the effects of 
psychotherapy, pharmacotherapy and their combination on improvements in functioning and 
QoL in depressive disorders. The study demonstrates that the combination between 
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psychotherapy and pharmacotherapy perform significantly better than each intervention alone for 
both outcomes. Psychotherapy and pharmacotherapy alone are also efficacious for improving 
functioning and QoL, although showing only small to moderate effects. When compared 
directly, in initial analysis there was no significant difference between the interventions. After 
adjusting for publication bias psychotherapy was more efficacious than pharmacotherapy for 
QoL. 
Our results are consistent with the two previously published meta-analyses on 
psychotherapy for social functioning. Both Renners et al. (2014) and De Silva et al. (2013) found 
effect sizes of g=0.46 in favor of psychotherapy over control condition, which was similar to the 
result obtained in this study – 0.43. Even though psychotherapy showed slightly superior 
absolute effects to medication on both functioning and QoL, it has to be noted that the great 
majority of included pharmacological studies involved random assignment to a blinded control 
condition as opposed to the psychological trials, comparing interventions to WL or TAU control 
groups. It has been argued that awareness of treatment assignment might produce expectancy 
effects in the intervention group and despair in the control group, leading to inflated effect sizes 
in favor of psychotherapy. On the other hand, assignment to a blinded condition controls for 
expectancy effects and induction of hope, thus suggesting eventual underestimation of the effects 
of medication compared to psychotherapy (Gaudiano and Herbert, 2005). Nonetheless, a recent 
meta-analysis by Cuijpers et al. (2015) comparing pharmacological studies involving or missing 
double blind condition to psychotherapy did not find any difference in the effects of both groups.  
We compared the effect of both interventions on functioning and QoL but no significant 
differences were found. This is consistent with previous meta-analytic evidence on depressive 
symptoms, where no superiority was found for any of the intervention types (Cuijpers et al., 
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2013). Still, when studies were adjusted for publication bias, psychotherapy was slightly better 
for improving functioning (g=0.12) and statistically superior than pharmacotherapy on quality of 
life (g=0.21). These results, although suggesting the slight superiority of psychological over 
antidepressant treatment for functioning and QoL, are not robust enough to suggest priority when 
clinical or policy decisions are made. There is no clear economic evidence that psychotherapy 
should be a preferable treatment choice compared to pharmacotherapy (Bosmans et al., 2008). 
However, a recent meta-analysis reveals a strong patient preference for psychological treatment 
over medication (McHugh et al., 2013). Moreover, evidence states that the majority of people 
expressing personal preference for psychological therapy choose not to get treated at all rather 
than receive medication (Layard et al., 2007). Alongside the benefits of pharmacotherapy for 
depression, it is also worth taking into account that potential side-effects and adverse events 
related to the use of medication may have a detrimental impact on functioning and QoL. A 
review by Kelly et al. (2008) showed that people with depression experience diminished quality 
of life related to troublesome side effects. Further research is needed to investigate the role of 
side effects in the efficacy of interventions for depression. Even though the number of studies 
directly comparing psychotherapy and pharmacotherapy was not very high, our results warrant 
future research to determine the economic costs and benefits of eventual enhanced provision of 
psychotherapeutic treatment.   
 The subgroup analyses found higher effect estimates for psychotherapy against waiting 
list compared to TAU and placebo for functioning and QoL. This finding was somewhat 
expected and consistent with previous meta-analyses for depression (Cuijpers et al., 2008b). 
Waiting list control conditions involve no actual treatment and thus positive outcomes for 
psychotherapy are relatively easy to attain. Comparison to treatment as usual is more demanding, 
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because it involves usual care provided in health care settings and the effect estimate shows the 
true additional benefit of psychotherapy on the outcome. Although not to a significant level, we 
found that studies applying clinician-rated scales yielded slightly higher effect sizes than studies 
that relied on self-rated tools. The absence of significance may be partly explained by an absence 
of power – only a small number of studies used clinician-rated tools. Tentatively, this trend is in 
line with the results of previous psychotherapy meta-analyses indicating that clinician-rated 
instruments are associated with higher effect-sizes of functioning and depressive symptom 
severity (Cuijpers et al., 2010, Renner et al., 2014). In the absence of a gold standard measure 
for functioning (Lam et al., 2015, Madden et al., 2015), inclusion of both types of outcome 
measures may be warranted to facilitate comprehensive assessments in future meta-analyses. 
 Psychotherapy and pharmacotherapy showed higher effect sizes on reducing depressive 
symptoms although there was a strong indication for publication bias. When the effects of 
psychotherapy and pharmacotherapy on depressive symptoms were compared to control 
conditions, psychotherapy showed better results (g=0.60 vs. g=0.33, respectively). This result, 
however, has to be considered with caution, because in studies directly comparing both 
interventions, we did not find a significant difference between the interventions (g=-0.03). 
Moreover, a previous meta-analysis (Cuijpers et al., 2013) found no superiority of one 
intervention over another. Future meta-analyses of comparative outcome studies should shed 
more light on potential differences in efficacy between psychotherapeutic and pharmacological 
treatments. Such investigations should also take into account patient preferences and costs.  
 The results from the meta-regression analysis suggest that functioning and QoL improve 
when symptom severity improves, but which is the leading factor is still unknown. Previous 
research suggests that functional recovery appears later than the symptomatic one and certain 
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level of  impairment continues even after the symptomatology is ameliorated, and that depressive 
symptoms and QoL do not share high proportion of common variance (Coryell et al., 1993, 
Trompenaars et al., 2006). The residual functional impairment has been found to evoke relapse 
and recurrences (Vittengl et al., 2009); therefore functioning and QoL should be directly targeted 
in the response and remission criteria for a more comprehensive assessment of treatment 
efficacy. There are already steps in this direction. Individual Burden of Illness Index for 
depression was created to measure treatment impact and recovery in depression by incorporating 
symptom severity, functioning, and quality of life outcomes (Cohen et al., 2013). Zimmerman et 
al. (2014) validated the Remission from Depression Questionnaire, including different domains 
of functioning and QoL along with symptomatology. However, all attempts for implementation 
of such criteria are still in their infancy and future research is warranted.  
The present meta-analysis demonstrates that the combination of psychotherapy and 
pharmacotherapy is significantly better than any of the treatments alone for both functioning and 
QoL. The number of studies comparing treatments for QoL was limited, but still our result has an 
important clinical implication for primary and secondary mental health professionals when 
choosing their treatment lines. Recent data showing the trends in treatment of depression report 
decrease in the use of combined treatment and psychotherapy and a substantial increase in the 
prescription of antidepressants (Gemmill et al., 2008, Marcus and Olfson, 2010). This might be 
driven by various factors such as availability of resources in terms of money and personnel. 
However, a recent analysis by Sado et al. (2009) shows that combined therapy for depression 
appears to be cost-effective from health-care system and social perspective. More cost 
effectiveness and comparative long-term data on combined treatment is needed (McAllister-
Williams, 2006).  
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This study has to be seen in light of certain limitations. First, half of the included trials 
had low quality. This questions the robustness of the results. However, the sensitivity and 
subgroup analysis we performed did not reveal significant differences in the effects between high 
and low quality studies. Second, for some of the individual analyses the number of studies was 
not large enough to allow for generalizability of results. Furthermore, mainly overall 
improvements in functioning and quality of life were assessed. There was a lack of domain-
specific reporting that could have provided information on the effects of interventions on specific 
areas of functioning and QoL. This meta-analysis was based on study-level data. Individual 
patient level meta-analysis based on original datasets of the included studies could have revealed 
differences among first cases of depression and recurrent depression, level of severity, or 
allowed better analysis of predictors of depression. A further limitation was our inability to 
analyze long-term outcomes and their interactions, due to the lack of follow-up data. Follow-up 
data would allow for investigating long-term effects of interventions and temporal relationships 
between changes in functioning, QoL and severity of symptoms. Future longitudinal 
epidemiological studies could fill this research gap and provide important information on the 
course of functioning in depression. Lastly, only articles in English were considered. This might 
have omitted relevant information.  
In conclusion, this meta-analysis provides comprehensive evidence that existing 
psychological and pharmacological interventions are efficacious for improving functioning and 
QoL in depression. There is no robust evidence that one of the interventions is superior, although 
psychotherapy appears slightly superior to medication. The combination between psychotherapy 
and medication performs significantly better for both outcomes when compared to each 
treatment alone. The relatively modest effects suggest that future research should focus on 
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tailoring therapies to better cover the needs of individuals, implementation of instruments 
assessing both outcomes as primary outcome measures in trials, and reporting domain-specific 
changes across treatments for better understanding of the course of depression. 
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Abstract 
Background: Despite the strong evidence for the efficacy of Cognitive Behavioral Therapy 
(CBT) in reducing depression symptoms, less is known about the effects of CBT on other 
relevant outcomes such as functioning and quality of life (QoL). The aim of this meta-analysis 
was to examine the absolute and relative efficacy of CBT on functioning and QoL. 
Methods: Outcome trials were identified through database searching in PubMed, PsycINFO and 
the Cochrane Central Register of Controlled Trials. 
Results: CBT was superior to control conditions (g=0.38) but not to medication (g=-0.13) at 
improving functioning. It was superior to control conditions (g=0.41) at improving QoL. CBT 
showed better results at reducing depressive symptoms (g=0.62) compared to functioning and 
QoL, although there was a strong indication for publication bias. In a subgroup analysis CBT 
showed higher effect size (g=0.49) for functioning when studies allowed participants in the 
treatment group to continue with their prescribed medication compared to studies that did not 
allow medication (g=0.19).  
Conclusions: Despite the relatively modest effect sizes, CBT is an efficacious therapy for 
improving functioning and QoL. However, the robustness of the results is insufficient due to the 
small number of trials and the lack of long-term outcome assessment data. 
Keywords: Cognitive Behavioral Therapy; functioning; quality of life; depression 
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Introduction 
Several meta-analyses on CBT have demonstrated its efficacy for reducing depressive 
symptoms (Butler, Chapman, Forman, & Beck, 2006; Cuijpers et al., 2013) and best-practice 
guidelines recommend CBT (in face-to-face, computerized and guided self-help formats) as a 
first-line treatment for mild to moderate depression (McAllister-Williams, 2006; Patten et al., 
2009). Moreover, based on its efficacy but also economic rationale, many countries have rolled 
out initiatives aiming to increase the provision of CBT in primary care (Clark, 2011). 
 Despite the strong evidence for CBT’s efficacy for reducing depression symptoms, less 
is known about the effects of CBT on other relevant outcomes such as functioning and QoL. 
Recent literature has suggested that functioning and QoL improvement is equally important for 
people with depression as their symptom improvement (IsHak et al., 2011; Lam, Parikh, 
Michalak, Dewa, & Kennedy, 2015; Zimmerman et al., 2006). Patients have prioritized 
functional over symptomatic outcomes and a return to a normal level of functioning at work, 
home or school has been seen as a significant factor for remission in depression (Zimmerman et 
al., 2006). Furthermore, despite being a symptom-focused psychotherapy (Patten et al., 2009), 
CBT also includes techniques initially developed to facilitate functional areas such as 
participation in enjoyable activities or to create problem solving and social skills in depressed 
persons (Hawton, 1989). Therefore, evidence pertaining to the efficacy of CBT on functioning 
and QoL is needed. To our knowledge, only one meta-analysis focused on computerized CBT 
(CCBT) has addressed functional improvement, but the results show no superiority of CCBT 
over control conditions (So et al., 2013). In addition, social functioning was the outcome of 
interest of two other meta-analyses for depression (De Silva, Cooper, Li, Lund, & Patel, 2013; 
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Renner, Cuijpers, & Huibers, 2014), but the reviews assessed the pooled effect of all 
psychotherapies without specific focus on CBT.  
More comprehensive data on all delivery formats is needed. Meta-analytic data on 
functioning would provide evidence of the efficacy of CBT for facilitating daily or social 
activities, whereas data on QoL would demonstrate the performance of CBT on one’s 
satisfaction with these activities and perception of his/her health (IsHak., Burt, & Sederer, 2002). 
Therefore, the objective of this meta-analysis of randomized controlled trials was to determine 
the efficacy of CBT for functioning and QoL. Additionally, sensitivity, subgroup and meta-
regression analyses were undertaken.  
Methods 
Methods and results are presented according to the PRISMA statement for reporting 
systematic reviews (Moher, Liberati, Tetzlaff, Altman, & Group, 2010).  
Search Strategy 
A systematic literature search combining the terms depressive disorder OR depression 
OR major depressive disorder (Mesh terms) AND functioning OR disability OR disabled persons 
OR sick leave OR activities of daily living OR leisure activities OR quality of life AND 
treatment OR intervention OR clinical trial OR therapy (MeSH terms, key words and text words) 
was performed in Pubmed, PsycINFO and the Cochrane Central Register of Controlled Trials. 
The search in the first two databases was limited to randomized controlled trials. We did not 
include terms specifically related to cognitive behavioral therapy to guarantee the inclusion of 
any possible relevant study applying CBT but not as a central topic.  In addition, references of 
published meta-analyses were manually checked. Articles, published in English between January 
2000 and November 2015 (last search performed in December 2015) were considered.  
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Manuscripts were included if they met the following criteria: 
1) Use of a randomized controlled research design. 
2) Inclusion of a CBT treatment arm. CBT had to include at least cognitive restructuring and 
behavioral activation procedures for depression.  
3) Inclusion of participants aged 18 or more 
4) Report of at least one validated outcome measure assessing functioning or QoL. 
Functioning was defined as any difficulty experienced in maintaining daily activities or 
participation in social life (Lam et al., 2015). QoL is understood as one’s satisfaction with 
these activities and perception of one’s health (IsHak. et al., 2002; World Health 
Organization Quality of Life Group, 1997).  Individual measures of marital or 
employment status were not included.  
5) Diagnosis of depression, established by a standardized diagnostic interview according to 
DSM-IV, DSM-IV-TR and ICD-10 criteria (American Psychiatric Association, 1994, 
2000; World Health Organization, 1992). We did not consider papers which included 
participants merely defined by a self-rated questionnaire scores.  
Studies comparing CBT to control conditions, other psychotherapies or pharmacotherapy 
were included. Studies including bipolar disorder or reporting results from maintenance or 
continuation therapies were excluded. The abstract screening was done by one researcher (K.K.) 
and a random selection of 30% of the abstracts was double checked independently by another 
two researchers (M.C. and C.T.) 
Data extraction and quality assessment 
Data from the selected studies were extracted by one author (K.K.) and all checked for 
accuracy by an independent reviewer.  Disagreements were resolved through discussion. The 
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selected variables were collected in a standard data extraction form including demographic and 
clinical data for participants, treatment groups, outcome measures and effect estimates. In cases 
of missing data, authors of the studies were contacted. When more than one outcome measure 
assessing the same concept (either functioning or QoL) was used in a study, data from all 
instruments were extracted and combined as a mean effect size. In the case of SF-36 (Ware & 
Sherbourne, 1992), the questionnaire was included as an outcome measure of QoL (Ishak. et al., 
2011) but if a study reported scores on the social functioning subdomain, it was considered 
separately as a measure of functioning. To avoid double counting, when a single study reported 
the effects of different intervention arms representing the same generic intervention (e.g. when 
both face-to-face CBT and Internet based CBT were compared with a control), they were 
averaged and entered once in the analysis (Senn, 2009). However, in subgroup analyses, the 
effects of each treatment arm were entered separately. Information on symptom severity was 
extracted only from validated instruments that explicitly measured symptoms of depression (e.g. 
Hamilton Depression Rating Scale (HDRS) (Hamilton, 1960). Data on effect estimates were 
extracted at post-assessment. Data on long-term effect of CBT are not presented, because a very 
small number of studies reported follow-up data and the follow-up periods differed significantly 
(e.g. 3 months vs 24 months). In addition, the nature of the follow-ups was distinct - some 
studies reported only naturalistic outcomes, whereas others delivered booster sessions and 
maintenance treatments during the follow-up period.  The instruments extracted were patient 
self-assessments and clinician-rated tools.  
Four over six criteria of the Cochrane Collaboration risk of bias tool were used for 
assessing methodological quality of the studies —sequence generation, allocation concealment, 
blinding of assessors, and incomplete outcome data (Higgins. et al., 2011). Since the majority of 
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psychotherapeutic designs cannot employ a double blind design, blinding of assessors in these 
studies included only outcome assessors in masking procedures. The other two criteria - selective 
outcome reporting and other sources of bias were not included due to the unavailability of study 
protocols needed to optimally assess them. Moreover, by examining study methodologies we 
found no clear indication that these biases were present. 
Statistical Analyses 
All statistical analyses were performed using the program Comprehensive Meta-Analysis, 
version 2.0. The effect size for each study was calculated aggregating the pooled difference 
between the two groups of treatments at the end of the intervention. Hedges’ g was preferred as 
an effect estimate because it provides better effect estimate for small sample sizes (Deeks, 
Higgins, & Altman, 2008). Random effects models accounting for the heterogeneity among 
studies were used for the mean effect sizes. Higgins’ I² statistic was calculated to test the 
heterogeneity. A value of 0% indicates no heterogeneity, 25% indicates low heterogeneity, 50% - 
moderate heterogeneity, and 75% high heterogeneity (Higgins., Thompson, Deeks, & Altman, 
2003). Statistics were based on intention-to-treat (ITT) data, but when missing, on completer 
data. It has been suggested that this approach is more realistic rather than excluding completer 
data, on the prerequisite that all subsequent differences between studies will be discussed and 
considered as a source of heterogeneity (Higgins & Green, 2009). 
Due to the inclusion of a wide range of outcome measures, sensitivity analyses were 
performed. Here, instruments measuring functioning were checked individually for their 
potential impact on the effect size of CBT on functioning. The same procedure was repeated for 
QoL. The following subgroup analyses were performed in order to examine whether certain 
characteristics of the studies were related to the effect sizes: 
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- Differences between age groups (adults vs. older adults)  
- Delivery format (face-to-face vs. internet or telephone delivered CBT) 
- Differences in the control group (WL or TAU) 
- Quality of studies (high vs. lower quality; ITT vs. completer data) 
- Stable medication usage in the CBT group (if not begun or changed in the last month 
before the trial) (allowed vs. not-allowed) 
Subgroup analyses were performed when there were at least five studies per group (to 
ensure sufficient statistical power). We intended to assess also type of depressive disorder 
(major depression vs other depressive disorders), but there was not sufficient data on other 
depressive disorders to allow performance of the analysis. We used a mixed effects model for 
the subgroup analyses, combining a random-effects model within subgroups and a fixed-
effect model across subgroups. In addition, simple meta-regression analyses were performed 
to explore whether 1) there was any association between the effect size of depressive 
symptoms and the estimates of functioning and QoL, 2) sample size had an impact on the 
estimates, and 3) the amount of psychotherapeutic sessions were important. We used a fixed 
effects model for the meta-regression analyses. Publication bias was assessed by visual 
inspection of funnel plots and the trim-and-fill procedure to analyze the changes after the 
accounting for publication bias (Duval & Tweedie, 2000).  
Results 
Study Selection 
After duplicates were removed, 2851 articles were identified for abstract check. Of these, 
149 were selected for full-text screening. Only 31 articles met the inclusion criteria and were 
included in the analyses. The rest were excluded mainly due to the absence of functioning or 
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QoL outcome measures, treatment not meeting the criteria for CBT or non-standardized 
diagnosis of depression. Some of the included studies reported outcomes on both functioning and 
QoL, which resulted in their inclusion in more than one individual analysis. The whole selection 
process and exclusion reasons can be seen in Figure 1. 
Figure 1. Flow chart of Study Selection 
 
Description of included studies 
 Selected characteristics of the studies can be seen in Table 1. A total of 4715 
participants were included in the trials. Mainly adults, aged between 18-65, diagnosed with 
major depressive disorder according to DSM IV (American Psychiatric Association, 2000) 
criteria (53.1%) were recruited. The duration of the trials ranged from five to 20 sessions. The 
most commonly used instruments for measuring functioning were Sheehan Disability Scale 
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(SDS) (Sheehan, 1983) and Social Adjustment Scale (SAS) (Weissman, Prusoff, Thompson, 
Harding, & Myers, 1978), as for QoL – SF-36. The quality of the studies varied. There were 15 
trials (48%) meeting all four criteria for publication bias, whereas 8 studies (26%) were missing 
two or three components of the Cochrane risk of bias tool.            
                  Insert here Table 1. Selected characteristics of the included studies.  
CBT vs. control condition for functioning and QoL  
 When compared to control conditions (WL or TAU), the effect of CBT on 
functioning was small to moderate (g=0.38, 95% CI 0.24-0.53).  The heterogeneity between the 
19 studies included was high (Q=65.74, p<.001, I²=72.62). No publication bias was observed. 
The results of the overall analysis are presented in Figure 2.  
 For QoL, the effect of CBT compared to control condition in 16 studies was also 
small to moderate (g=0.41, 95% CI 0.31-0.52). The heterogeneity was moderate (Q=28.37, 
p<.01, I²=47.12). After adjusting for publication bias, the effect size decreased to 0.38 (95% CI 
0.27-0.49).  
 When the effect of CBT on depressive symptoms was assessed, the pooled estimate 
of all studies was g=0.62 (95% CI 0.50-0.75, I²=79.13) (supplementary file 1). After adjusting 
for publication bias and applying the trim-and-fill procedure, however, the effect size dropped 
down to g=0.49 (95% CI 0.36-0.62).  
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Figure 2. Effects of CBT vs. control condition for functioning and QoL 
 
CBT vs. other psychotherapies and pharmacotherapy 
 Meta-analysis comparing directly CBT to other types of psychotherapies on 
functioning or QoL could not be performed, because there were only two studies reporting 
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functional or QoL outcome measures. The same applied for the direct comparison between CBT 
and pharmacotherapy on QoL. However, CBT could be compared to pharmacotherapy on 
functioning in four studies (Faramarzi et al., 2008; Husain et al., 2014; Miranda et al., 2003; Zu 
et al., 2014). The pooled effect size was g=-0.13 (95% CI -0.30-0.04, p=.14) slightly in favor of 
medication. After adjusting for publication bias the effect size increased to g=-0.15 in favor of 
medication (p=NS).  
Sensitivity, Subgroup and Meta-Regression Analyses 
The sensitivity analyses did not detect any significant difference in the overall effect sizes 
when each of the instruments was excluded, indicating that no outcome measure had a strong 
impact on the overall effect estimates. In the subgroup analysis CBT showed significantly higher 
effect size (g=0.49) for functioning when continuation of previously prescribed medication was 
allowed in the treatment group compared to the “no medication allowed” group (g=0.19). There 
were not enough studies without medication usage to perform analysis for QoL. Table 2 shows 
the effect estimates for all subgroups. Type of depressive disorder could not be assessed due to 
the insufficient data on depressive disorders different than MDD. The same applied for 
differences in age groups for both outcomes and the direct comparison between CBT and 
medication. 
 Furthermore, a series of simple meta-regression analyses assessing potential predictors 
were performed. First, associations between depressive symptoms and functioning and QoL were 
found (slope: 0.60, p<.001 for functioning; slope: 0.58, p<.001 for QoL), suggesting that when 
the effect size of CBT on reducing depressive symptom severity increases with 1 unit, the effect 
size of CBT on improving functioning and QoL increases with 0.60 and 0.58, respectively.  
Second, higher number of treatment sessions was significant predictor when CBT was compared 
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to control condition for functioning (slope: 0.02, p=.05). The slope of 0.02 indicated that with an 
increase of 5 sessions of CBT, the effect size of functioning increased by 0.10. Finally, lower 
sample size was found to be a significant predictor (p<.01) when CBT was compared to control 
condition for functioning. The heterogeneity in all meta-regression analyses was moderate to 
high. The analyses performed on the comparison between CBT and pharmacotherapy for 
functioning did not reveal any significant associations between the variables considered and the 
effect estimate.  
Insert here Table 2. Subgroup analyses exploring associations between effect sizes and study 
characteristics 
Discussion 
Main findings 
This meta-analysis including 4715 depressed participants was the first to analyze the 
efficacy of CBT on functioning and QoL in depression. We found that CBT was more 
efficacious at improving functional outcomes than non-active controls (g=0.38) but not 
pharmacological treatment. Furthermore, CBT was more efficacious at improving QoL (g=0.41) 
than non-active controls. However, CBT showed better results at reducing depressive symptoms 
(g=0.62) than at improving functioning and QoL.  
The effect sizes that we found for CBT on functioning (g=0.38) in this study are 
consistent with the pooled effect estimates of all psychotherapies for functioning found in 
previous meta-analyses (De Silva et al., 2013; Renner et al., 2014). Both Renner et al. (2014) and 
De Silva et al. (2013) reported an effect size of 0.46 in favor of psychotherapy against non-active 
control for functioning. Thus, CBT appears to show similar small to moderate efficacy as all 
psychological therapies pooled. We could not make further investigations on differences among 
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CBT and other psychotherapies due to the insufficient number of clinical trials directly 
comparing both. Furthermore, we found significant effect estimate of g=0.37 in favor of internet 
based CBT compared to control conditions, which was inconsistent with the previously found 
non-significant effect of d=-0.05 by So et al. (So et al., 2013). The inconsistence might be due to 
the fact that the meta-analysis of So and colleagues included studies in which the patients had 
only depressive symptoms without being formally diagnosed with depression. Another 
explanation may be that the authors considered instruments assessing well-being and QoL as 
outcome measures for functional improvement.  
We performed series of subgroup analyses to further investigate whether some study 
characteristics were related to the effect of CBT. We found that CBT had a significantly higher 
effect size for functioning when the studies allowed participants in the treatment group to 
continue with their prescribed medication compared to studies that did not allow medication.  
However, firm conclusions cannot be made due the absence of information on the number of 
participants within each trial who have taken medication together with CBT, and the number of 
participants not following a structured pharmacological treatment. Future research is warranted 
to explore whether combined treatment is more efficacious than CBT alone and whether pre-
existing pharmacological treatment might have an impact on the effectiveness of CBT. 
Furthermore, the effect size of CBT compared to WL was not significantly different to the effect 
size of CBT on TAU, tentatively indicating that treatment as usual may be no more effective 
than waiting list conditions for functioning and QoL. For depressive symptoms we found a 
significant difference between WL and TAU (g=0.78 for WL vs. g=0.54 for TAU). However, 
these results should be seen with caution considering the low number of studies. The failure to 
find significant differences may have been due to low statistical power rather than equivalency 
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across subgroups. Secondly, TAU is a broad concept and included studies generally did not 
define clearly all the elements included within. Some of the studies described TAU as a mixture 
of psychological and pharmacological treatment monitored by the general practitioner, some as 
only medication. Finally, there exists the possibility of confounding by additional study-level 
characteristics.  
Furthermore, we did not find sufficient evidence to directly compare the effect of CBT 
and pharmacotherapy on QoL. However, there were few but enough trials to indicate no 
significant differences between CBT and pharmacotherapy on functioning. The results can be 
considered consistent with precedent meta-analyses indicating no superiority of CBT over 
medication for reducing depressive symptoms (Cuijpers et al., 2013). However, only four studies 
were included in the analysis. The lack of comparative studies limits any firm conclusions, but 
future long-term outcome data might reveal superiority of one of the interventions.  
 
Depressive symptoms, functioning and QoL 
The results suggest that CBT performs better at reducing depressive symptoms than at 
improving functioning or QoL. Even though the effect size on depressive symptoms is an 
overestimation as we found a clear indication for publication bias, this finding calls for attention. 
There is a large body of research suggesting that functional recovery appears later than the 
symptomatic one (Kennedy, Foy, Sherazi, McDonough, & McKeon, 2007). Moreover, studies 
have found that depressive symptoms and QoL do not share considerable proportion of common 
variance (Coryell et al., 1993; Trompenaars, Masthoff, Van Heck, Hodiamont, & De Vries, 
2006). In this line, to further investigate the association between symptomatology, functioning 
and QoL, we performed meta-regression analyses. The results suggest that functioning and QoL 
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improve when symptom severity improves, but the design does not reveal which is the leading 
factor. It is clear that symptoms and functioning are interconnected, but causal relationships and 
potential precursors can be explored only through longitudinal research. Nonetheless, the fact 
that we found lower effect sizes for functioning and QoL than for depressive symptoms has an 
important prognostic implication for the course of depression after ending treatment. Studies 
have already found that residual functional impairment evokes relapse and recurrences (Vittengl, 
Clark, & Jarrett, 2009). The lack of long-term assessment does not allow us to further investigate 
the interrelations between both outcomes, but this finding stresses the importance of including 
functioning and QoL tools as primary outcome measures in clinical trials. 
Future research  
All this said, we think that future steps towards better performance of CBT on 
functioning and QoL are warranted. Firstly, more studies are needed. We found only 31 trials 
reporting the efficacy of CBT on functioning or QoL outcomes. This is in line with recent 
findings that only 5 - 20% of all clinical trials for depression measure and report functional 
outcomes (Kamenov, Cabello, Coenen, & Ayuso-Mateos, 2015; McKnight & Kashdan, 2009). 
Furthermore, there is need of long-term assessment data in RCTs. Very few studies reported 
follow-up data longer than one year. We still do not know what the long-term benefits of CBT on 
functioning and QoL are. Secondly, there is no gold standard tool for measuring functioning in 
depression to date (Lam et al., 2015). Therefore, development and application of more sensitive 
and user friendly instruments assuring a comprehensive assessment of both domains, or simply 
inclusion of a battery of already existing tools as primary outcome measures is warranted. 
Second, improvement can be achieved through tailoring of treatment to better meet the needs of 
people with functional or QoL problems. There are examples of studies that have adapted the 
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original treatment manual of CBT resulting in considerably high effect sizes. Naeem et al. 
(Naeem et al., 2014) have applied a culturally adjusted CBT manual for treating depressed 
people with functional impairment in Pakistan, resulting in improved functioning in the 
treatment group by an effect size of g=0.74.  A new functional Cognitive Behavioral Therapy 
(fCBT) for improving social functioning in schizophrenia created and tested by Cather (Cather, 
2005) shows promising results in reducing persistent positive symptoms. Stronger focus on 
facilitation of relevant functional areas or improvement of QoL areas might be a key for better 
results.  
Lastly, we argue that functioning and QoL should be directly targeted in the response and 
remission criteria for a more comprehensive assessment of treatment efficacy. There are already 
initial steps in this direction. Cohen et al (Cohen, Greenberg, & IsHak, 2013) have created an 
Individual Burden of Illness Index for depression to measure treatment impact and recovery in 
depression by incorporating multidimensional patient-reported outcomes of symptom severity, 
functioning, and QoL. Later on, Zimmerman et al. (Zimmerman et al., 2014) have validated a 
new instrument – the Remission from Depression Questionnaire, encompassing different 
domains of functioning and QoL along with symptomatology. The authors conclude that the new 
tool provides a broader perspective of depressed patients’ condition than purely symptom based 
measures and is more consistent with the biopsychosocial approach in the treatment of 
depression. Another possibility involves a separate definition of functional recovery in trials. A 
study by Mancini et al. (Mancini et al., 2012) has applied such criteria based on the Sheehan 
Disability Scale. However, all attempts for implementation of such criteria in research are still in 
their infancy. Much needs to be done in order to gain better understanding on the treatment 
trajectories.  
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Limitations 
This study has to be seen in the light of certain limitations. First, the number of studies 
was relatively small and we were not able to perform some of the analyses we intended to. 
Second, half of the studies did not meet one or more quality criteria. Even though the subgroup 
analyses did not find statistically significant differences between the high and low quality 
studies, given their small number, it might be that the effect sizes have been overestimated. 
Third, only overall rather than domain-specific improvements in functioning and QoL were 
assessed. Hence, we are not able to know whether certain aspect of functioning (e.g. work 
functioning or interpersonal relationships) improves more. We found an indication of publication 
bias, which might have led to an overestimation of the effect sizes. Obtaining data from 
unpublished studies and grey literature may negate this problem in future investigations, 
although locating such literature is challenging, for various reasons (e.g. its diverse origins, the 
unwillingness of authors to provide data) (Sterne, Egger, & Moher, 2011). Only articles 
published in English between 2000 and 2015 were included. We selected studies within this 
search period, as more than 80% of the clinical trials on CBT have been published since year 
2000 (Hofmann, Asnaani, Vonk, Sawyer, & Fang, 2012) and functioning has not been 
investigated extensively as an outcome of interest before that year (Hirschfeld et al., 2000). 
Furthermore, one of our aims was to explore the impact of different delivery formats on the 
results- e.g. face-to-face vs. computerized CBT. The first internet-delivered CBT trials were 
conducted in late 1990s and early 2000s (Andersson G, Carlbring P, Ljótsson B, & E, 2013), 
therefore we assert that this time frame adequately captures the effectiveness of the whole range 
of CBT delivery formats on functioning and QoL in depression.  
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Conclusions 
Despite these limitations, this meta-analysis has important clinical and research 
implications. It shows that despite the relatively modest effect sizes, CBT is an efficacious 
therapy for improving both functioning and QoL. This is a substantial finding considering the 
importance of both outcomes from patient perspective. The study also shows that CBT is as 
efficacious as medication for improving functioning outcomes. The small number of studies and 
lack of long-term outcome assessment, however, warrants future research to provide more robust 
results. Lastly, our findings suggest that CBT works better for symptoms than for functioning 
and QoL. This is in line with the current state-of-art of research on depression, focused more on 
symptom severity rather than functioning and QoL. Inclusion of existing or application of new 
and comprehensive instruments assessing both outcomes in longer clinical trials, or therapy 
adjustment to better meet the needs of patients having functional and QoL deteriorations are the 
initial steps that have to be taken towards a more complete definition of treatment effects.  
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Table. 1 Selected characteristics of the included studies. 
Study Definition Target 
Group 
Therapy (format) N Sessions/
Modules 
Control N Medication  
allowed in 
CBT 
group 
Outcome Measure 
Functioning/QOL 
Outcome Measure 
Depression 
Quality (0-4) Country 
Andersson et al. (2005)  MDD Adults ISH, based on CBT 36 5 Web-based 
discussion 
49 Yes QOLI BDI/MADRS 4 Sweden 
Berger et al. (2011) MDD Adults GSH, based on CBT 25 10 WL 26 Yes IIP-64/WHOQOL-BREF BDI-II 4 Switzerland 
Buntrock et al. (2015) SD Adults iCBT 202 6 Enhanced 
TAU 
204 Yes SF-12 CES-D 4 Germany 
Carta et al. (2012) Depression Adults CBC 34 12 TAU 30 Yes WHOQOL-BREF BDI 1 Italy 
Choi et al. (2012) MDD Adults GSH, based on CBT 25 6 WL 30 Yes SDS BDI 2 Australia 
Cramer et al. (2011) Depression Women Group CBT 45 12 TAU 19 Yes SF-12 PHQ-9 2 UK 
de Graaf et al. (2009) Depression Adults iCBT 100 8 TAU 103 Yes WSAS/SF-36  BDI-II 2 Netherlands 
Dobkin et al. (2011) MDD/Dys/
D NOS 
Adults CBT (individual) 41 10 TAU 39 Yes SF-36 Social 
Functioning/SF-36 
HAMD/BDI 4 USA 
Duarte et al. (2009) MDD Adults CBT (individual) 41 12 TAU 44 Yes KDQOL-SF BDI 3 Brazil 
Faramarzi et al. (2008) MDD Women CBT (group) 29 10 TAU/ 
Fluoxetine 
30/ 
30 
No GHQ social dysfunction GHQ depression 1 Iran 
Furukawa et al. (2012) SD Adults tCBT 58 8 WL 60 No HPQ BDI-II 3 Japan 
Hoifodt et al. (2013) Depression Adults Therapist-assisted Web-
based CBT 
52 5 WL 54 Yes EQ-5D BDI-II 4 Norway 
Husain et al. (2014) Depression Women PI (group), based on 
CBT 
32 10 Fluoxetine 32 No BDQ/ EQ-5D HAMD 4 UK/Pakistan 
Johansson et al. (2012) MDD Adults iCBT tailored/no tailored  36/3
7 
8 Other  42 Yes QOLI BDI/MADRS 3 Sweden 
Jonkers et al. (2012) MDD/Dys Older 
Adults 
MPI, based on CBT 125 10 TAU 133 No ADL/ IPA  4 Netherlands 
Kessler et al. (2009) Depression Adults iCBT 99 10 TAU 91 Yes EQ-5D BDI 4 UK 
Laidlaw et al. (2008) MDD Older 
Adults 
CBT (individual) 20 8 TAU 20 No WHOQOL Social Rel. 
Scale/WHOQOL  
HAMD/BDI/GDS 2 UK 
Miranda et al. (2003) MDD Women CBT (individual/group) 90 8 TAU/AD 89/ 
88 
No SAS-CR; SF-36 soc. 
funct.scale 
HAMD 4 USA 
Moritz et al. (2012) Depression Adults Self Help iDeprexis 80 10 WL 90 Yes Whoqol-BREF BDI 3 Germany 
Naeem et al. (2014) DE/RD Adults CaCBT 94 9 TAU 89 Yes BDQ HADS depression 4 Pakistan 
Perini, Titov, and 
Andrews (2009) 
MDD Adults GSH, based on CBT 27 6 WL 18 Yes SDS BDI-II 3 Australia 
Phillips et al. (2014) Depression Adults iCBT: MoodGym 171 5 Other 188 Yes WSAS PHQ-9 3 UK 
Scott et al. (2000) RD Adults CBT+CM 80 16 CM 78 Yes SAS-SR BDI/HAMD/ 4 UK 
Serfaty et al. (2009) Depression Older 
Adults 
CBT (individual) 70 12 TAU 67 Yes SFQ/EQ-5D BDI-II 4 UK 
Titov et al. (2010) MDE Adults iCBT + technician/ iCBT 
+ clinician 
41/4
6 
6 WL 40 Yes SDS BDI-II/PHQ-9 4 Australia 
Vernmark et al. (2010) MDD Adults iGSH CBT vs. 
Individualized CBT 
Email Therapy 
29/3
0 
7 WL 29 Yes QOLI BDI/MADRS 4 Sweden 
Ward et al. (2000) Depression Adults CBT (individual) 67 6 TAU 67 No SAS-M BDI 3 UK 
Wiles et al. (2013) Depression Adults CBT (individual) 201 12 TAU 209 Yes SF-12 BDI 4 UK 
Williams et al. (2013) MDE Adults iCBT 35 13 WL 28 Yes WHODAS BDI/PHQ-9 2 Australia 
Wong (2008) MDD Adults CBT (group) 163 10 WL 159 Yes Q-LES-Q-18 BDI 1 China 
Zu et al. (2014) MDD Adults CBT (individual) 12 20 TAU/AT 16/ No WSAS HAMD/QIDS-SR 3 China 
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Note: AT= Antidepressant Treatment, BDI= Beck Depression Inventory, BDI-II= BDI Second Edition, BDQ= Brief Disability Questionnaire, CaCBT= Culturally adjusted 
Cognitive Behavioural therapy, CBC= Cognitive Behavioural Counselling, CBT= Cognitive Behavioural therapy, GSH= Guided Self-Help, CES-D= Centre for Epidemiologic 
Studies Depression Scale, D NOS= Depression Non otherwise Specified, Dys= Dysthymia, GDS= Geriatric Depression Scale, HAMD= Hamilton Rating Scale for Depression, 
HPQ= World Health Organization Health and Work Performance Questionnaire, iCBT=internet-based CBT, IIP=  Inventory of Interpersonal Problems, ISH= Internet 
administered self-help, KDQOL-SF= Kidney Disease and Quality of Life Short Form, MADRS= Montgomery–Åsberg Depression Rating Scale, MDD= Major Depressive 
Disorder, QIDS= Quick Inventory of Depressive Symptomatology, RD= Recurrent Depression, SAS= Social Adjustment Scale, SAS-SR= Social Adjustment Scale, Self-Report, 
SCL-90= Symptom Checklist-90, SDS= Sheehan Disability Scale, SF-36= 36-item Short-Form Health Survey, TAU= Treatment as usual, WHOQOL= World Health Organization 
Quality of Life, WL= waiting list, WSAS= Work and Social Adjustment Scale. 
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Table 2. Subgroup analyses exploring associations between effect sizes and study characteristics 
 
 
 
 
 
 
 
 
 
 
 
 
Note: *The p in this column indicates whether the difference between the effect sizes in this subgroup is significant 
 
 
 
Comparison N g 95% CI Q I² P* 
CBT vs. control for functioning       
Delivery format 
Face-to-face 
 
10 
 
0.40 
 
 0.18-0.61 
 
36.06 
 
75.04 
 
   0.9 
iCBT/tCBT   9 0.37  0.15-0.59 29.54 72.92  
Control condition 
CBT vs. WL 
 
  6 
 
0.50 
 
 0.23-0.77 
 
19.41 
 
74.24 
 
   0.3 
CBT vs. TAU 13 0.33  0.16-0.51 42.16 71.54  
Quality of studies 
High Quality 
 
14 
 
0.35 
 
 0.19-0.52 
 
50.60 
 
74.31 
 
   0.5 
Lower Quality   5 0.49  0.17-0.81 14.26 71.95  
Medication in CBT group 
Yes 
 
12 
 
0.49 
 
 0.30-0.68 
 
38.80 
 
71.65 
 
   0.02 
No   7 0.19  0.01-0.36 12.91 53.53  
CBT vs. control for QoL       
Delivery Format 
Face-to-face 
 
  8 
 
0.45 
 
 0.31-0.60 
 
10.62 
 
34.08 
 
   0.5 
iCBT/tCBT   8 0.37  0.21-0.53 15.73 55.5  
Control Condition 
CBT vs. WL 
 
  5 
 
0.53 
 
 0.35-0.72 
 
3.03 
 
0.00 
 
   0.1 
CBT vs. TAU 11 0.36  0.24-0.48 21.02 52.43  
Quality of studies 
High Quality 
 
11 
 
0.44 
 
 0.30-0.57 
 
10.31 
 
3.04 
 
   0.7 
Lower Quality   5 0.36  0.17-0.56 17.33 76.92  
ITT vs. Completers 
ITT                                                                                                                   
Completer Analysis 
 
10 
  6 
 
0.41
0.42 
 
0.25-0.58 
0.30-0.54 
 
24.2 
4.13 
 
62.82 
0.00 
 
   0.9 
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5.2. Collection of empirical evidence for further improvement of treatment 
effectiveness measurement in depression  
  The second part of the Results section is dedicated to the collection of 
empirical evidence for the improvement of the current measurement of treatment 
effectiveness in depression. This part is designed as a response to all the limitations 
of the current literature identified in the first part of the thesis. The evidence is 
collected from a multi-country cross-sectional study, a qualitative study with patients 
with depression, and an expert survey with representatives from clinical practice. A 
brief summary of the results from the papers is presented before the articles. 
5.2.1. Summary of findings: 
 There was a variation in the level of impairment in different functioning 
domains across countries. 
 Gender differences in the impact of functional impairment on quality of life in 
depression were found 
 The most burdensome functional domains were identified 
 Clinicians and depressed patients highlighted the importance of both 
symptoms and functional areas beyond symptoms. 
 A set of the most important functional areas in depression, namely mental 
functions, sleep, energy level, somatic problems, interpersonal relationships and 
interaction, recreation and daily activities, communication, social participation, daily 
tasks and demands, work and educational difficulties and personal factors such as 
self-efficacy, self-esteem or self-awareness was defined.  
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 Clinicians and patients identified a number of differences regarding the areas 
improved by psychotherapeutic or pharmacological interventions that were not 
addressed by the pertinent literature.  
 A set of recommendations for future improvement of treatment efficacy 
measurement was provided 
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Background: The study aimed to identify the most burdensome functioning domains
in depression and their differential impact on the quality of life (QoL) of individuals from
nine countries in Asia, Africa, Europe, and Latin America.
Materials and Methods: Data from two multi-country projects—the World Health
Organization’s Study on Global Ageing and Adult Health (SAGE) and the Collaborative
Research on Ageing in Europe (COURAGE)—were analyzed. Eight functioning domains
(pain, mobility, self-care, cognition, interpersonal activities, domestic life, and work, sleep
and energy, and affect) and QoL were assessed in 4051 individuals with depression.
Results: The analyses of the pooled sample showed that affect (ß = –0.21, p < 0.001),
domestic life and work (ß = –0.16, p < 0.001) and interpersonal activities (ß = –0.15,
p< 0.001) were the most affected functioning domains. When the analysis was stratified
by gender, women showed similar patterns to the total sample, whereas mobility, self-
care, cognition and pain were not significant amongst men. The cross-national analysis
revealed that difficulties in affect and interpersonal activities were common across
countries, whereas the rest of the domains showed country variability. In addition, being
a woman (ß = –0.05), being older (ß = 0.07), being married (ß = 0.05), not having
a comorbid condition (ß = –0.03) and having a higher education (ß = 0.04) were all
factors associated with higher levels of QoL.
Conclusion: There was a variation in the level of decrements in different functioning
domains across countries. This is in line with the growing evidence that reporting
functioning sum-scores obscures potential differences among people. Functioning
tools should capture the distinctiveness among individuals in order to provide tailored
responses.
Keywords: functioning, disability, quality of life, depression, cross-national study
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INTRODUCTION
In spite of all evidence based treatments, depression still
represents a huge burden to society (Chisholm et al., 2004) due
to the disability it causes (Ferrari et al., 2013), its high mortality
rates (Cuijpers and Schoevers, 2004), suicide risk (World Health
Organization, 2012), and economic impact (Sobocki et al., 2006).
The diagnosis of depression is based on a number of symptomatic
criteria (World Health Organization, 1992; American Psychiatric
Association, 2000, 2013), but it has been argued that this
broad diagnosis might lump individuals suffering from different
syndromes into one category (Fried and Nesse, 2014). Therefore,
there is a growing body of literature suggesting that the depressive
symptoms need to be analyzed individually (Lux and Kendler,
2010), shifting the focus from assessing not only the number
but also their nature (Lux and Kendler, 2010). Fried and Nesse
(2014) analyzed the concurrent effects of individual depressive
symptoms on the functional state of depressed individuals and
found that the symptoms vary substantially in their associations
with impairment. Sad mood and concentration problems were
found to be the most debilitating symptoms.
There is also a growing recognition of the importance
of improving functioning when treating depression; in fact,
normalization of a patient’s overall functioning is considered an
important criterion for remission (Zimmerman et al., 2006a,b).
However, more than 80% of interventional studies published
in the last decade have reported only sum-scores of the
instruments assessing functioning – e.g., Social Adjustment Scale
(Weissman et al., 1978), Sheehan Disability Scale (Sheehan,
1983), WHODAS (Ustun et al., 2010), rather than domain-
specific information (Kamenov et al., 2015). These sum-scores
do not provide information on the differential impact of
each functioning domain on the overall state of a person
with depression. Thus, a higher score might indicate either
a large number of mildly affected functioning areas or a
few domains with marked decrements. It remains unclear
whether distinct areas of functioning weight differently in
terms of individual burden. The International Classification of
Functioning, Disability and Health (ICF) Research Branch of
the World Health Organization (WHO) developed an evidence-
based Core Set for depression (Cieza et al., 2004) to address
the broad spectrum of disability and functioning in depression.
Until now the Core Set has not been sufficiently implemented in
research studies, perhaps due to the complexity of the model or
the large number of categories selected (Alvarezz, 2012). Cieza
et al. (2014) proposed a minimal generic set of functioning
domains, based on the ICF model, which reflects the experience
of individuals with regard to their global health, but the article
did not provide any disease-specific information related to
depression.
Therefore, the first objective of this study was to identify the
most burdensome domains of functioning according to their
impact on the quality of life (QoL) of patients with depression.
QoL was chosen as an indicator of the overall condition of
depressed individuals because it refers to one’s satisfaction with
life activities and one’s appraisal of life in general (IsHak et al.,
2002). Moreover, QoL improvement and restoration have been
considered the ultimate barometer of treatment success in
depression (IsHak et al., 2011).
Furthermore, many studies found cross-national differences
in the prevalence and symptom profiles of depression.
A population-based study with more than 38000 participants
from 10 countries revealed remarkable differences in the lifetime
prevalence of depression ranging from 1.5/100 adults in Taiwan
to 19.0/100 adults in Beirut (Weissman et al., 1996). The WHO
Psychological Problems in General Health Care (PPGHC)
study further showed a 15-fold variation in major depression
prevalence, from lowest prevalence in Japan and China to highest
prevalence in Brazil and Chile (Simon et al., 2002). On the other
hand, cross-national differences in symptom profiles were also
identified. Loss of energy, insomnia, concentration difficulties
and thoughts of death appeared in all countries, whereas weight
loss, increased appetite, hypersomnia, retardation, agitation
and decrease in sexual interest were determined as country-
specific (Weissman et al., 1996). A study by Waza et al. (1999)
found that Japanese depressed patients experienced more and
different somatic symptoms than American patients. Despite
the rich evidence on prevalence and symptom differences in
depression, little has been done in regard to potential cross-
national differences in functional impairment. Studies have
predominantly assessed functioning as a general concept rather
than domain-specific. A study by Bromet et al. (2011) based
on the World Mental Health survey found that the association
between prevalence of depression and functional impairment
was positive across high- and low-income countries. Moreover,
Simon et al. (2002) showed that depression was universally
associated with disability across countries with low, middle, and
high prevalence rates of depression.
It is still unknown, however, whether there are cross-national
differences in the level of impairment of individual functioning
areas in depression. Such information could shed light on
the distinctiveness among individuals across countries in order
to facilitate the assessment of disability and provide tailored
responses. Therefore, the second objective of this paper was to
examine the cross-national diversity of the relationship between
the functioning domains and QoL of depressed patients in nine
countries: Finland, Poland, Spain, China, Ghana, India, Mexico,
Russian Federation, and South Africa.
MATERIALS AND METHODS
Sample and Procedure
The study used data obtained from the WHO’s Study on Global
Ageing and Adult Health (SAGE) and the Collaborative Research
on Ageing in Europe (COURAGE in Europe), two multi-country
projects conducted between 2007 and 2012. The COURAGE
survey was conducted in Finland, Poland, and Spain, whereas the
SAGE survey was undertaken in China, Ghana, India, Mexico,
the Russian Federation, and South Africa. The selected countries
represent different geographical locations and levels of socio-
economic and demographic status. Both projects collected data
on participants aged 18+ years, with an emphasis on people aged
50+ years, from nationally representative samples. The details of
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the design and methods for Courage in Europe and SAGE are
published elsewhere (Kowal et al., 2012; Leonardi et al., 2014).
The sample comprised 4051 non-institutionalized adults
(18+) who were currently experiencing an episode of depression
from China (296), Ghana (428), India (1522), Mexico (291),
Russia (321), South Africa (168), Poland (288), Finland (136) and
Spain (601). Trained lay interviewers undertook the face-to-face
interviews at the respondents’ homes. The interviews in Mexico,
Poland, Finland and Spain were completed by computer-assisted
personal interview (CAPI), whereas in the remaining countries
the researchers used a paper and pencil interview (PAPI). China
was the only country where both CAPI and PAPI were used.
Quality control procedures were undertaken during the fieldwork
(Üstun et al., 2005). Informed consent from all participants was
obtained. Ethical approval was obtained from the WHO Ethical
Review Committee for SAGE and by Neurological Institute Besta
for COURAGE, and by all local ethics research review boards
(Helsinki and Uusimaa Hospital District, Finland; Jagiellonian
University Medical College, Krakow, Poland; Parc Sanitari Sant
Joan de Déu, Barcelona, Spain; La Princesa University Hospital,
Madrid, Spain; Shanghai Municipal Centre for Disease Control
and Prevention, Shanghai, China; Ghana Medical School, Accra,
Ghana; International Institute of Population Sciences, Mumbai,
India; National Institute of Public Health, Cuernavaca, Mexico;
School of Preventive and Social Medicine, Russian Academy
of Medical Sciences, Moscow, Russia; and Human Sciences
Research Council, Pretoria, South Africa). The individual
response rate ranged from 53% in Finland and Mexico to 93%
in China.
Measures
The process of translation and adaptation of instruments aimed
to achieve conceptually equivalent versions of all instruments in
each of the countries. The first step was a forward translation,
where a health professional familiar with the terminology of
the specific area translated the instruments from English to
the particular language following series of instructions. Then,
a bilingual expert panel including health experts and experts
with experience in instrument development and translation
revised the translation. The third step was a back-translation
by an independent translator. Finally, a pre-testing on a target
population representative of those who will be administered the
questionnaire was done. The whole process was based on a
method previously refined in the course of several WHO studies
(World Health Organization, 2009).
Depression
Participants who had been diagnosed with depression by a
physician and had been receiving treatment during the last
12 months were included in the study. In addition, since
there are many cases of undiagnosed persons who actually
experience depressive episodes (Sheehan, 2004; Volicer et al.,
2011), we assessed depression with a set of symptomatic questions
derived from the World Mental Health Survey version of
the Composite International Diagnostic Interview (CIDI) for
depression (Kessler and Ustun, 2004). The individual items were
included in a diagnostic algorithm generating a diagnosis of
“depressive episode” according to the criteria specified in the
International Statistical Classification of Diseases and Related
Health Problems, 10th revision, Diagnostic Criteria for Research
(World Health Organization, 1992).
Functioning Domains
Functioning was assessed with a multi-domain measure
(Salomon et al., 2003) that was developed as an answer to
the WHO statement: “functioning and functioning domains
constitute the operationalization that best captures our intuitive
notion of health” (Cieza et al., 2014). The measure had been
previously used in 70 countries from the World Health Survey
(Salomon et al., 2003). Participants were asked about the
difficulties they had experienced in the last 30 days in each of
these domains. The responses to each question were recorded
on a 5-point scale ranging from 1 (no difficulty/problem) to 5
(extreme difficulty/inability).
Mobility
The domain of mobility assessed the ability of a person to move
and get around. The participants were asked whether in the
last 30 days they have had any difficulty in “vigorous activities,”
“walking a long distance such as a kilometer (or equivalent),”
“walking 100 meters,” “moving around inside your home,” “getting
out of your home,” “getting where you want to go, using private
or public transport if needed,” “stooping, kneeling or crouching,”
“standing up from sitting down,” “getting up from lying down,”
“sitting for long periods,” “standing for long periods such as
30 min,” “picking up things with your fingers (such as picking up
a coin from a table),” “extending your arms above your shoulder
level” and “carrying things (such as carrying grocery bags, water
bottles, etc.).”
Self-Care
This domain measured the capacity of a person to perform self-
care activities by answering the following items: “Overall, in the
last 30 days, how much difficulty did you have in: ‘taking care of
and maintaining your general appearance (for example, grooming,
looking neat and tidy),’ ‘staying by yourself for a few days,’ ‘washing
your whole body,’ ‘getting dressed,’ ‘getting to and using the toilet,’
‘eating (including cutting up your food).”
Cognition
This domain measured communication and thinking activities.
The two items included “Concentrating on doing something for 10
min” and “learning a new task, for example, learning how to get to
a new place.”
Pain
Pain was assessed with two items: “How much of bodily aches or
pain did you have?” and “how much difficulty did you have in your
daily life because of your pain?”
Interpersonal Activities
This domain assessed the ability of individuals to interact with
other people through five items: “Joining in community activities
(for example, festivities, religious or other activities) in the same
way as anyone else can,” “personal relationships or participation in
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the community,” “dealing with conflicts and tensions with others,”
“ making new friendships” and “dealing with people you do not
know.”
Domestic Life and Work
This domain assessed difficulties with day-to-day activities, such
as “taking care of your household responsibilities” and “your day-
to-day work/school.”
Sleep and Energy
This domain assessed difficulties in sleep patterns (“sleeping, such
as falling asleep, waking up frequently during the night or waking
up too early in the morning”) and energy level (“not feeling rested
and refreshed during the day (for example feeling tired, not having
energy).”
Affect
This domain assessed the emotional functioning of participants.
The domain included four items: “feeling sad, low or depressed,”
“worry or anxiety,” “emotionally affected by your health problems”
and “how much did these difficulties interfere with your life.”
Quality of Life
Quality of life was assessed using a short version of the
WHO Quality of Life (WHOQOL) instrument (Power, 2003;
Skevington et al., 2004). This questionnaire has shown good
cross-cultural validity (da Rocha et al., 2012). It was designed
as a short and concise instrument of eight items reporting four
domains—psychological, social, physical, and environmental,
each assessed by two items. The overall QoL score (ranging
between 0 and 100) was formed by the sum of the scores of the
eight items, with higher scores indicating better quality of life.
Control Variables
Country, age, sex, marital status, presence of comorbid physical
chronic conditions (angina, hypertension, asthma, arthritis, or
diabetes) and level of education were included in the analysis as
control variables.
Statistical Analysis
Descriptive statistics including summary of the socio-
demographic data of the participants were obtained.
Factor scores for each functioning domain were obtained and
then the scores were transformed into a scale ranging from
0 to 100, with lower scores representing better functioning.
Before calculating the factor scores for each of the domains of
functioning, confirmatory factor analyses (CFA) were performed
to assess the goodness-of-fit of the domains.
To examine the independent contributions of all domains
of functioning on QoL, a multiple regression analysis was
conducted. Age, sex, country, marital status, comorbidity, and
educational level were introduced as covariates to control for
potential confounders. In addition, the analysis was carried
out on the entire sample of depressed individuals, on men
and women and on each country separately. The independent
variables were introduced simultaneously in the model because
we examined the effect of different domains of functioning
on QoL rather than introducing previously established models.
The ordinary least squares (OLS) estimation was employed,
since it has been shown to yield the best fit of data (Alonso
et al., 2011). Standardized (β) coefficients indicated the level of
association between the functioning domains and the covariates
and QoL, since (β) can be applied as effect size in regression
models. Since we conducted multivariate regression models, with
several independent variables, the presence of multicollinearity
was assessed by means of the Variance Inflation Factor (VIF).
Values below 5 were considered adequate (Rogerson, 2001) and
providing evidences for little or no multicollinearity in the data.
STATA version 11.0 (Stata Corp, 2009) was used to analyze
the socio-demographic data, to calculate the factor scores and
to conduct the regression models. Amos version 22 (Arbuckle,
2013) was used for the CFA. Confidence intervals (CI) for
hypothesis tests were constructed at the 95% confidence level.
RESULTS
Characteristics of the Sample
Socio-demographic and clinical characteristics of the sample in
each country are presented in Table 1. A total of 4051 people
with depression took part in the study. The mean age of the total
sample was 60 years (SD = 14.36). Women were the majority
(66.3%) and 67% of the sample had not completed higher
education. Differences could be seen in Russia and Finland, where
more than 85% of the sample had completed secondary school.
The mean QoL score was 53.59 (16.69).
The Impact of Functioning Areas on
Quality of Life
Confirmatory factor analyses were performed to find evidence for
unidimensionality and the use of a global score in each domain.
In each case, a single-factor model was proposed considering
the items assigned to the domain. Then the factor structure was
tested. All functional areas presented an acceptable fit according
to the goodness-of-fit indices: Comparative Fit Index (CFI)>0.90
and Root Mean Square Error of Approximation (RMSEA) <0.08
in all cases. For the domains that included only two items,
Cronbach’s alpha value was calculated, being higher than 0.70.
Inter-item correlation was also higher than 0.50 in each case,
indicating a strong relationship between the two items and also
providing evidence of unidimensionality.
The results from the multiple regression analysis (Table 2)
revealed that affect (ß= –0.21, p < 0.001), domestic life and work
(ß = –0.16, p < 0.001) and interpersonal activities (ß= –0.15,
p < 0.001) were the most important functioning domains
associated with QoL. Sleep and energy, mobility and cognition
were also statistically significant, but their effect sizes were smaller
compared to the former three. Pain (p = 0.14) and self-care
(p = 0.86) were the only domains that were not statistically
significant.
When the analysis was separated by gender (Table 2), women
showed similar patterns as the total sample, with the only
difference being that sleep and energy was only marginally
significant (ß = –0.04, p = 0.06). Affect remained the most
important functioning area (ß = –0.24, p < 0.001), followed
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) by interpersonal activities, domestic life and work, mobility and
cognition. Interpersonal activities were more strongly associated
with their QoL compared to the total sample. Men, however,
showed different patterns compared to the total sample and
women in particular. Affect was still the most fundamental factor,
but sleep and energy (ß = –0.13, p < 0.001) appeared to be the
second major functioning area for men as opposed to women.
Self-care was only marginally significant (ß = –0.08, p = 0.06),
whereas cognition (ß = –0.06, p = 0.12), mobility (ß = –0.09,
p = 0.08), and pain (ß = 0.001, p = 0.84) were not statistically
significant functioning domains in men.
Furthermore, with respect to the control variables, being a
woman (p = 0.001), being older (p < 0.001), being married
(p= 0.001), not having a comorbid condition (p= 0.005), having
a higher education (p = 0.017) and living in a specific country
(compared to China; p < 0.001) were associated with higher
levels of QoL in people with depression. There were gender
differences only in terms of educational level, comorbidity and
marital status—the former two not being significant for women
and the latter for men. All the variables considered in the analyses
had an associated VIF value lower than 5, indicating that the
assumption of no perfect multicollinearity can be assumed to
conduct the regression model.
Cross-National Differences in the Level
of Impairment in Different Functioning
Areas
We did a further cross-national analysis, controlling again for sex,
age, marital status, level of education and comorbid conditions
by exploring the most relevant functioning domains in each of
the nine countries. Affect was significant in all countries except
China. The second most commonly important domain was
interpersonal activities, significant in all countries except Mexico,
China and South Africa. Pain was significantly associated with
QoL in Spain, Poland, India and Ghana. Domestic life and work,
cognition, and sleep and energy showed statistical significance
only in three of the nine countries. Mobility (ß = –0.34,
p < 0.001) was the least represented domain across countries,
being significant only in Spain. On the other hand, looking at the
number of significant areas for each country, in India seven out of
eight domains were significant (only mobility was not significant),
followed by Spain with five (interpersonal activities, mobility,
pain, self-care, and affect). China was the only country where only
one functioning domain was found statistically significant – sleep
and energy (ß= –0.15, p< 0.05). Detailed results for each country
can be seen in Figure 1.
DISCUSSION
The present study examined the differential association of eight
functioning domains on QoL in a large and representative
sample of 4.051 depressed individuals across nine countries. Our
findings suggest that affect, interpersonal activities and domestic
life and work had the highest impact on QoL in depression. Sleep
and energy, mobility and cognition were also important factors,
but their effect was smaller. Self-care and pain were the only
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TABLE 2 | Effect estimates of functioning domains on quality of life using multiple regression analysis.
Variables Total Women Men
B (95% CI) p ß∗ B (95% CI) p ß B (95% CI) p ß
Cognition –0.04 (–0.07–0.01) 0.001 –0.07 –0.04 (–0.08–0.01) 0.007 –0.07 –0.04 (–0.08–0.01) 0.12 –0.06
Mobility –0.05 (–0.09–0.01) 0.007 –0.08 –0.05 (–0.1–0.001) 0.046 –0.07 –0.06 (–0.13–0.01) 0.08 –0.09
Pain –0.02 (–0.04–0.01) 0.14 –0.03 –0.03 (–0.05–0.004) 0.09 –0.04 0.01 (–0.04–0.04) 0.84 0.01
Self-care –0.01 (–0.04–0.03) 0.86 0.01 0.02 (–0.02–0.07) 0.32 0.03 –0.07 (–0.13–0.01) 0.06 –0.08
Interpersonal act. –0.11 (–0.14–0.08) <0.001 –0.15 –0.13 (–0.16–0.10) <0.001 –0.18 –0.07 (–0.12–0.03) 0.003 –0.11
Domestic life/Work –0.09 (–0.12–0.06) <0.001 –0.16 –0.10 (–0.13–0.06) <0.001 –0.17 –0.08 (–0.12–0.03) 0.001 –0.13
Sleep and energy –0.04 (–0.07–0.02) <0.001 –0.07 –0.03 (–0.05–0.01) 0.06 –0.04 –0.08 (–0.11–0.04) <0.001 –0.13
Affect –0.15 (–0.18–0.12) <0.001 –0.21 –0.17 (–0.20–0.13) <0.001 –0.24 –0.11 (–0.16–0.06) <0.001 –0.16
Controlling variables
Sex –1.75 (–2.75–0.75) 0.001 –0.05
Age 0.09 (0.05–0.12) <0.001 0.07 0.09 (0.04–0.14) <0.001 0.08 0.08 (0.01–0.14) 0.022 0.06
Educational level 1.41 (0.26–2.56) 0.017 0.04 1.05 (–0.46–2.56) 0.17 0.03 1.98 (0.14–3.82) 0.035 0.06
Marital status 1.71 (0.71–2.71) 0.001 0.05 1.64 (0.42–2.85) 0.008 0.05 1.52 (–0.39–3.43) 0.12 0.04
Comorbidity –1.46 (–2.47–0.45) 0.005 –0.03 –0.75 (–2.19–0.3) 0.14 0.03 –2.47 (–4.18–0.76) 0.005 –0.07
*Effect size, ß coefficient; Country was introduced as a covariate in the model. ∗ In bold, significant p-values at 95% confidence level.
FIGURE 1 | Relationship between functioning domains and quality of life by country. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001. Age, sex, marital status,
comorbidity, and educational level were introduced as covariates to control for potential confounders. SA, South Africa.
domains that were non-significant for men or women. A possible
explanation might be that the participants showed relatively
higher levels of self-care and lower levels of pain, and severe
decrements in these domains were rare.
Only one study to date has attempted to identify a set
of the most relevant functioning domains but does not
provide anything disease-specific, but rather general clinical
information (Cieza et al., 2014). The authors of the study
suggested that mobility, pain, sleep and energy, and affect were
the most important functioning domains associated with the
general health of both clinical and general populations. Our
study coincides with some of these findings, but the degree
of importance varied. Affect was the most relevant domain
associated with QoL, but pain was not significant in our sample.
Interpersonal activities, however, which was the second most
important domain in our study, was not considered in the
final set of Cieza et al. (2014). This result is not surprising,
as previous studies have already reported that people with
depression experience significantly poorer intimate relationships
and less satisfying social interactions than individuals with other
psychiatric disorders, or the general population (Fredman et al.,
1988).
We further examined differences across the included
countries. Affect was significant in all countries except China.
This supports previous evidence that emotional problems, such
as low mood, are a core part of the experience of depression
(Fried and Nesse, 2014) and chronic physical or mental
conditions in general (Weigl et al., 2004). However, most of the
generic functioning tools, such as WHODAS-II or SF-36 (Ware
and Sherbourne, 1992), do not include affect as a single domain.
Difficulties in interpersonal activities were also prevailing in most
of the countries. However, the rest of the domains were country
specific. Cognition was associated with QoL in Poland, India
and Mexico; mobility in Spain; and sleep and energy in India,
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South Africa and China. In India we found a significant positive
association between pain and QoL (ß = 0.07, p = 0.025) after
controlling for sociodemographic variables and the remaining
functioning domains. This finding is counterintuitive, as it
indicates that a higher pain is associated with better QoL. In
the rest of the countries where pain was associated with QoL—
Spain, Poland and Ghana—we found a negative relationship
between both. We examined the correlation coefficient between
QoL and pain and found a significant value of r = –0.340
(p < 0.001). However, after controlling for affect we found a
non-significant partial correlation coefficient. After we ran the
previous regression model without considering affect as covariate
we did not find any significant association between pain and
QoL. This suggests that the relationship between pain and QoL
in India was moderated by affect. Similarly, a counterintuitive
association was found between self-care and QoL in Spain. We
found a highly significant correlation between self-care and
mobility in the Spanish sample (r = 0.764), which suggested
potential multicollinearity in the model. After mobility was
removed from the regression model, self-care was no longer
significantly associated with QoL.
The reason why some functioning domains were associated
with QoL only in some countries but not in others is unclear,
but certain cultural contrasts might be responsible for these
variations. For instance, in our study mobility was more
important for the Spanish population than for any other
country. Previous studies evaluating the health status in general
population confirm this result, showing that Spanish raters place
more importance on mobility as a functioning domain compared
to other countries due to cultural or lifestyle characteristics (Badia
and Alonso, 1995; Badia et al., 2001).
Even though many of the effect sizes associated with the results
obtained from the regression models were small or moderate,
the results of this study have considerable practical implications.
Firstly, in a research perspective, our results boost future changes
in the measurement of disability in depression. The study proves
that there is a variation in the level of decrements in different
functioning domains across countries. Furthermore, it provides a
basis for further development of more sensitive, cross-nationally
validated and user-friendly instruments weighting the domains
according to their importance and providing a better picture
on the living experience of depressed individuals. This action
is urgent, given the fact that only 5–20% of all clinical trials
for depression report functioning outcomes (McKnight and
Kashdan, 2009; Kamenov et al., 2015) and to date there is no
gold standard tool for measuring functioning in depression (Lam
et al., 2015). Symptoms of depression, which are the main focus
of clinical trials, provide early signs of treatment response, but the
functional outcomes provide an indicator of meaningful change,
thus making the inclusion of functional tools in clinical trials a
pressing issue (McKnight and Kashdan, 2009). One reason for
the lack of comprehensive data on functioning is the complex
conceptualization of the term and the lack of disease-specific
information on all relevant areas. Another explanation is that
they lack comprehensiveness and cultural validity. Therefore,
the Canadian Network for Mood and Anxiety Treatments
(CANMAT) depicts as a primary aim the development of a
scale for measuring functioning outcomes in clinical trials that
could be used or adapted for different clinical care settings (Lam
et al., 2015). Although several recent trials have attempted to
apply newly developed measures designed to capture a more
comprehensive array of functioning difficulties, all of them are
still in their infancy, do not provide domain-specific information
or have not been validated in cross-national samples (Cohen
et al., 2013; Zimmerman et al., 2013).
Secondly, the study reveals particular gender differences in
the functional impairment of depression. This is an important
finding which needs further exploration in other cross-national
samples, given the higher prevalence of depression in women
compared to men. Different level of impairment in specific
functioning areas might be a key to the understanding of
these different prevalence rates. Thirdly, our study promotes
the need of reporting domain-specific information in studies for
better understanding the living experience of depression. Studies
predominantly report only the sum-scores of the instruments.
These sum-scores do not provide information on the differential
impact of each functioning domain on the QoL of individuals.
A higher sum-score might indicate either a large number of
mildly affected functioning areas or a few domains with marked
decrements. Potentially important information on functioning is
lost, and a detailed analysis of these functioning domains is likely
to reveal important information hidden by the sum-scores. Last,
but not least, our study raises the question about the importance
of assessing functioning in clinical trials and expanding the
diagnostic criteria for depression. Gaining insight on the socio-
culturally based differences in the areas of functioning in
depression might be the key of promoting future culture-sensitive
nosology accounting for functional impairment (Juhasz et al.,
2012). At clinical level, with the development of a new instrument
for functioning, clinicians experiencing time restraints should be
given the opportunity to prioritize and meet the needs of patients
promptly. Future studies following our line of research should
be able to provide sufficient evidence for implementing national
programs focusing on prevention and treatment of functional
impairments in depression.
The present study has certain limitations. The data was cross-
sectional, thus both QoL and functioning impairment were
assessed at the same measurement point. However, our objective
was to rank the importance rather than to explore temporal
relations or infer causal relationships. Secondly, there were
certain variations in the sample size of each country. For this
study we selected only participants with depression, but both the
COURAGE and SAGE samples were nationally representative.
The differences in the number of depressed participants in
each country might be due to differences in the prevalence
of depression or cross-national differences in reporting in the
self-reported instruments (Kessler and Bromet, 2013).
This is the first study to our knowledge to explore the
differential impact of functioning domains on QoL in depression
across different regions of the world. One of the strengths of
the study is its large sample size and geographically and socio-
economically diverse participants. Although more than 85% of
the world’s population lives in low- and middle-income countries,
most of the evidence comes from high-income countries
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(Saxena et al., 2006). Our paper, however, contributes with
data not only from high-income countries, but also low and
middle income countries. Our results showed that there was a
variation in the importance of different functioning domains
across countries. This is in line with the growing evidence
that reporting functioning sum-scores blurs potential differences
among people. The concealed variability within the concept of
functioning has further led to disappointing findings—treatment
in depression is only low-to-moderately efficacious for improving
functioning (De Silva et al., 2013; Renner et al., 2014). Future
research should focus on a more personalized approach to the
assessment of functioning.
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Abstract 
Background: Despite the steadily escalating psychological and economic burden of depression, 
there is a lack of evidence for the effectiveness of available interventions on functioning areas 
beyond symptomatology. Therefore, the main objective of this study was to give an insight into 
the current measurement of treatment effectiveness in depression and to provide 
recommendations for its improvement. 
Methods: The study was based on a multi-informant approach, comparing data from a 
systematic literature review, an expert survey with representatives from clinical practice (130), 
and qualitative interviews with patients (11) experiencing depression.  
Results: Current literature places emphasis on symptomatic outcomes and neglects other 
domains of functioning, whereas clinicians and depressed patients highlight the importance of 
both. Interpersonal relationships, recreation and daily activities, communication, social 
participation, work difficulties were identified as being crucial for recovery. Personal factors, 
neglected by the literature, such as self-efficacy were introduced by experts and patients. 
Furthermore, clinicians and patients identified a number of differences regarding the areas 
improved by psychotherapeutic or pharmacological interventions that were not addressed by the 
pertinent literature.  
Limitations: The literature review covered the last ten years of research and qualitative data was 
obtained from only 11 patients. 
Conclusions: Creation of a new cross-nationally applicable measure of psychosocial 
functioning, broader remission criteria, report of domain-specific information, and a personalized 
approach in treatment decision-making are the first crucial steps needed for the improvement of 
the measurement of treatment effectiveness in depression. A better measurement will facilitate 
the clinical decision making and answer the escalating burden of depression. 
 
Keywords: depression; functioning; intervention; outcome measure; treatment effectiveness 
 
 
 
 
Introduction 
Clinical guidelines recommend antidepressant medication (selective serotonin reuptake 
inhibitors [SSRIs], serotonin–norepinephrine reuptake inhibitors [SNRIs] and tricyclic 
antidepressants [TCAs]) or psychotherapy (e.g. cognitive behaviour therapy, interpersonal 
psychotherapy) as first choice treatment options for depression (McAllister-Williams, 2006; 
Patten et al., 2009). Results from randomized controlled trials and clinical guidelines suggest that 
internet based treatments and some complementary or alternative therapies, such as exercise or 
sleep deprivation, are also effective in the short term (Caliyurt and Guducu, 2005; Kvam et al., 
2016). There is a large body of research on the effectiveness of these interventions in reducing 
depressive symptoms. Symptom improvement remains the main focus of clinical trials for 
depression, and the regulatory approval process for new medications and other interventions is 
based on symptomatology (Lam et al., 2015).  
In spite of the large number of available interventions for depression and the huge evidence 
base on their effectiveness in terms of reducing symptom severity, the data show that more than 
30% of all cases of depression are not adequately solved by first agent treatments (Kohn et al., 2004; 
National Collaborating Centre for Mental Health, 2010). The meta-analytical evidence of treatment 
effectiveness is also modest (Cuijpers et al., 2010; Khan and Brown, 2015). Moreover, depression has 
been ranked as one of the leading causes of burden in the Global Burden of Disease studies since 1990 
(Whiteford et al., 2013). Some predictions indicate that it will be the greatest cause of disability 
worldwide by 2030 (World Health Organization, 2003). According to the World Health 
Organization (WHO), approximately 1 million people die from suicide every year (World Health 
Organization, 2003), and the majority of cases occur in the context of depression (Mann et al., 
2005). In addition to the psychological burden on individuals, depression also has significant 
socio‐economic costs. The direct and indirect costs of depression in the EU were estimated to be 
€92 billion in 2010 (Olesen et al., 2012). Nearly half of the costs were the result of productivity 
losses, indicating the enormous negative impact depression has on the economy.  
 Even though the lack of early detection and treatment of depression has been considered 
the main reason for the continuous burden of depression (World Health Organization, 2008), the 
lack of robust results poses the question of whether the current way of measuring depression is 
adequate or should be improved. Between 80% and 95% of all areas covered by the outcome 
measures in interventional studies represent clinical symptomatology (Brockow et al., 2004; 
Kamenov et al., 2015; McKnight and Kashdan, 2009). Other relevant areas of functioning 
beyond symptoms, such as activity limitations or participation restrictions in different domains 
of life, like social functioning and daily activities (World Health Organization, 2001), are mostly 
secondary outcomes and often do not account for systematic analyses (Williams et al., 2000). A 
number of studies state that these areas might more accurately predict the clinical course of 
depression (Stefos et al., 1996), whereas qualitative research shows that patients have prioritized 
these functioning outcomes over symptomatic outcomes and determined the return to a normal 
level of functioning at work, home or school as a major factor for remission in depression 
(Zimmerman et al., 2006a). Concurrently, some studies provide evidence that these outcomes do 
not correspond to symptom-based outcomes (Lam et al., 2015). It has been suggested that if 
symptoms provide early signs of treatment response, functioning outcomes beyond symptoms 
rather provide an indicator of meaningful change for the patient (McKnight and Kashdan, 2009).  
 Recently, the Canadian Network for Mood and Anxiety Treatments (CANMAT) 
highlighted the need for conceptualization and measurement of functioning outcomes in clinical 
trials (Lam et al., 2015). The lack of gold standard measures for assessing functioning has also 
been a major critique in recent studies (Lam et al., 2015; Madden et al., 2015). To fill this 
research gap, the WHO developed an evidence-based Core Set for depression (Cieza et al., 2004) 
to address the broad spectrum of functioning in depression. However, this tool has not been 
sufficiently implemented in research studies due to its complexity and large number of categories 
(Alvarezz, 2012). In addition, two instruments incorporating symptomatic outcomes, 
functioning, and quality of life were created—the Individual Burden of Illness Index for 
depression (Cohen et al., 2013) and the Remission from Depression Questionnaire (Zimmerman 
et al., 2013)—but their validity is still insufficiently researched and therefore prevents broader 
usage in international research.  
 Thus, one of the potential reasons for the persisting burden of depression might be the 
lack of evidence on relevant and meaningful functioning difficulties for this disorder, possibly 
due to the lack of adequate functioning instruments (as mentioned above) or to the insufficient 
implementation of measures of functioning in clinical trials in general (Kamenov et al., 2015; 
Lam et al., 2015; Madden et al., 2015), which can assess comprehensively all areas affected by 
depression. This research gap was the impetus for the current study, which aimed to provide 
research recommendations for improving the measurement of treatment effectiveness in 
depression. More specifically, the study aimed to 1) provide information on the current areas 
included in the measurement of treatment effectiveness; 2) identify the areas that representatives 
from clinical practice and patients with depression consider relevant for inclusion in the 
assessment of psychotherapeutic, pharmacological or other complementary interventions; 3) 
compare the current status quo in research with the clinician and patient perspectives in order to 
identify the gaps in the measurement of treatment effectiveness; and 4) provide 
recommendations for its improvement and integration in future research.  
 To our knowledge, no previous study has focused on the improvement of treatment 
effectiveness measurement in depression. Such information would be very important for 
acquiring policy-relevant information on treatment effectiveness, disability and rehabilitation, as 
well as for linking the available evidence to the best possible care of depressed patients.  
Methods 
 The present study was based on a comprehensive multi-informant approach, including 
data from a systematic literature review, expert clinicians in the field of depression, and patients 
currently diagnosed with depression. The opinion of clinical experts is essential for overcoming 
the gap between clinical research and the care of individual patients (Tonelli, 1999). However, 
qualitative research on patients living with a mental disorder was identified as one of the 
research priorities for public mental health in Europe (Forsman et al., 2015). 
1. Systematic literature review 
 Full details of the systematic literature review are provided elsewhere (Kamenov et al., 
2015); a concise description is presented below. An electronic search for studies assessing 
interventions in depressive disorders was performed using four databases: PsycINFO, PubMed, 
Web of Science, and the Cochrane Central Register of Controlled Trials. Studies published 
between 2005 and 2015 were identified by including a set of sensitive MeSH terms and 
keywords indicative for intervention, depression and functioning. Studies were included if 1) 
participants were older than 18, 2) the diagnosis of depression was established by a standardized 
diagnostic tool, and 3) the sample included at least ten participants. 
 We grouped the treatments into three main categories: psychotherapy, pharmacotherapy 
and “other” therapies, such as sleep deprivation and exercise therapy (Patten et al., 2009). All 
primary and secondary outcome measures assessing functioning, quality of life or severity of 
symptoms that were already validated in depression samples were selected, and all individual 
items of the selected tools were extracted. The extracted items were analyzed and were linked to 
the International Classification of Functioning, Disability and Health (ICF) for operationalization 
purposes by applying the established linking rules (Cieza et al., 2005). The linking process was 
performed by two researchers. The items were grouped into ten overarching categories based on 
the ICF classification. A frequency analysis was conducted after all functioning problems were 
identified to present the percentage of the areas stratified by type of intervention. 
2. Expert survey 
 The survey was available between March 2015 and March 2016. It was designed to 
collect data from practicing clinicians in the field of depression, assessing interventions used in 
their daily practice and the psychosocial difficulties addressed by these treatments.The short 
survey consisted of two questions: 1) “Choose the type of intervention(s) you usually use in your 
daily practice”; and 2) “List the psychosocial difficulties that this intervention(s) aims to improve 
in individuals with depression”. Participants could choose up to ten interventions. The aim was 
to obtain experts’ opinion on the areas that are captured by the specific treatments and that 
should be included in the assessment of interventions for depression. All answers concerning 
psychosocial difficulties were linked to the ICF categories according to the existing rules (Cieza 
et al., 2005). Additionally, some demographic data were collected.  
 To reflect different opinions and achieve a maximum variation sampling, a wide range of 
clinicians were approached: psychiatrists, psychotherapists, primary health care doctors and 
other physicians, social workers, and nurses, amongst others. Clinicians were selected if they had 
at least two years of clinical expertise in depression. In addition, we searched for the highest 
possible variability in terms of age, gender, nationality and type of therapy used in daily practice 
by the clinicians. Potential participants were identified through a number of sources—internal 
databases of international experts working in depression, heads of psychiatric hospitals and 
departments, professional websites for clinicians working in depression (e.g. 
www.commonlanguagepsychotherapy.org) —and through a snowball approach. Experts were 
sent an email invitation for participation in the survey. We expected a 50-70% non-response rate 
(Archer, 2008; Horgan and Dimitriou, 2015). Our target was to obtain a sample of 100 experts, 
and therefore the survey was sent to nearly 250 experts in depression. The study aimed to 
approach European experts; therefore, the majority of clinicians resided in Europe. However, for 
comparison purposes, data from non-European experts were also collected.  
3. Qualitative interviews with patients with depression 
 The aim of the present study was to collect data from individuals diagnosed with 
depression on the treatments they were receiving/had received for depression and the 
psychosocial difficulties addressed by the interventions. Therefore, qualitative individual 
interviews with outpatients diagnosed with depression were performed. Participants had to meet 
the following inclusion criteria: 1) current, or history of, depressive episode in the previous 12 
months as main diagnosis (depressive episode [F32], recurrent depressive episode [F33], or 
currently in partial or total remission [F33.4] according to the International Classification of 
Diseases) (World Health Organization, 1992); 2) sufficient cognitive capacity to participate in an 
interview (score > 26 on the mini-mental status examination (MMSE) (Folstein et al., 1975); 3) 
knowledge of the local language (Spanish); 4) age ≥ 18 years; 5)  currently receiving treatment 
for depression, namely psychotherapy, pharmacotherapy or other treatment prescribed by their 
mental health professional; and 6) written informed consent. Ethics approval was obtained by the 
Hospital La Princesa Ethics Committee for Clinical Research in Madrid. 
The recruitment of participants and data collection was performed in a public outpatient 
mental health unit at Hospital La Princesa (Madrid, Spain). Two mental health professionals 
working in the unit (one psychologist and one psychiatrist) collected the data between September 
2015 and March 2016. All patients who met the inclusion criteria were informed about the study 
and invited to participate. All participants who agreed to participate gave their consent. The 
study consisted of a face-to-face interview with a research team member and comprised two 
parts. The first part was a series of demographic and clinical questions, which aimed to collect 
information on the patients’ background (e.g. gender, age, type of depression, number of 
previous episodes, onset of the disorder and occupation). The second part assessed the type of 
treatment (psychotherapeutic, pharmacological or other) patients had received or were receiving, 
and their experience with the respective treatment. During an open personal interview, 
participants were asked about the psychosocial difficulties they were experiencing or had 
experienced in the past, and the ones that had or had not improved with the specific treatment 
they received. Data collection continued until a saturation point was reached, i.e. when the 
collection of new data did not shed any further light on the investigation we stopped recruiting 
(Glaser and Strauss, 1967). More specifically, the major rule for determining saturation was 
when three consecutive patients in the same group of treatment did not report a new psychosocial 
difficulty.  Participants receiving psychotherapy were allowed to receive additional 
antidepressant pharmacotherapy when they met the following criteria: no antidepressant dosage 
change one month prior to the start of the psychotherapeutic sessions or during the 
psychotherapeutic treatment. As only two patients had been treated with other (alternative or 
complementary) therapies, no data on “other” therapies is available from this qualitative study. 
Recordings of the individual interview sessions were transcribed verbatim. The transcripts 
were checked by the moderator and the information was extracted and double-checked. All 
content  concerning psychosocial difficulties was translated into English and coded  according  to  
ICF categories following the existing ICF linking rules (Cieza et al., 2005). Codification of 
themes and subthemes for interventions and psychosocial difficulties was double-checked by an 
independent researcher and analyzed by NVIVO program, version 11. All frequencies were 
analyzed with SPSS, version 21. 
Results 
1. Study characteristics 
1.1. Literature review  
 A total of 247 articles, including 71,904 participants, were included in the final synthesis. 
A total of 66 interventions were identified, all of them grouped into three main categories: 
psychotherapies, pharmacotherapies or other therapies. The most common intervention within 
the psychotherapeutic category was CBT. Fluoxetine in particular and the group of SSRIs in 
general were the most prevalent antidepressants. Among the remaining therapies, St. John’s wort 
was the first agent. A full summary of the study characteristics can be found elsewhere 
(Kamenov et al., 2015). 
1.2. Expert survey 
 The study was sent to 250 practicing clinicians, with a 52% response rate. 130 clinicians 
from around the world filled out the survey. 95 were practicing specialists from 21 countries in 
Europe, and 35 (27%) were residing outside Europe. Among the non-Europeans, there were 
representatives from all continents, primarily from North and South America, with 15. The 
average age of the participants was 43 years (SD = 10.5). Males were a slight majority (55%). 
Experts’ characteristics can be seen in Table 1.  
 Table 1: Characteristics of the experts (N=130) participating in the online survey 
Variable N (%) 
Age 
18-34                                                                                  
35-49 
50-64 
65+ 
 
32 (24.6%) 
65 (50%) 
31 (23.8%) 
2 (1.5%) 
Females  59 (45%) 
Years of experience mean (SD) 14 (10.23) 
Non-European experts 35 (27%) 
Psychiatrists 73 (56%) 
Psychologists 44 (34%) 
Others 13 (10%) 
 
1.3.Qualitative interviews with patients  
 We conducted individual interviews with 11 patients who were receiving/had received in 
the last 12 months pharmacological or psychological treatment. Patients’ diagnoses varied from 
being in partial remission (N = 4) to experiencing a current moderate episode (N = 5) of a major 
depressive disorder. The average age of the participants was 58 years (SD = 12), with a higher 
prevalence of women (73%). Patients’ characteristics can be seen in Table 2.  
 
Table 2: Sociodemographic and clinical characteristics of the patients with depression 
Case Age Gender Occupation Diagnosis Number of 
previous 
episodes 
Age of 
diagnosis 
Comorbidity 
1 42 Female Retired Mild episode, currently in 
partial remission 
0 40 Fibromyalgia  
2 68 Female Retired Severe episode, currently in 
partial remission 
1 64 No 
3 48 Male Currently working Moderate episode, currently 
in partial remission 
0 33 No 
4 55 Female Unemployed Recurrent depression, 
currently in partial 
remission 
10 25 Personality 
disorder 
5 62 Female Housewife Recurrent depression, 
current moderate episode 
2 55 No 
6 86 Female Retired Recurrent depression, 
current moderate episode 
No info No info No 
7 54 Male Currently working Moderate episode 0 52 Psoriasis 
8 60 Female Currently working Moderate episode 0 58 Psoriasis 
9 65 Female Housewife Mild episode with somatic 
symptoms 
1 53 No 
10 48 Male Unemployed Moderate episode 2 38 HIV 
11 55 Female Unemployed Mild episode 3 25 Cancer 
 
 
2. Comparison between literature, clinician and patient perspectives on treatment 
effectiveness  
 Results from the literature review showed that items related to clinical symptoms—such 
as global mental functions (confidence, temperament, personality functions), specific mental 
functions (emotional functions, cognitive functions, body image), energy (energy level, appetite) 
and sleep functions—accounted for about 65% of the total number of areas addressed within the 
outcome measures. Body functions representing somatic symptoms (e.g. pain, digestive or sexual 
problems) accounted for an additional 15–18% across studies. Other areas of functioning beyond 
symptomatology; such as interpersonal relationships, leisure activities, daily tasks and demands; 
or major life areas, such as employment or education, represented a very small percentage: 15–
20% varying across the categories of interventions. Domains such as social participation or 
communication represented a negligible percentage. 
 Unlike results from the literature review, expert clinicians gave minor importance to 
areas related to clinical symptoms (65%, varying across therapies - from 54% in psychotherapy 
to 67% in pharmacotherapy). To the contrary, the areas beyond symptomatology had higher 
importance compared to their role in the literature (from 30% in pharmacotherapy to 43% in 
psychotherapies). Interpersonal relationships, general tasks and demands, employment and 
education were pointed out by clinicians as fundamental areas. Communication and social 
participation represented a major part (up to 10%) of the functioning problems covered by 
therapies. There were no major differences between the areas identified and the types of therapy 
used by European and non-European experts.  
 The qualitative interviews with patients showed patterns similar to those of the expert 
reports. Patients highlighted the importance of a set of symptoms that represented 54% of all 
functioning areas. The importance of symptoms such as weight change or change in appetite was 
underlined by the participants: “As something that has improved, I can point to my appetite. I 
have an appetite again and have gained weight. I lost five kilos and now I’ve regained them. I 
think the reason is that I feel more or less like I did before…” (P8). However, the areas beyond 
symptomatology (37% of all areas identified) were also important for patients with depression. 
Interpersonal relationships were the only domain that was mentioned by all patients: “Yes, now I 
go out and meet people. Before when I saw someone in a shop I would turn around and leave 
because I didn’t want him to stop me and talk to me” (P2). Participants also highlighted problems 
at work, communication and daily activities as crucial areas. A summary of all relevant areas 
found in literature, expert and patient reports can be seen in Figure 1. 
 
Figure 1: Comparison between the percentages of functioning areas identified in the literature, 
the expert survey with clinicians, and individual interviews with patients with depression 
 
  
 In addition, expert clinicians and patients identified a list of personal factors introducing 
the concept of “self”—self-perception, self-efficacy, self-acceptance, self-awareness, self-help, 
self-image and self-esteem—as a major part of the treatment process. These personal factors 
were neglected in the studies included in the systematic review, but constituted a relevant 
percentage in the answers of clinicians (4%) and patients (9%).  
 When the analysis was stratified by type of intervention, the literature did not reveal any 
differences among functioning areas included in studies applying psychotherapy, 
pharmacotherapy or other interventions. However, such differences were found in the expert 
reports. Pharmacological treatment appeared to address symptomatic areas much more than 
psychotherapy (67% vs. 53%), whereas psychotherapy focused more on functioning areas 
beyond symptoms. Interpersonal relationships and communication constituted 30% of the total 
number of areas covered by psychotherapies, whereas both had a substantially smaller share in 
pharmacotherapy (7%) and other therapies (13%). Furthermore, communication represented 13% 
of the total number of areas covered by psychotherapy, but in pharmacological interventions it 
constituted only 2%. Likewise, in patient reports, symptomatic areas (54%) were predominantly 
reported by patients under pharmacological treatment. Lack of motivation for doing things was a 
salient area on the list of difficulties, with 80% of all patients reporting it as an area improved by 
medication. , Regarding psychotherapeutic interventions, patients identified interpersonal 
relationships, communication and emotional difficulties as the three main areas of improvement. 
More specifically, problems within the family, with an intimate partner or close friends were the 
most commonly reported improved difficulties: “Also, I have my family around now. It affects 
me in a positive way, because it’s my family that I’m spending time with; I’m hiking in the 
mountain with my mother and my aunts. And this makes me happy” (P4).  
Discussion  
 This study breaks new ground by identifying the drawbacks of the current measurement 
of treatment effectiveness in depression and by providing research recommendations for its 
improvement. This was done by comparing a systematic review of the literature, examining the 
areas of functioning included in the measurement process, and the clinician and patient 
perspectives on the actual areas addressed by the treatments. Our results showed that current 
research emphasizes symptomatic outcomes and neglects other domains of functioning, as 
opposed to the opinion of clinicians and depressed patients, who highlighted the importance of 
both. The “self” concept (e.g. self-efficacy, self-awareness), which was not considered in the 
literature, was introduced by experts and patients as a domain that can be improved by treatments 
and has a huge impact on the overall condition of individuals. Furthermore, clinicians and 
patients identified a number of differences regarding the areas improved by psychotherapeutic, 
pharmacological and other treatments. Pharmacological treatments generally improved 
symptomatic domains to a higher extent. Experts expressed their preference in choosing 
antidepressants when targeting certain symptomatic difficulties, such as sleep or emotional 
functioning. Lack of motivation was an important issue for patients and they acknowledged the 
role of medications in its improvement. On the other hand, psychological treatments were the 
first choice for patients and experts when areas beyond symptoms were affected. Interpersonal 
relationships, problems in communication or lack of social participation were areas susceptible 
to change by psychotherapies. Self-care activities such as eating, dressing, taking care of one’s 
look were also recovered by psychological interventions. Based on the obtained results, the 
following section provides a summary of recommendations for the improvement of the 
measurement of treatment effectiveness in depression. 
 
1. Identification of the most burdensome functioning areas in depression and creation 
of a new measure of psychosocial functioning 
 
 Our results show that a small percentage of studies apply instruments measuring 
functioning areas beyond symptoms. The few studies that implement such tools do not provide 
comprehensive information on functioning, mainly due to the limited number of areas covered 
by the instruments. All clinicians and patients taking part in the present study identified a number 
of functioning domains (Table 3) as susceptible to change and crucial for assessment. This list of 
domains is the first step for the creation of a new instrument, which should include all relevant 
areas of psychosocial functioning, addressing together symptomatology and areas of functioning 
beyond symptoms. This unique tool should be comprehensive enough in regard to the health 
condition, and quick to administer if needed, to be applied in a clinical settings where 
practitioners have limited time and resources (Wittchen et al., 2001)— something that would 
provide comparability across studies. The instrument should also take into account differences 
across groups of patients by weighting the domains according to their importance. Thus, if for a 
certain group of patients who share similar characteristics, difficulties in communication and 
daily activities are prominent domains these should be given more weight than the other 
domains. However, our study is the first to assess this broad spectrum of psychosocial 
difficulties, and therefore more quantitative and qualitative research is needed to replicate our 
results and determine the most relevant domains of functioning.  
Table 3: Functioning areas identified for inclusion in the measurement of treatment effectiveness 
 
Mental functioning  
 
Global and specific mental functions. Represents 
symptoms such as emotional functions, rumination, 
anxiety, anhedonia, feelings of hopelessness and guilt, 
suicidal ideation, or impaired cognitive functioning 
 
Sleep Problems in the onset, maintenance and quality of sleep  
Energy level Fatigue, loss of energy and motivation  
Somatic functioning Somatic symptoms, pain or impaired sexual functioning  
Interpersonal interactions and relationships Relationships within the family, intimate relations, 
relations with friends, or informal social relationships 
Recreational and leisure activities Hobbies, socializing, sports, arts and culture  
Communication and social participation Problems in communication, receiving and producing 
messages, participation in society, social activities, etc. 
General tasks and demands Problems in daily activities, household responsibilities, 
self-care, handling stress 
Major life areas Employment, education, economic life 
Personal factors Self-esteem, self-efficacy, self-image, self-awareness 
 
2. A cross-nationally applicable measure of functioning 
 The majority of studies included in the systematic review provided evidence only from 
high-income countries. Knowledge on relevant areas in depression from low- and middle-income 
countries is sparse. The results from the expert survey did not reveal major differences in the 
answers of European and non-European clinicians; however, these results are not generalizable 
due to the small number of non-European clinicians. This lack of evidence suggests that a new 
instrument comprehensively assessing all relevant functioning areas should be also validated in 
different cross-national samples. Moreover, the instrument should be sensitive to country 
differences and be validated in different settings. More research from low-, middle-, and high-
income countries is needed to provide country-specific functioning information.  
 
3. Broader remission criteria 
 Remission of depression is currently defined solely in terms of symptom reduction 
(Zimmerman et al., 2006b) according to cut-off scores on symptom severity scales, such as 
the Hamilton Rating Scale for Depression (HRSD) (Hamilton, 1967), Beck Depression Inventory 
(BDI) (Beck et al., 1961) or the Montgomery–Åsberg Depression Rating Scale (Montgomery 
and Asberg, 1979). A more comprehensive definition of remission is needed to adequately 
reflect the experience of depressed patients under treatment. Our results show that improvement 
in functioning areas beyond symptoms is as important as the reduction in symptomatology. One 
possibility is the creation of a new instrument covering not just symptomatic aspects, but all 
relevant affected areas. There are already initial steps in this direction. Cohen et al. (Cohen et al., 
2013)  created an Individual Burden of Illness Index for depression to measure treatment impact 
and recovery in depression by incorporating multidimensional patient-reported outcomes of 
symptom severity, functioning, and quality of life (QoL).  Zimmerman et al. (2014) subsequently 
validated a new instrument: the Remission from Depression Questionnaire, encompassing 
different domains of functioning and QoL, along with symptomatology. These authors conclude 
that their new tool provides a broader perspective on depressed patients’ condition than purely 
symptom-based measures and is more consistent with the biopsychosocial approach in the 
treatment of depression. However, these tools are still in their infancy and need further 
validation. Another possibility involves a separate definition of functional remission alongside 
symptom assessment. An example is a study by Mancini et al. (2012), which applied such 
criteria, based on the Sheehan Disability Scale (Sheehan, 1983). Future studies should aim to 
achieve such broader remission criteria. 
 
4. Reporting  domain-specific information rather than sum-scores of questionnaires for 
functioning 
 Results from the literature review showed that more than 80% of the interventional 
studies published in the last decade reported only sum-scores of instruments assessing 
functioning rather than domain-specific information. Despite some methodological and practical 
advantages of aggregating scores from different domains, these sum-scores also obscure 
potential differences among people and do not provide detailed information on the differential 
impact of certain functioning domains on the overall state of depressed persons. A higher sum-
score might mean a higher number of less affected functioning areas or a smaller number of 
domains with marked deterioration. Reporting domain-specific information will potentially 
reveal differential trajectories in the course of depression, interrelations between distinct domains 
of functioning, and most importantly, will lead to a more personalized approach in the treatment 
of depression.  
5. Personalized approach in treatment decision making 
 Current treatment decision making is primarily based on evidence-based medicine. Thus, 
clinical guidelines recommend psychotherapy and pharmacological agents for all patients as 
first-line treatments. The regulatory approval process for new medications and other 
interventions is based primarily on symptomatology. Our results, however, showed that 
psychotherapeutic and pharmacological interventions targeted the range of functioning 
difficulties in the population to a different extent. Moreover, patients and experts highlighted the 
importance of functioning difficulties beyond symptoms in the recovery process. There is a need 
for a more personalized approach in treatment decision-making that acknowledges specific 
patient needs and accounts for a more comprehensive array of functioning domains. More 
research is also needed to explore the effectiveness of the available interventions in each of the 
relevant functioning areas.  
 
 Even though the present study considered all possible perspectives on the measurement 
of treatment effectiveness, some methodological limitations should be mentioned. First of all, the 
literature review covered only the last ten years of research, because we aimed to explore the 
latest trends in assessing treatment effectiveness. Secondly, approximately 70% of the clinicians 
that took part in the online survey were European. Even though we achieved a representation of 
non-European experts, wider participation of the latter may have provided different perspectives 
on the topic. Finally, data was obtained from only 11 patients from Spain. Our approach was the 
attainment of a saturation point in individuals’ answers, but more patients, with different cultural 
backgrounds, could have enriched the data.  
 The present study is the first to our knowledge to provide recommendations for improved 
treatment measurement using a methodology based on a multi-informant approach. Clinician and 
patient perspectives are essential for informing the context of clinical research, and overcoming 
the gap between clinical research and the care of individual patients. We believe that more 
accurate and comprehensive evidence on the effectiveness of available interventions for 
depression is needed to answer the steadily escalating societal and economic burden of the 
disease. Moreover, future research should explore the results of this study further, and apply its 
recommendations. 
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6. DISCUSSION 
6.1. Evaluation of the current measurement of treatment effectiveness for 
psychosocial impairment in depression, limitations identified and arguments for 
creating new evidence 
 Results from the systematic literature review showed that despite the 
enormous importance of disability in depression, the effectiveness of all available 
interventions for depression is still assessed mainly in terms of reduction of clinical 
symptoms, whereas other areas of functioning are neglected. This was imposingly 
demonstrated by the fact that every study analyzed in our review applied at least one 
measure of severity of symptoms, but only less than 20% of the applied 
questionnaires addressed other areas of functioning. More specifically, QoL 
measures represented between 14%, and 19% of the overall number of instruments 
used in studies, whereas tools that measured other areas of functioning (e.g. social 
functioning) were between 3% and 7.5%.  
 Similarly, the elaborate content item analysis revealed that around 80% of 
the areas covered by the outcome measures represented clinical symptomatology. 
Items related to clinical symptoms like global mental functions (confidence, 
temperament, and personality functions), specific mental functions (emotional 
functions, cognitive functions, body image, etc.), energy (e.g. energy level, appetite), 
sleep functions and body functions representing somatic symptoms (e.g. pain, 
digestive or sexual problems) were prevailing. Other areas of functioning that were 
not strictly linked to symptomatology, such as interpersonal relationships (family 
and partner relationships, informal relationships with friends), leisure activities, daily 
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tasks and demands (daily activities, domestic life, doing housework), or major life 
areas, such as employment or education, represented a very small percentage.  
 The meta-analyses that we conducted aimed to reveal the effectiveness of 
available interventions for depression on psychosocial functioning and to review the 
process of assessment, the instruments used and the level of evidence provided in 
literature. The articles provided comprehensive evidence that existing psychological 
and pharmacological interventions are efficacious for improving psychosocial 
difficulties. This is a substantial finding considering the importance of these 
outcomes from patient perspective. There was no robust evidence that one of the 
groups of interventions was superior, although psychotherapy appeared slightly 
superior to medication. Both psychotherapeutic and pharmacological interventions 
and CBT in particular showed better results at reducing symptoms of depression than 
improving the level of functioning and QoL. This is in line with the current state-of-
art of research on depression, focused more on symptom severity rather than 
functional areas beyond symptoms.  
 Functional impairment beyond symptoms is seen by current research as a 
consequence of the health condition and the betterment of symptoms is hence the 
primary source of improving functioning.  However, it might be that the functional 
instruments used to measure level of functioning are not sensitive and 
comprehensive enough to reflect the real experience of patients with depression. It 
has been suggested by researchers (Kamenov et al., 2015; Lam et al., 2015; Madden 
et al., 2015) that the current functional instruments are somehow limited and do not 
assess accurately other areas of functioning beyond symptoms.  
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 Another interesting finding comes from the series of meta-regression 
analyses that we performed, suggesting that functional outcomes beyond symptoms 
improve when symptom severity improves. However, which is the leading factor is 
still unknown. Previous research suggests that functional recovery appears later than 
the symptomatic one and certain level of impairment continues even after the 
symptomatology is ameliorated. The residual functional impairment has been found 
to evoke relapse and recurrences (Vittengl et al., 2009); therefore functional 
outcomes should be directly targeted in the response and remission criteria for a 
more comprehensive assessment of treatment efficacy.  
 The meta-analyses revealed several major limitations in the current 
measurement of treatment effectiveness in depression. Firstly, the effect sizes from 
all analyzes performed were relatively modest, suggesting that interventions are 
efficacious for improving psychosocial outcomes, but do not reach out successfully 
to every patient. One reason for this phenomenon might be the nature of the 
interventions, which are rather created and designed to alleviate symptom severity 
than improving functional outcomes beyond symptomatology. Another reason might 
be the small number of studies applying functional outcomes, which did not allow 
for generalizability of the results. A third reason might be the inability of functional 
outcome measures to accurately reflect changes in functional impairment. This 
suggests that new instruments should be designed to comprehensively assess the 
effectiveness of different therapies on psychosocial functioning in depression.  
 A second limitation, as mentioned above, was the very small number of 
studies that were found to apply outcome measures for functional areas beyond 
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symptoms. The small number of studies did not allow us to perform some analyses, 
such as a direct comparison of different psychotherapies or antidepressants, and 
lowered the powered of some of the analyses we conducted. More studies applying 
functioning and QoL instruments are needed to provide sufficient data for robust 
conclusions. Secondly, there were a large number of instruments used in the clinical 
trials, which were heterogeneous in their nature, even though they assessed domains 
of functioning in general. Some questionnaires assessed general functioning, such as 
Global Assessment of Functioning (GAF) (Aas, 2010), others assessed only 
components of psychosocial functioning, such as social functioning (Weissman et 
al., 1978), mental functioning or work-related functioning (Mundt et al., 2002). Even 
though the subgroup analyses we performed to analyze the impact of each 
questionnaire on the general effect of therapies did not reveal any significant 
difference between the instruments, this lack of coherence in the assessment process 
suggests further consistency in the selection of instruments and new evidence for a 
better and more comprehensive outcome measure.  
 A third major limitation that we detected was the lack of long-term data on 
the effectiveness of different therapies. Less than one third of the studies reported 
any follow-up data, which did not allow for separate analysis of long-term 
effectiveness. Long-term assessment would allow to further investigate the 
interrelations between different functional outcomes and to capture more 
comprehensively the changes in the psychosocial functioning of individuals. The last 
limitation we identified was the sole report of sum-scores of questionnaires. Despite 
some methodological and practical advantages of aggregating scores from different 
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domains, the sum-scores obscure potential differences among people and do not 
provide detailed information on the differential impact of certain functioning 
domains on the overall state of depressed persons. Without knowing how different 
functional areas react to different therapies, we would not be able to obtain more 
personalized information on the needs of particular groups of individuals. 
Personalization of therapies is needed to further explore potential differences among 
patients. It is possible that the psychological treatments are less effective in some 
populations, and the added value of pharmacological treatments increases, or the 
other way around. Future studies should report domain-specific information for 
better understanding of the trajectories of change in psychosocial functioning in 
depression.  
 In conclusion, the findings from the systematic literature review and the two 
meta-analyses revealed discordance between established research priorities, namely 
the importance of functional outcomes in depression research, and their actual 
implementation in literature. This discrepancy poses the question how much do we 
know about the level of effectiveness of interventions for depression on vital areas of 
everyday life. Furthermore, it warrants future empirical steps towards improving the 
current assessment of treatment effectiveness in depression. 
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6.2.  Empirical evidence collected to address the limitations in the current 
measurement of treatment effectiveness in depression 
 The best possible way to address the limitations in current research and the 
need for better assessment of functional effectiveness of interventions for depression 
is to directly collect empirical evidence. For that purpose we firstly analyzed data 
from two multi-country projects—the World Health Organization’s Study on Global 
Ageing and Adult Health (SAGE) and the Collaborative Research on Ageing in 
Europe (COURAGE) in order to identify 1) the most burdensome functional 
domains in depression, 2) gender differences in functional impairment and 3) 
country variability in psychosocial functioning. This information serves as a basis 
for further development of more sensitive, cross-nationally validated and user-
friendly instrument weighting the domains according to their importance.  
 Our findings suggest that affect or emotional functioning, interpersonal 
relationships and domestic life and work had the highest impact on quality of life in 
depression. Sleep and energy, mobility and cognition were also important factors, 
but their effect was smaller. Self-care and pain were the only domains that were non-
significant for men or women. A possible explanation might be that the participants 
showed relatively higher levels of self-care and lower levels of pain, and severe 
decrements in these domains were rare. The importance of emotional functioning has 
been already determined in previous studies for depression (Cieza et al., 2014). 
Interpersonal activities, which was the second most important domain in our study, 
the notion that people with depression experience significantly poorer intimate 
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relationships and less satisfying social interactions than individuals with other 
psychiatric disorders, or the general population (Fredman et al., 1988). 
 The study also revealed particular gender differences in the functional 
impairment of depression. For example, for women affect remained the most 
important functioning area, followed by interpersonal activities, domestic life and 
work, mobility and cognition. Men, however, showed different patterns compared to 
women. Affect was still the most fundamental factor, but sleep and energy appeared 
to be the second major functioning area. Self-care was only marginally significant, 
whereas cognition, mobility, and pain were not statistically significant functioning 
domains in men. This is an important finding which needs further exploration in 
other cross-national samples, given the higher prevalence of depression in women 
compared to men. Different level of impairment in specific functioning areas might 
be a key to the understanding of these different prevalence rates.  
 We further examined differences across the nine included countries. Affect 
was significant in all countries except China. This supports previous evidence that 
emotional problems, such as low mood, are a core part of the experience of 
depression (Fried and Nesse, 2014) and chronic physical or mental conditions in 
general (Weigl et al., 2004). However, most of the generic functioning tools, such as 
WHODAS-II (Ustun et al., 2010), do not include affect as a single domain. 
Difficulties in interpersonal activities were also prevailing in most of the countries. 
However, the rest of the domains were country specific. Cognition was associated 
with QoL in Poland, India and Mexico; mobility in Spain; and sleep and energy in 
India, South Africa and China. The reason why some functioning domains were 
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associated with QoL only in some countries but not in others is unclear, but certain 
cultural contrasts might be responsible for these variations. For instance, in our study 
mobility was more important for the Spanish population than for any other country. 
Previous studies evaluating the health status in general population confirm this 
result, showing that Spanish people place more importance on mobility as a 
functioning domain compared to other countries due to cultural or lifestyle 
characteristics (Badia and Alonso, 1995; Badia et al., 2001).  
 In summary, in terms of research, our study raises the question about the 
importance of assessing functioning in clinical trials and expanding the diagnostic 
criteria for depression. Gaining insight on the socio-culturally based differences in 
the areas of functioning in depression might be the key of promoting future culture-
sensitive nosology accounting for functional impairment (Juhasz et al., 2012). At 
clinical level, with the development of a new instrument for functioning, clinicians 
experiencing time restraints should be given the opportunity to prioritize and meet 
the needs of patients promptly.  Future studies following our line of research should 
be able to provide sufficient evidence for implementing national programs focusing 
on prevention and treatment of functional impairments in depression. 
 Furthermore, we collected information from representatives from clinical 
practice and patients experiencing depression. Clinical experts opinion was essential 
for informing the context of clinical research and necessary to overcome the gap 
between clinical research and the care of individual patients (Tonelli, 1999). On the 
other hand, qualitative research with patients living with a mental disorder has been 
identified as one of the research priorities for public mental health in Europe 
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(Forsman et al., 2015). Obtaining patient perspective provides a fundamental 
knowledge on the complexity of public mental health and enhanced understanding of 
the community context.  
 The results from the expert survey and qualitative interviews highlighted the 
incongruity between the current research giving emphasis on the symptomatic 
outcomes and neglecting other domains of functioning beyond depressive symptoms 
and the opinion of clinicians and depressed patients underlining the importance of 
both. Interpersonal relationships, recreation and leisure activities, communication 
and social participation, daily activities, work and educational difficulties were 
identified by experts and patients as crucial for recovery from depression. 
Furthermore, some personal factors, such as the “self” concept (self-efficacy, self-
awareness, self-image), which was not considered in the literature, was introduced 
by experts and patients as a domain that can be improved by treatments and has a 
huge impact on the overall condition of individuals.  
 Another important contribution of clinicians and patients was the 
identification of a number of differences regarding the areas improved by different 
types of interventions – psychotherapeutic or pharmacological. Pharmacological 
treatments generally improved to higher extent symptomatic domains. Experts 
expressed their preference in choosing antidepressants when certain symptomatic 
difficulties such as sleep or emotional functioning should be targeted. Motivation 
was an important feature for patients and they acknowledged the role of medications 
for its improvement. On the other hand, psychological treatments were the first 
choice when other functional areas beyond symptoms were affected. Interpersonal 
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relationships, problems in communication or lack of social participation were areas 
susceptible to change by psychotherapies. Self-care activities such as eating, 
dressing, taking care of one’s look were also recovered by psychological 
interventions. Thus, in summary, patients and clinicians acknowledged the entirety 
of the concept of psychosocial functioning, giving similar importance to both 
symptoms and areas of functioning beyond symptoms. Findings from the literature, 
however, showed the total prevalence of depressive symptoms over other areas of 
psychosocial functioning.  
 
 Based on the obtained empirical results, which aimed to address the 
limitations of the current research, the following section provides a set of 
recommendations for improving the measurement of treatment effectiveness in 
depression. These recommendations are an initial step towards more comprehensive 
and adequate assessment of interventions in depression but do not pretend to be 
exhaustive. Future studies are needed to replicate our findings or expand our 
research line. 
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6.3.  Research recommendations for improving the assessment of treatment 
effectiveness in depression 
1. Identification of the most burdensome functioning areas in depression and 
creation of a new measure of psychosocial functioning 
 Our results proved that there is a variation in the level of decrements in 
different functioning domains including symptoms and functional areas beyond 
symptomatology. The results were validated in nine different countries in Asia, 
Africa, Europe, and Latin America. On the other hand, literature shows that only a 
minor percentage of studies apply instruments measuring functional areas beyond 
symptoms. The few studies that implement such tools do not provide comprehensive 
information on functioning mainly due to the limited number of areas covered by the 
instruments. Therefore, based on the data obtained in the present thesis several 
domains of functioning identified as susceptible to change and crucial for assessment 
are presented in table 3.  
 This is the first step for the creation of a new instrument that should include 
all relevant areas of psychosocial functioning addressing together symptomatology 
together with other relevant areas of functioning in depression. This unique tool 
should be comprehensive enough in regard to the health condition and quick to 
administrate if needed to be applied in a clinical settings where practitioners have 
limited time and resources (Wittchen et al., 2001). This option would provide 
comparability across studies. The instrument should also take into account 
differences across groups of patients by weighting the domains according to their 
importance. Thus, if for certain groups of patients sharing similar characteristics 
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employment problems and daily activities are prominent domains, they should be 
given more weight than the rest of the domains. However, our study is the first to 
assess this broad spectrum of psychosocial difficulties and therefore more 
quantitative and qualitative research to replicate our results and determine the most 
relevant domains of functioning is needed.  
Table 3. Functional areas identified for inclusion in the measurement of treatment 
effectiveness  
 
Mental functioning  
 
Global and specific mental functions. 
Represents symptoms like emotional 
functions, rumination, anxiety, anhedonia, 
feelings of hopelessness and guilt, suicidal 
ideation, or cognitive functioning 
 
Sleep Problems in the onset, maintenance and 
quality of sleep  
Energy level Fatigue, loss of energy and motivation  
Somatic functioning Somatic symptoms, pain or sexual 
functioning  
Interpersonal interactions and relationships Relationships within the family, intimate 
relations, relations with friends, or 
informal social relationships 
Recreational and leisure activities Hobbies, socializing, sports, arts and 
culture  
Communication and social participation Problems in communication, receiving and 
producing messages, participation in 
society, social activities, etc. 
General tasks and demands Problems in daily activities, household 
responsibilities, self-care, handling stress 
Major life areas Employment, education, economic life 
Personal factors Self-esteem, self-efficacy, self-image, self-
awareness 
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2. A cross-nationally applicable measure of functioning in depression 
 Firstly, the majority of studies included in the systematic review provided 
evidence from high-income countries. Evidence for relevant areas in depression from 
low- and middle-income countries was sparse. Secondly, the results from our expert 
survey did not reveal major differences in the answers of European and non-
European clinicians, or in the reports of clinicians working in high-, middle- or low-
income countries. However, the representation of non-European experts in our study 
was not high enough to provide robust results. More research in low- and middle-
income countries is warranted. Finally, findings from the two multi-country projects, 
namely World Health Organization’s (WHO) Study on Global Ageing and Adult 
Health (SAGE) and the Collaborative Research on Ageing in Europe (COURAGE in 
Europe),  revealed gender and country specific differences in the importance of 
several functioning domains in depression. If interpersonal interactions were 
significant in all countries except Mexico, China and South Africa, physical pain 
was significantly associated with QoL only in Spain, Poland, India and Ghana. There 
is a need of a newly developed instrument comprehensively assessing all relevant 
functioning areas that should be validated in different cross-national samples. 
Moreover, the instrument should be sensitive to the country differences and provide 
information that is specific for the particular setting. This can be done by weights in 
the calculation of the scores. However, more research is needed to assess differences 
across countries.  
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3. Broader remission criteria in depression 
 Remission of depression is currently defined solely in terms of symptom 
reduction (Zimmerman et al., 2006b) according to cut-off scores on symptom 
severity scales such as the Hamilton Rating Scale for Depression (HRSD) 
(Hamilton, 1967), Beck Depression Inventory (BDI) (Beck et al., 1961) or the 
Montgomery–Åsberg Depression Rating Scale (Montgomery and Asberg, 1979). As 
our qualitative and expert study underlined, a more comprehensive definition of 
remission is needed to adequately reflect the experience of depressed patients under 
treatment. Our results show that improvement in functioning areas other than 
symptoms is as important as the reduction in functional areas related to 
symptomatology.  
 One possibility is the creation of a new instrument covering not just the 
symptomatic, but all relevant affected areas. There are already initial steps in this 
direction. Cohen et al. (2013) have created an Individual Burden of Illness Index for 
depression to measure treatment impact and recovery in depression by incorporating 
multidimensional patient-reported outcomes of symptom severity, functioning, and 
QoL. Later on, Zimmerman et al. (2014) validated a new instrument – the Remission 
from Depression Questionnaire, encompassing different domains of functioning and 
QoL along with symptomatology. The authors conclude that the new tool provides a 
broader perspective of depressed patients’ condition than purely symptom based 
measures and is more consistent with the biopsychosocial approach in the treatment 
of depression. However, these tools are still in their infancy and need further 
validation. Another possibility involves separate definition of functional remission 
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alongside depressive symptom assessment. An example is a study by Mancini et al. 
(Mancini et al., 2012), which applied such criteria based on the Sheehan Disability 
Scale (Sheehan, 1983). Future studies should be designed towards the achievement 
of such broader remission criteria. 
4. Report of domain-specific information  
 Results of the literature review revealed that more than 80% of the 
interventional studies published in the last decade reported only sum-scores of 
instruments assessing global functioning rather than domain-specific information 
(Kamenov et al., 2015). Despite some methodological and practical advantages of 
aggregating scores from different domains, the sum-scores obscure potential 
differences among people and do not provide detailed information on the differential 
impact of certain functioning domains on the overall state of depressed persons. A 
higher sum-score might mean a higher number of less affected functioning areas or a 
smaller number of domains with marked decrements.  
 Reporting domain-specific information will potentially reveal differential 
trajectories in the course of depression, interrelations between distinct domains of 
functioning, and most importantly – will lead to a more personalized approach in the 
treatment of depression. Some of the findings of this thesis supported the importance 
of reporting domain-specific information. Findings from the World Health 
Organization’s (WHO) Study on Global Ageing and Adult Health (SAGE) and the 
Collaborative Research on Ageing in Europe (COURAGE in Europe),  two multi-
country projects, revealed that different domains of functioning had differential 
impact on the overall conditions of patients with depression. Moreover, there were 
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certain gender differences in terms of impaired domains. Thus, reporting only a sum-
score combining the results of distinct functional domains should obscure valuable 
and important differences among individuals.  
5. Personalized approach in treatment decision making 
 Current treatment decision making is based on evidence-based medicine. 
Thus, clinical guidelines recommend psychotherapy and pharmacological agents for 
all patients as first line treatments. The regulatory approval process for new 
medications and other interventions is based primarily on symptomatology. 
However, different psychological and pharmacological interventions are also 
designed to improve other areas of functioning beyond symptoms. This is confirmed 
by the results obtained from clinician and patient opinions, showing that 
psychotherapeutic and pharmacological interventions targeted to a different extent 
the range of functional difficulties in the population. Moreover, patients and experts 
highlighted the importance of functional difficulties beyond symptoms in the 
recovery process. There is a need of a more personalized approach in treatment 
decision making acknowledging specific patient needs and accounting for a more 
comprehensive array of functional domains. More research is also needed to explore 
the effectiveness of the available interventions on each of the relevant functioning 
areas.  
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6.4.  Limitations of the thesis 
 The present thesis has certain weaknesses which need to be presented. The 
limitations of each study are listed below. 
Systematic literature review 
First, the literature search was limited to articles published between 2005 and 2014. 
This time period was chosen because we intended to analyze the trends in measuring 
treatment effectiveness in depression after the publication of the last published 
review of literature on this topic (Brockow et al., 2004). Second, articles were only 
selected if published in English. This could have left out relevant information 
published in other languages. Third, because of the wide variety of studies, we 
analyzed only instruments used in more than three studies included in the review. 
Thus, we might have omitted a comprehensive outcome measure with a broader 
scope. Another methodological limitation is the inclusion of trials that did not meet 
any quality criteria. This was done to avoid any publication bias and capture in a 
comprehensive way the literature on depression in its current form. 
Meta-analyses 
 The number of studies was relatively small and the results of some of the 
analyses we performed relied on less than five individual trials. In the meta-analysis 
assessing the efficacy of CBT on functioning and call we were not even able to 
perform some of the analyses we intended to. Second, half of the studies did not 
meet one or more quality criteria. Even though the subgroup analyses did not find 
statistically significant differences between the high and low quality studies, given 
their small number, it might be that the effect sizes have been overestimated. 
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Furthermore, mainly overall improvements in functioning and quality of life were 
assessed. There was a lack of domain-specific reporting that could have provided 
information on the effects of interventions on specific areas of functioning and QoL.  
 Furthermore, the meta-analyses were based on study-level data. Individual 
patient level meta-analysis based on original datasets of the included studies could 
have revealed important differences among patients. A further limitation was our 
inability to analyze long-term outcomes and their interactions, due to the lack of 
follow-up data. Follow-up data would allow for investigating long-term effects of 
interventions and temporal relationships among psychosocial areas. Lastly, only 
articles in English were included. This might have omitted relevant information. In 
the meta-analysis on CBT only articles published between 2000 and 2015 were 
included. We selected studies within this search period, as more than 80% of the 
clinical trials on CBT have been published since year 2000 (Hofmann et al., 2012) 
and functioning has not been investigated extensively as an outcome of interest 
before that year (Hirschfeld et al., 2000).  
Empirical multi-country study 
 The data included in this study was cross-sectional, thus both QoL and 
functioning impairment were assessed at the same measurement point. However, our 
objective was to rank the importance rather than to explore temporal relations or 
infer causal relationships. Secondly, there were certain variations in the sample size 
of each country. For this study we selected only participants with depression, but 
both the COURAGE and SAGE samples were nationally representative. The 
differences in the number of depressed participants in each country might be due to 
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differences in the prevalence of depression or cross-national differences in reporting 
in the self-reported instruments (Kessler and Bromet, 2013). 
Study based on data from expert survey and qualitative interviews with patients 
 Firstly, the way of recruiting experts might not be representative due to the 
broad, unsystematic invitation to participate in the survey. Around 70% of the 
clinicians that took part in the online survey were mainly European. Even though we 
achieved representation of non-European experts, a wider participation of the latter 
may have provided different perspective on the topic. Furthermore, data from only 
11 patients from Spain was obtained. Our approach was the attainment of a 
saturation point in individuals’ answers, but more patients with different cultural 
backgrounds could have enriched the data.  
6.5.  Implications and future directions 
 The aim of this thesis was to provide practical recommendations for 
improving measurement of treatment effectiveness in depression based on the 
current limitations in research. Therefore, several implications for research can be 
drawn out from our findings.   
 Firstly, our results boost and provide grounds for future changes in the 
measurement of disability in depression. The study proves that there is a variation in 
the level of decrements in different functioning domains across countries. Moreover, 
it shows that literature does not address the areas of functioning mostly impaired in 
depression and provides a set of domains for further development of more sensitive, 
cross-nationally validated and user-friendly instruments weighting the domains 
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according to their importance and providing a better picture on the living experience 
of depressed individuals. This action is urgent, given the fact that only 5% to 20% of 
all clinical trials for depression report functioning outcomes ( Kamenov et al., 2015; 
McKnight and Kashdan, 2009) and to date there is no gold standard tool for 
measuring functioning in depression (Lam et al., 2015). Symptoms of depression, 
which are the main focus of clinical trials, provide early signs of treatment response, 
but the functional outcomes provide an indicator of meaningful change, thus making 
the inclusion of functional tools in clinical trials a pressing issue (McKnight and 
Kashdan, 2009).  
 Although several recent trials have attempted to apply newly developed 
measures designed to capture a more comprehensive array of functioning difficulties, 
all of them are still in their infancy, do not provide domain-specific information or 
have not been validated in cross-national samples (Cohen et al., 2013;  Zimmerman 
et al., 2013). This gap warrants future studies to continue developing better measures 
of functioning and clinical trials to provide a more exhaustive measurement of 
treatment effectiveness.  
 Secondly, the thesis reveals particular gender differences in the functional 
impairment of depression. This is an important finding which needs further 
exploration in other cross-national samples, given the higher prevalence of 
depression in women compared to men. Different level of impairment in specific 
functioning areas might be a key to the understanding of these different prevalence 
rates.  
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 Thirdly, the thesis promotes the need of reporting domain-specific 
information in studies for better understanding the living experience of depression. 
Studies predominantly report only the sum-scores of the instruments. These sum-
scores do not provide information on the differential impact of each functioning 
domain on the QoL of individuals. A higher sum-score might indicate either a large 
number of mildly affected functioning areas or a few domains with marked 
decrements. Potentially important information on functioning is lost, and a detailed 
analysis of these functioning domains is likely to reveal important information 
hidden by the sum-scores.  
 Fourthly, the thesis raises the question about the importance of assessing 
functioning in clinical trials and expanding the diagnostic criteria for depression. 
Gaining insight on the socio-culturally based differences in the areas of functioning 
in depression might be the key of promoting future culture-sensitive nosology 
accounting for functional impairment (Juhasz et al., 2012). At clinical level, with the 
development of a new instrument for functioning, clinicians experiencing time 
restraints should be given the opportunity to prioritize and meet the needs of patients 
promptly. Future studies following our line of research should be able to provide 
sufficient evidence for implementing national programs focusing on prevention and 
treatment of functional impairments in depression. 
 The research recommendations that this thesis provides are the first practical 
step towards improved measurement of treatment effectiveness. The multi-informant 
approach used in the study, including empirical evidence and data from clinicians 
and patients is essential for overcoming the gap between clinical research and the 
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care of individual patients. We believe that more accurate and comprehensive 
evidence on the effectiveness of available interventions for depression is needed to 
answer the steadily escalating societal and economic burden of the disease.  
 Besides the implications for research, this thesis has also implications for 
clinical practice. It was the first to systematically assess the efficacy of the whole 
spectrum of interventions for psychosocial functioning in depression. The meta-
analyses included in the thesis provide comprehensive evidence that existing 
psychological and pharmacological interventions are efficacious for improving 
functioning and QoL in depression. There is no robust evidence that one of the 
interventions is superior, although psychotherapy appears slightly superior to 
medication. The combination between psychotherapy and medication performs 
significantly better for both outcomes when compared to each treatment alone. The 
relatively modest effects, however, suggest that future research should focus on 
tailoring therapies to better cover the needs of individuals. 
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7. CONCLUSIONS 
 The impetus for this thesis was the knowledge gap between the continuously 
escalating burden of depression and the lack of evidence for the effectiveness of 
available interventions on important psychosocial areas in depression. To address 
this gap, the first part of the thesis critically reviewed the current measurement of 
treatment effectiveness and systematically assessed the effectiveness of all available 
psychological and pharmacological interventions on psychosocial functioning in 
depression. Based on the limitations identified in the first part, the second part of the 
thesis provided empirical data for improving the treatment effectiveness 
measurement in depression.  
 Five main recommendations for future improvement of the treatment 
effectiveness measurement were derived from the research we carried out.  
 A new instrument comprehensively assessing all relevant psychosocial 
difficulties in depression has to be created. This thesis laid the foundations for its 
design by providing empirical data from nine different countries in Asia, Africa, 
Europe, and Latin America, and obtained by clinicians and patients, on the areas 
found to be susceptible to change and crucial for assessment.  
 As the results of the thesis revealed gender and country specific differences 
in the importance of several functioning domains in depression, the new functional 
tool has to be cross-nationally applicable. 
 Report of domain-specific information is needed. Our results show that the 
vast majority of the interventional studies report only sum-scores of instruments, 
which, despite some methodological and practical advantages, obscures potential 
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differences among people. Our results confirmed the differential impact of 
functioning domains on the overall state of individuals. 
 Broader remission criteria for depression including functioning areas beyond 
symptomatology are needed to adequately reflect the experience of depressed 
patients under treatment.  
 There is a need of a more personalized evidence approach in treatment 
decision making acknowledging specific patient needs and accounting for a more 
comprehensive array of functional domains.  
 With this thesis and the recommendations provided we imply that a more 
accurate and comprehensive evidence on the effectiveness of available interventions 
for depression is needed to answer the escalating societal and economic burden of 
the disease. Future research, however, is warranted to explore further the results of 
the study and apply the provided recommendations. 
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7. CONCLUSIONES 
  El motivo de realización de la presente tesis doctoral se basó en la brecha ente la 
creciente carga de la depresión y la falta de evidencia sobre la efectividad de las 
intervenciones psicosociales en áreas importantes de la depresión más allá de los 
síntomas. En respuesta a dicha brecha, en la primera parte de la tesis se revisó de manera 
crítica la medición actual de la efectividad de los tratamientos, y se evaluó 
sistemáticamente la efectividad de las intervenciones psicológicas y farmacológicas en el 
funcionamiento psicosocial en la depresión. Sobre la base de las limitaciones 
identificadas en la primera parte, la segunda parte de la tesis doctoral proporcionó datos 
empíricos y cualitativos para la mejora de la medición de la efectividad de los 
tratamientos en la depresión. 
  De la investigación llevada a cabo en esta tesis doctoral, se obtuvieron cinco 
recomendaciones principales para la futura mejora de la medición de la efectividad de los 
tratamientos en depresión. 
• Existe la necesidad de creación de un nuevo instrumento de evaluación capaz de 
integrar todas las dificultades psicosociales relevantes en depresión. Esta tesis doctoral 
sentó las bases de su diseño, proporcionando datos empíricos procedentes de nueve 
países en Asia, África, Europa y América Latina, y también de médicos y pacientes, 
sobre las áreas de funcionamiento expuestos a cambios y crucial para la evaluación. 
• A medida que los resultados de la tesis revelaron diferencias específicas en términos de 
sexo y país en la importancia de varios dominios de funcionamiento en la depresión, el 
nuevo instrumento de funcionamiento a crear tendría que ser aplicable a nivel 
transnacional. 
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• Se hace necesaria la creación de un instrumento que recoja  información sobre dominios 
específicos. Nuestros resultados muestran que la gran mayoría de los estudios sólo 
informan de las puntuaciones totales de los instrumentos, los cuales, a pesar de algunas 
ventajas metodológicas y prácticas, oscurecen las diferencias potenciales entre las 
personas. Nuestros resultados confirman el efecto diferencial de los dominios de 
funcionamiento sobre el estado general de los individuos. 
• Se necesitan criterios más amplios de remisión de la depresión, incluyendo áreas de 
funcionamiento psicosocial diferentes a las de la sintomatología depresiva para reflejar 
adecuadamente la experiencia de los pacientes deprimidos bajo tratamiento. 
• Existe la necesidad de un enfoque basado en evidencia personalizada que ayude la toma 
de decisiones sobre los tratamientos y que reconozca las necesidades específicas del 
paciente considerando una gama más amplia de dominios funcionales. 
  Con esta tesis doctoral y las recomendaciones propuestas, se quiere dar a 
entender la necesidad de  una evidencia más precisa y completa sobre la efectividad de 
las intervenciones disponibles para la depresión para responder a la creciente carga social 
y económica de la enfermedad. De todas formas,  futuras investigaciones deberán 
explorar más a fondo los resultados del presente estudio y aplicar las recomendaciones 
proporcionadas. 
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